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 Abstract 
 
Regulation of the long non-coding RNA  
FAM83H-AS1 by human papillomavirus in cervical cancer  
 
Jamie A. Barr 
 
   
 Non-coding RNAs (NcRNAs), such as long non-coding RNAs (lncRNAs) and microRNAs 
(miRNAs), have been found to be involved in a variety of critical biological processes, and dysregulation 
of ncRNAs have been involved with several human diseases including cancer.  
 
 High-risk human papillomavirus (HPV) infection is one of the first events in the process of 
carcinogenesis in cervical and a subset of head and neck cancers. The expression of the viral oncoproteins 
E6 and E7 is essential in this process by inactivating the tumor suppressor proteins p53 and Rb, 
respectively, in addition to their interactions with other host proteins and regulation of ncRNAs. Our 
group identified novel regulation of host lncRNAs by HPV oncoprotein E6. More specifically, we 
discovered that a lncRNA known as FAM83H-AS1 is involved with proliferation, migration, and 
apoptosis in cervical cells, and high expression of this lncRNA correlates with poor overall cervical 
cancer patient survival. FAM83H-AS1 is a nuclear RNA, and mechanistically it is regulated through the 
E6-p300 pathway in a p53-independent manner. These findings provide knowledge of a specific lncRNA 
that could be studied further as a biomarker and/or therapeutic target not only in HPV-related cancers but 
also in other types of cancers where FAM83H-AS1 expression is dysregulated.  
 
 In parallel with these studies, our group identified a specific subgroup of miRNAs that are 
induced during quiescence and processed by a non-canonical biogenesis pathway by using primary 
human cells. miRNA expression is dysregulated when cells undergo a reversible state of growth arrest 
known as quiescence. These primary (pri-)miRNAs are modified with a 2,2,7-trimethylguanosine (TMG)-
cap such that they are processed downstream in an Exportin-1 (XPO1)-dependent manner, independent of 
the canonical Exportin-5 (XPO5) protein used for exportation to the cytoplasm. The discovery of a new 
alternative miRNA pathway in quiescent primary human cells opens the door to future studies in other 
types of cells, such as stem cells and cancer stem cells, where the state of quiescence is important in their 
biological functions.  
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Chapter 1 
 
Introduction and Literature Review 
 
I. Non-coding RNAs (NcRNAs) 
 
NcRNAs - Overview 
 
 In 1961, the concept of messenger RNAs (mRNAs) was determined as the intermediate messenger 
between DNA and protein synthesis(1). This led to the central dogma of biology that DNA containing the 
genetic information is transcribed to mRNA, which in turn is translated to a protein; the protein is 
considered the critical functional product. Non-coding RNAs contribute to the translational process, 
including ribosomal RNA (rRNA) and transfer RNA (tRNA) processing. rRNA associates with proteins to 
form ribosomes, which catalyze the assembly of amino acids into protein chains. Each amino acid is 
covalently bound to a specific tRNA, which guides it to the polypeptide chain and helps decipher the next 
desired amino acid to add to the chain(2).  
 
 In 1982, the first "enzymatically active" RNA was identified (ribozyme) with a specific biological 
function(3). These RNA enzymes catalyze their own intronic excision during RNA splicing (self-splicing 
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introns)(4). These early findings opened the door to research additional RNAs exhibiting non-coding 
functions and, to date, there are various other functional housekeeping and regulatory ncRNAs summarized 
in Figure 1.  
 
 Advancement of sequencing technologies, the Encyclopedia of DNA Elements (ENCODE) 
work(5), and completion of the Human Genome Project revealed that ~80% of the human genome is 
transcribed and the majority of transcribed genes do not code for proteins (<3% of the human genome codes 
for proteins)(6). It was initially thought that the majority of the non-coding genomic regions were 
"transcriptional noise", but it is now appreciated that many of these have more biologically relevant 
functions.  
 
 These various ncRNAs once considered 
to be "junk" have been identified to rebel 
against the status quo and have other 
biological functions besides coding for 
proteins. NcRNAs typically lack an open 
reading frame (ORF) such that they do not 
code for proteins. Some ncRNAs contain 
very small ORFs that produce small 
peptides(7, 8), but this does not prove they 
are functional. More evolutionary complex 
organisms have a greater abundance of 
ncRNAs than less complex organisms 
(Figure 2) leading towards the theory that ncRNAs contribute to the development and control of more 
complex cellular processes. Most ncRNAs form RNA-protein complexes called ribonucleoproteins (RNPs), 
however, they can have a multitude of alternative interactions. NcRNAs can also act as competing 
endogenous RNAs (ceRNAs) such that the ncRNA can mimic an RNA binding partner and inhibit the 
function of the alternative binding partner interaction.  NcRNAs are typically classified based on their size, 
into small and long non-coding RNAs (lncRNAs). Common small ncRNAs include small nuclear RNAs 
(snRNAs), small nucleolar RNAs (snoRNAs), microRNAs (miRNAs), small interfering RNAs (siRNAs), 
and PIWI-interacting RNAs (piRNAs) (Figure 1).  
 
 In mRNA processing, pre-mRNA is the initial product transcribed, which contains both exons and 
introns. In 1993, a Nobel Prize in Physiology and Medicine was earned for identifying that introns can be 
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spliced out by spliceosomes (Philip Sharp and Richard Roberts). The spliceosomes are composed of several 
small nuclear (sn) RNP-specific proteins interacting with non-coding snRNAs. The snRNA can form an 
RNA-RNA pair with pre-mRNA in the required alignment for downstream splicing steps(9).  
 
 RNA interference (RNAi) is the process of RNAs directing enzymes to mRNAs to induce post-
transcriptional gene silencing and therefore regulate vital cellular processes. The first RNAi type of 
phenomenon was reported in 1990 in plants(10). In 1998, RNAi was identified in C. Elegans and they 
further identified that it was double-stranded RNAs triggering gene silencing(11). In 2006, Andrew Z. Fire 
and Craig C. Mello were awarded the Nobel prize for discovering RNAi. Two central types of ubiquitously 
expressed RNAi are miRNAs and siRNAs, while piRNAs are another form of RNAi that are expressed 
mainly in germline cells(12). Pseudogenes resemble functional genes, but have coding-sequence 
deficiencies. RNAi genes, such as siRNA(13), can derive from pseudogenes. Additionally, pseudogene 
ncRNAs can act as RNAi, such as miRNA sponges, to regulate gene expression(14).  
  
 Whereas RNAi mechanisms of 
action in gene regulation are well understood, 
lncRNAs are not yet well characterized. 
LncRNAs are defined as RNAs greater than 
200 nucleotides in length that are not 
translated to proteins. In 2002, lncRNAs 
were officially identified as a significant new 
class of non-protein coding RNA molecules 
after the sequencing of a full-length cDNA 
library in mouse(15). Since then, they have 
been found to function as signal, guide, 
decoy, and scaffold RNAs (Figure 3).  
 
 All of these types of ncRNAs have 
been found to play roles in a variety of 
pathological conditions, including cancer. 
Specific ncRNAs expression has been 
correlated with survival and therefore are 
being studied as biomarkers for disease 
diagnosis and prognosis. Additionally, 
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specific ncRNAs have been identified to be functionally related to hallmarks of cancer and are being 
pursued as therapeutic targets. 
 
II. Small non-coding RNAs 
 
A. RNAi - Overview   
 
 In 1993, the first microRNA, lin-4, was identified in C. Elegans, by the Ambros and Ruvkun 
labs(16). However, miRNAs were not respected as functionally critical until 2002 when Carlos Croce at 
the Kimmel Cancer Institute (now at The Ohio State University) identified, for the first time, two miRNAs 
involved in human cancer(17). Around that time, hundreds of other miRNAs were reported and discovered 
to be conserved amongst species(18). These small ncRNAs were initially referred to as "small temporal 
RNAs (stRNAs)" prior to 3 publications in Science in 2001 that transitioned the field towards the term 
"microRNAs"(19-21).  
 
 MicroRNAs are short, single stranded ncRNAs that are ~22 nucleotides long. They function by 
binding to the miRNA response elements (MREs) in the 3' untranslated region (3'-UTR) of mRNAs and 
targeting them for degradation and/or preventing their translation. MiRNAs contain an eight-base seed 
region that is well conserved and binds with perfect complementarity to the mRNA target. miRNAs with 
similar seed sequences with likely target a similar set of genes, however miRNAs with different seed 
sequences can still target and regulate similar gene sets.  
 
 miRNAs have been found to be well conserved in many species, including humans, and are master 
regulators of almost every biological process. In humans, it is predicted that miRNAs can regulate more 
than 90% of genes, and a single miRNA can target multiple genes(22). They are involved with immunity, 
development, and metabolism, and dysregulation of these miRNAs is implicated in most human diseases, 
including cancer, cardiovascular diseases, and neurological diseases. Currently, there are 2,654 annotated 
human miRNAs(23).   
 
 In 1999, a similar ncRNA known as small interfering RNA (siRNA) was identified in plants(24). 
A long double-stranded RNA is cleaved by the endonuclease Dicer to form a small interfering RNA 
(siRNA) that is ~20-25 nucleotides in length. SiRNA can enter into a cell, get incorporated into other 
proteins to form the RNA-Induced Silencing Complex (RISC). At this point, the siRNA is unwound and 
separated to form a single stranded siRNA. The single-stranded siRNA that remains part of the RISC 
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complex then binds to complementary target mRNA to induce mRNA cleavage, and leads to mRNA 
degradation.  
 
 miRNAs and siRNAs show many similarities, but there are some distinctive traits between the two 
RNAs. siRNAs are derived from longer regions of double-stranded RNA. Both siRNA and miRNA are 
similar in length and mediate downregulation of their specific mRNA target. miRNAs are regulators of 
endogenous genes, while siRNAs regulate in response to foreign entities (e.g. viruses). It is suggested that 
siRNA destabilizes mRNA, while miRNA primarily inhibits mRNA translation without affecting the 
mRNA level. miRNA can sequester and degrade mRNA by P-bodies, which are sites for RNA decay(25). 
The main difference between siRNA and miRNA is that siRNA has perfect complementarity to its target, 
while most miRNA only has complementarity in the seed region with variable complementarity of the target 
to the rest of the miRNA. This feature allows miRNAs to have greater plasticity to target several mRNAs, 
while siRNAs only can target mRNA that have perfect complementarity. Additionally, miRNAs and 
siRNAs can be synthetically developed and utilized as a research tool as well as clinical therapeutic 
applications.  
  
 More recently, another form of RNAi known as piRNAs were identified to prevent genome 
instability in germ line cells. piRNAs interact with piwi proteins to form RNA-protein complexes that are 
involved in post-transcriptional silencing of transposons and other cellular genes. piRNAs are transcribed 
from single-stranded precursor transcripts that are processed in a Dicer-independent mechanism and are 
slightly longer (~24-31 nucleotides) than miRNAs and siRNAs (12).  
  
B. MiRNA Biogenesis - Canonical Pathway 
 
 The canonical biogenesis of miRNAs has been elucidated as a stepwise process in normal and 
aberrant cells (Figure 4). The initial step of miRNA biogenesis is transcription of a long primary (pri)-
miRNA, typically by RNA Polymerase II (Pol II)(26). Some miRNAs are transcribed by RNA Polymerase 
I (Pol I). The majority of pri-miRNA are transcribed from intergenic regions or antisense to host genes 
while others are transcribed from intronic regions; thus, miRNA may be formed independently or as part 
of host genes. The size of a pri-miRNA ranges from several hundred nucleotides to several kilobases, and 
contains a stable 7-methylguanosine (m7G) cap at its 5' end and polyadenylated cap at its 3' end. These pri-
miRNAs contain one or more bulged structures. The canonical biogenesis pathway then consists of two 
cleavage events, one nuclear and one cytoplasmic, to produce a mature miRNA. 
 
6 
 
 In the nucleus, the microprocessor consisting of the RNase III nuclease Drosha(27) and double 
stranded RNA binding protein DiGeorge Syndrome Critical Region 8 (DGCR8)(28) recognizes the bulged 
hairpin structure of the pri-miRNA and cleaves the pri-miRNA to precursor (pre-) miRNA. This leaves the 
pre-miRNA with a ~70 nucleotide stem-loop structure. More specifically, Drosha cleavage generates 3' 
protruding ends that are later recognized by Exportin-5 (XPO5) and Dicer(27, 29, 30).   
 
 Notably, RNase III protein homologs conservation and interactions can vary between species. 
Initially Pasha was identified as Drosha's partner required for miRNA maturation and miRNA-mediated 
gene regulation in Drosophila and Caenorhabditis elegans (C. Elegans)(31) and it was later identified as 
DGCR8 in other organisms(28). 
 
 Pre-miRNA intermediates 
are bound by XPO5 and exported 
from the nucleus to the 
cytoplasm(30, 32, 33) in a Ran-
GTP dependent manner. 
Subsequently, pre-miRNAs are 
cleaved by the cytoplasmic RNase 
III protein Dicer1 and Dicer-
transactivating response RNA-
binding protein (TRBP) complex 
into ~22 nucleotide miRNA 
duplexes(34-38). This miR/miR* 
(miR-3p/miR-5p) duplex is then 
unwound by a helicase. One strand 
of the cleaved duplex, sometimes 
referred to as the "passenger 
strand" (miRNA*), can be non-
functional and degraded by a 
nuclease (39). The other "guide 
strand" preferentially remains a 
functional mature miRNA(40, 41). 
The miRNA* terminology is now 
used less, however, because some 
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miRNA* sequences were found to be functional. Currently, the two miRNA strands are named miR-3p and 
miR-5p based on the direction of the strand it derived from, and both strands have the potential to be 
functional(42). The single-stranded mature miRNA guide strand is loaded into the Argonaute-2 (Ago2) 
containing RNA-induced silencing complex (RISC). Each RISC can only contain one of the two strands. 
The stability of the base pairs at the 5' end of each predetermines which strand is loaded into the RISC (41); 
the strand with the less stable 5' end usually survives. The mature miRNA contained in the RISC will then 
base-pair incompletely with the target mRNA. Depending on the degree of complementarity between the 
miRNA and mRNA target will determine the fate of the mRNA. Most miRNAs exhibit imperfect 
complementarity with target mRNA and will inhibit the mRNA's translation(43) by inhibiting the ribosome 
progression. Perfect complementarity will induce degradation of the mRNA(44). For example, miR-196 is 
perfectly complementary to its mRNA target HOXB8 (except for a wobble base pairing) and the miRNA 
induces degradation of the mRNA(44). miRNA binding destabilizes the mRNA by speeding up the 
deadenylation of the mRNA and contributing to mRNA degradation(45).  
 
C. miRNA Biogenesis- Alternative Pathways 
 
 Even though the canonical pathway is well studied, deep sequencing of systems with deletions of 
miRNA biogenesis pathway components have identified non-canonical biogenesis pathways in different 
organisms and cells that can still produce functional miRNAs. These alternative pathways can differ in the 
number of cleavage events and enzymes responsible for miRNA processing. It appears that the biogenesis 
pathway that a miRNA takes to be processed is determined by its genomic site of origin, sequence, and 
thermodynamic stability.  
 
 In the same human cell line, Drosha, XPO5, and Dicer were deleted to analyze for effects on 
miRNA biogenesis. Drosha-depleted cells exhibited completely abolished canonical miRNA biogenesis. 
From this analysis, they detected three miRNAs processed independent of Drosha (miR-7706, miR-3615, 
and miR-1254), while canonical miRNA production was completely abolished in cells with Drosha 
depletion. Dicer depletion led to reduced levels canonical miRNAs, but many were still detected. In cells 
with Dicer knockdown, pre-miRNAs were loaded directly onto Argonaute protein and trimmed at the 3' 
end to produce miRNAs from the 5' strand (5p miRNAs). Unexpectedly, XPO5 depletion only partially 
affected miRNAs expression(46), suggesting there are alternative miRNA exportation pathways. This study 
contributes to the idea that certain miRNAs can be processed independent of the main proteins involved 
with canonical biogenesis.  
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 Mirtrons  
 
 In 2007, the Bartel and Lai laboratories described a group of RNAs in Drosophila melanogaster(47, 
48) and Caenorhabditis elegans (C. Elegans)(48) termed "mirtrons" (pre-miRNA/intron) that follow a non-
canonical miRNA biogenesis pathway as they are Drosha- and DGCR8-independent. Similar to canonical 
miRNAs, mirtrons are encoded within short stem-loop structures. However, while miRNAs utilize the 
microprocessor complex for processing, mirtrons are instead generated from the excised intron of protein-
coding genes that are released during mRNA splicing. More specifically, a small intron lariat is linearized 
by the lariat debranching enzyme to produce a pre-miRNA-like short hairpin. Thus, mirtrons are processed 
independently of the microprocessor complex, but follow the canonical miRNA pathway during nuclear 
export and thereafter(47, 48). Subsequently, mirtrons were found to be well-conserved and expressed in 
diverse vertebrates(49-52).  
 
 With conventional mirtrons, both of their ends are defined by splicing; however, some mirtrons 
contain 5’-(52) or 3’-(52, 53) single-stranded RNA tails that need to be trimmed by nucleases before Dicer 
processing. For example, certain 3’-tailed mirtrons (e.g. hsa-miR-4745 and hsa-miR-6869) are trimmed by 
the RNA exosome(52, 53). 
 
 Simtrons 
 
 While mirtrons are splicing-dependent, a subset termed "simtrons" (splicing-independent mirtron-
like miRNAs) do not require DGCR8, Dicer, Exportin-5, or Argonaute 2 (AGO2). They can however 
interact with Argonaute proteins. They are exported from the nucleus in an unknown mechanism. They are 
bound by, and dependent on, Drosha. Simtrons function by silencing target transcripts and are found in the 
RISC complex. Some examples are miR-1225 and miR-1228(54).  
 
 snoRNA-miRNAs 
 
 In 2008, Ender C. et al. discovered small RNAs derived from snoRNA ACA45 that are processed 
independent of the microprocessor Drosha/DGCR8 complex and function like miRNAs. The processing of 
this RNA is still dependent on Dicer and interacted with Ago proteins to silence mRNA (CDC2L6) 
expression post-transcriptionally in a miRNA-like manner(55).   
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 Since then, other snoRNAs with dual roles as miRNAs (e.g. miR-140, miR-605) have been 
identified. Based on sequence and structure, there are two classes of snoRNAs (box H/ACA and box C/D), 
both of which produce snoRNA-derived RNAs(55-59). 
 
 miRNAs from tRNAs 
 
 In 2008, Babiarz et al. identified a pre-tRNA (miR-1983) that was Dicer-dependent and DGCR8-
independent(50). Later studies demonstrated other tRNA-derived small RNAs (tsRNAs) involved in gene 
silencing that were Dicer-dependent (type I tsRNAs) (60, 61), as well as some tsRNAs processed by RNase 
Z cleavage downstream from a tRNA gene in a Dicer-independent manner (type II tsRNAs)(61). These 
tsRNAs localize to the cytoplasm and associate with Argonaute proteins(61). 
  
 Virus-derived miRNAs 
 
 Other tRNA-derived small RNAs that were miRNA-like were identified to be generated from both 
host and viral genomes(62-64). Murine gamma-herpesvirus 68 (MHV68) miRNAs are co-transcribed fused 
to a tRNA from RNA polymerase III promoters(63). The resulting pri-miRNA is then processed by tRNase 
Z, independent of Drosha, to form a pre-miRNA that then exhibits canonical processing to yield mature 
viral miRNAs (e.g. MHV68 miR-M1-7)(64). 
 
 In certain instances, potentially to combat viral infection (e.g. Sinbis RNA virus), pri-miRNAs can 
be incorporated into a cytoplasmic virus. The pri-miRNA is downstream processed in a Dicer-dependent, 
DGCR8-independent manner to produce a viral mirtron-like product (virtron)(65). Following viral 
infection, Drosha is relocalized to the cytoplasm to aid in this processing of virus-derived miRNAs(66).  
 
 Expression of viral miRNAs from herpesvirus saimiri (HVS) relies on elements required for the 
synthesis and processing of Sm class U RNAs known as HVS U RNAs (HSURs). More specifically, these 
viral miRNAs are processed independent of the Microprocessor complex. Instead the Integrator complex 
(mediates processing of snRNA) cleaves to generate the 3' end of the HSUR and the pre-miRNA hairpin. 
To generate these mature viral miRNAs, the pre-miRNA is then processed downstream by the canonical 
pathway involving XPO5 and Dicer(67).  
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 Recently, viral miRNAs produced from certain low risk strains of HPV (17, 37, and 41) were 
identified. Further studies found that these viral miRNAs are processed by canonical miRNA biogenesis 
and can regulate viral transcripts (e.g. E1) and consequently control their own viral life cycle(68). 
 
 Dicer-independent miRNA biogenesis 
 
 miR-451 is a conserved vertebrate miRNA that is cleaved by Drosha/DGCR8 to generate a pre-
miRNA that is too short to be a substrate for Dicer. Instead, the pre-miRNA is loaded directly into 
Argonaute proteins. If the pre-miRNA is loaded into an Ago2 protein, it is cleaved(69-72).  
 
 XPO1-dependent miRNA biogenesis 
 
Previously, capped RNAs shorter than 200 nucleotides were found to be bound by CBC (cap-
binding complex)-PHAX and exported via XPO1 rather than XPO5.(73) In a similar manner, certain pre-
miRNAs (e.g. pre-miR-320 and 
pre-miR-688) were found to be 
processed differently with 
regards to pre-miRNA 
synthesis, nuclear-cytoplasmic 
transport, and guide strand 
selection in mice. They have a 
7-methylguanosine (m7G)-cap 
employed by eIF4E that is 
recognized by XPO1 via the 
adapter molecule PHAX.  These 
certain capped pre-miRNAs 
were processed independently 
of the Microprocessor. Once 
exported in an XPO5-
independent manner, they are 
cleaved by Dicer and only the 
3p-miRNA is efficiently loaded 
onto Argonaute to form mature, 
functional miRNA(74).  
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The Martinez lab recently discovered another XPO1-independent, non-canonical pathway of 
miRNA biogenesis in normal, human foreskin fibroblast (HFF) quiescent cells (Figure 5). XPO5 
expression is lost in quiescent cells by autophagy and the regulation of miR-34a. A group of miRNAs are 
induced during quiescence in HFFs and their biogenesis is XPO1-dependent (XPO5-independent). These 
pri-miRNAs (e.g. pri-miR-34a and pri-miR-3188) are modified with a 2,2,7-trimethylguanosine (TMG)-
cap by trimethylguanosine synthase 1 (TGS1), which allows them to bind to and be exported by XPO1. 
Additionally, pri-miR-34a was present in the cytoplasm along with a small isoform of Drosha, implying 
further potential alternative processing of this miRNA in quiescent cells.   
 
In summary, the importance of miRNAs is essential in so many processes that evolution gives the 
plasticity to process these miRNAs in non-canonical pathways as needed. 
 
D. miRNAs - Involvement in Cancer 
 
 MiRNAs involvement in cancer has been comprehensively reviewed(75-78). Global differential 
expression analyses of miRNAs in human cancer cells and tissues have revealed dysregulation of many 
miRNAs in human cancer and that most miRNAs are repressed in cancer tissues compared to normal(79, 
80). Global depletion of miRNAs via impaired miRNA processing, led to cell transformation and 
tumorigenesis, which implies miRNA alteration contributes to cancer development(81). Functionally, 
miRNAs can be both tumor suppressive or oncogenic depending on the context, and are involved in many 
aspects of cancer biology, including proliferation and apoptosis. In many cases, the trend of miRNA 
expression correlates with many clinical variables (e.g. tumor stage and overall survival) such that miRNA 
profiling of a patient can lead to improved diagnosis and prognosis in certain cancers(77). Additionally, 
some have proposed that miRNA profiling is even better at predicting clinical variables than mRNA 
profiling in certain cases explored thus far(79). 
 
 Mechanisms of miRNA alterations in cancer 
 
 There are multiple mechanisms of miRNA deregulation in cancers, including genomic abnormality, 
epigenetic factors, transcriptional regulation, and miRNA biogenesis regulation as described below. 
Notably, stoichiometry analysis of miRNA to target gene abundance can allow for the speculation of how 
likely the miRNA is to regulate the target and contribute to a biological effect. Higher levels of mRNA 
expression results in varied downregulation of targets by miRNA(82).  
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 The first example of a miRNA involved in cancer was miR-15a and -16-1, which are clustered at a 
region of the genome that is frequently deleted in B cell chronic lymphocytic leukemias (B-CLL). Thus, in 
the majority of CLL cases, both genes are deleted or down-regulated(17). Other groups have additionally 
showed deregulation of miRNAs in cancer due to chromosomal abnormalities (e.g. fragile sites)(83). 
 
 miRNA expression can be regulated by epigenetic factors, as many CpG islands are located near 
miRNAs(84). CpG hypermethylation repressed miRNAs (e.g. miR-9-1 and miR-124a) in cancer tissues 
compared to normal, and this miRNA hypermethylation affected known tumor suppressors and oncogenic 
factors (84, 85). Alternatively, miRNAs (e.g. miR-29) can counteract CpG methylation by directly targeting 
DNA methyltransferases and therefore de-repress downstream targets regulated by promoter methylation 
in cancer cells(86).   
 
 Well-known transcription factors involved in cancer can up-regulate the expression of certain 
miRNAs to contribute to carcinogenesis. For example, Myc(87) and p53(88) can alter expression of the 
miR-17-92 cluster and miR-34, respectively, in cancer cells.  
 
 Alterations in expression of mature miRNAs can occur due to decreased miRNA biogenesis 
processing efficiency or miRNA stability. In cancer, key regulators of the miRNA biogenesis pathway 
(Drosha or Dicer) have altered expression, which affected steady-state miRNA levels and led to tumor 
development(81). 
 
  In some cases, miRNA expression levels are not altered, but rather there is sequence variation in 
the miRNA binding sites in the target gene that affect miRNA-mRNA interactions and contribute to 
cancer(89). 
  
 Oncogenic or tumor suppressive miRNAs  
 
  Certain miRNAs are up-regulated in a cancer lineage-specific manner, while others are altered in 
many different types of cancers and thus critical tumor suppressors or oncogenes. Some of the most well-
known miRNAs that are altered in many cancers from different lineages are miR-17-92 cluster, miR-21, 
miR-155, let-7, and miR34s(77). Since miRNAs target and regulate expression of mRNAs, a miRNA is 
determined to be oncogenic or tumor suppressive depending on its target gene.  
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 The oncogenic miR-17-92 cluster (composed of miR-17, -18a, -19a, -20a, -19b-1, and -92a-1) is 
up-regulated in many human cancers(76). It is up-regulated by MYCN and binds the 3'UTR of the cyclin-
dependent kinase inhibitor CDKN1A (p21) and pro-apoptotic regulator BCL2L11 (Bim) mRNAs in 
neuroblastoma(90).  
 
 miR-21 regulates multiple target genes, including p53 and NF-kB, involved in hallmarks of 
cancer(91). miR-21 expression is up-regulated in many different types of cancers(76) and is considered to 
be a ubiquitous oncogene as it is expressed in all epithelial-cell derived solid tumors and many other 
cells(91). In the IL-6 signaling pathway, Stat3 transcriptionally activates miR-21 such that downstream it 
regulates invasion and metastasis(92).  
 
 miR-155 has been identified as a bona fide oncogene in breast cancer because it binds key cancer 
targets (e.g. FOXO3A and RhoA) for degradation or inhibition of translation to accelerate tumor 
development(93). miR-155 has also been found to drive therapy resistance in various tumor types and is 
being studied as a target for miRNA-based therapeutics(94). 
 
 Let-7 is a tumor suppressor that targets well-known oncogenes RAS, c-Myc(81), and HMGA2(76). 
The expression of let-7 has been reported to be down-regulated in many human cancers, including lung and 
colon(95). 
 
 miR-34a acts as a tumor suppressor by regulating of at least 700 transcripts involved in cellular 
processes such as proliferation (cyclin-dependent kinases), apoptosis (BCL2), and motility (SNAI1). 
miR34a is transcriptionally regulated by the tumor suppressor p53 in normal conditions, however miR-34a 
expression is decreased in many cancers likely due to alterations in p53(96).   
  
 Virus-regulation of miRNAs 
  
 The involvement of miRNAs in the pathogenesis of oncogenic viruses was comprehensively 
reviewed by Lin et al. in 2011(97). Certain oncogenic viruses can alter host miRNAs(98, 99) while others 
can encode their own viral miRNAs(100, 101) to control their viral life cycle, but consequently this can 
contribute to carcinogenesis(97).  
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 The high-risk human papillomavirus (HPV) E6 oncoprotein inhibits expression of the tumor 
suppressor miR-34a(99).  Additionally, Martinez et al. showed that high-risk HPV E6 inhibits miR-218, 
which up-regulates LAMB3 to contribute to HPV's tumor promoting function(98).  
  
 Kaposi sarcoma-associated herpesvirus (KSHV)(100) and Epstein-Barr virus (EBV)(101), can 
produce viral miRNAs to regulate carcinogenesis. For example, a cluster of KSHV miRNA decreases an 
anti-angiogenic, tumor suppressor thrombospondin 1 (THBS1)(100, 102).  
  
E. miRNA - Clinical Implications 
  
 Regulating miRNAs for application in a clinical setting has evolved by using antagomir and 
miRNA mimics. To counteract the up-regulation of oncogenic miR-17p-92 cluster in therapy-resistant 
neuroblastoma, in vitro  and in vivo antagomir-17-5p treatment was used to abolish the growth of MYCN-
amplified cancer cells by up-regulating p21 and BIM to blockade the cell cycle and activate apoptosis(90). 
A Phase 1 clinical trial was completed that tested intravenous injection of TargomiRs (targeted minicells 
containing a miRNA mimic) for the first time in humans. It was tested as a second- or third-line treatment 
for patients with recurrent malignant pleural mesothelioma (MPM) and non-small cell lung cancer 
(NSCLC). The TagomiR consisted of a synthetic miR-16 mimic, non-living bacterial minicells 
(nanoparticles), and an anti-EGFR specific antibody. At this time, no results have been posted for this 
specific study (NCT02369198).  
  
 Additionally, there is the potential of analyzing for expression of miRNA(s) for use as diagnostic 
and/or prognostic marker. There are various clinical trials underway to analyze circulating miRNAs in 
blood and plasma as biomarkers of different types of cancers to diagnose cancer and stratify patients by 
stage (to determine treatment). Certain Phase I clinical trials (e.g. NCT02509052). are combining their 
primary objectives with secondary and tertiary objectives to preliminarily analyze miRNA signatures 
associated with responses of cancer cells to therapeutic treatments. The Spanish Breast Cancer Research 
Group is sponsoring a clinical trial to analyze whole blood of metastatic breast cancer patients for a miRNA 
signature to predict response to bevacizumab therapy (NCT01598285). Analysis of ncRNA expression in 
exosomes is currently an actively pursued direction of clinical research. One clinical study is currently 
recruiting patients to analyze ncRNA expression via genetic sequencing of miRNA/lncRNA in the exosome 
of epithelia ovarian cancer patients. (NCT03738319). There are clinical trials researching miR-155 as a 
diagnostic marker in non-muscle invasive bladder cancer (NCT03591367). Notably, many clinical trials 
are looking for a miRNA signature of multiple miRNAs rather than relying on a single miRNA biomarker. 
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One specific colon cancer study is currently analyzing for expression of 6 miRNAs (miR-21, -20a-5p, -
103a-3p, -106b-5p, -143-5p, -215) in clinical surgical specimens to identify if a patient should additionally 
receive adjuvant chemotherapy (NCT02466113). A Phase 4 clinical trial detecting fifteen circulating 
miRNAs (identified from preclinical studies) as biomarkers of hormone sensitivity in breast cancer patients 
before and after first-line therapy was completed. In parallel, they analyzed a larger scale analysis of 
circulating miRNAs in these patients (NCT01612871).  Prospective studies are being conducted, such as 
profiling plasma miRNA expression in heavy smokers to assess its efficacy as a first-line screening for lung 
cancer screening of high-risk population (NCT02247453). There is a completed clinical trial analyzing for 
expression of miRNA biogenesis proteins (Dicer and Drosha) in epithelial skin cancer (NCT00849914). A 
clinical trial sponsored by MiraKind is validating the role of miRNA binding site mutations in cancer risk, 
prevention, and treatment (NCT02253251). Unfortunately, at this time, no results have been posted on 
clinicaltrials.gov for any of the studies mentioned above. 
  
 As miRNA mechanisms of action to function in gene regulation are well understood, lncRNAs are 
not yet well characterized. 
 
III. Long non-coding RNAs (LncRNAs) 
 
A. LncRNA - Overview 
 
 In 2009, Dr. John Rinn and Dr. Eric Lander's labs at the Broad Institute identified over a thousand 
lncRNAs that are highly conserved in mammals(103). This contributed to the great increase in research 
publications on lncRNAs in the past ~10 years(104). To date, there are currently over 127,000 annotated 
human lncRNA transcripts in the LNCipedia public database (lncipedia.org), however, few of these have 
been fully characterized. Admittedly, lncRNA transcription does not necessarily mean that it has a 
biological function, however many lncRNAs have been characterized as functionally important and it is 
critical to continue to dissect functions.  LncRNAs make up the majority of the non-coding portion of the 
genome (https://www.gencodegenes.org/human/stats.html), so it is critical to further research and 
characterize this class of RNAs.  
 
B. LncRNA - Characterization of lncRNA  
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 LncRNAs were initially identified as mRNA-like transcripts that do not code for proteins; however, 
further characterization of lncRNAs has distinguished them as their own class. It is still challenging to 
distinguish between coding and lncRNA transcripts.   
 
 Since lncRNAs as a class are not well characterized yet, there are only trends, not standard "rules", 
to classify lncRNA based on biogenesis, processing, localization, functions, etc. As expected, there are also 
lncRNAs that have been identified as exceptions to the trends of the majority of lncRNAs. A review in 
2016 summarized certain research techniques that could be used to identify and characterize a newly 
identified lncRNA(105). Once a specific lncRNA is identified, researchers can determine: 
biogenesis/processing, genomic location, non-protein coding potential; conservation; expression level, size, 
and primary sequence; secondary structure; localization; and biological function.  
 
 LncRNA - Biogenesis and Processing  
 
 In terms of biogenesis, lncRNAs and mRNAs share similar characteristics. LncRNAs are typically 
transcribed by RNA Polymerase II (Pol II) from genomic loci with similar chromatin states to 
mRNAs(103). In many cases, lncRNAs differ from mRNAs solely in that lncRNAs are lacking a translated 
ORF. Similar to mRNAs, lncRNAs are modified with a 5' cap and 3' polyadenylated tail(103) and undergo 
pre-RNA splicing. Some lncRNAs undergo non-canonical processing at their 5' and 3' ends(106-108).  
 
 The promoter regions of the majority of lncRNAs display similar epigenetic marks [e.g. increased 
trimethylation of lysine 4 of histone 3 (H3K4me3)] to mRNAs. LncRNAs have higher enrichment of 
acetylation of lysine of histone 3 (H3K27ac) and are more strongly repressed by certain chromatin 
remodeling complexes (e.g. Swr1, Isw2) than mRNAs(106). Some eukaryotic promoters are bi-directional 
such that a sense protein-coding gene could be transcribed while an antisense is transcribed in the opposite 
direction(109). Polyadenylation signals differ between sense (protein coding) and antisense strands 
(lncRNA) produced from divergent promoters; polyadenylation usually occurs during splicing of mRNAs, 
while it typically occurs during cleavage in lncRNAs. 
 
 Similar to mature tRNAs, some lncRNAs (e.g. MALAT1) use an alternative processing method 
consisting of cleavage by the RNase P ribonucleoprotein complex. These specific lncRNAs contain a 
tRNA-like structure at their 3' ends that RNase P cleaves to produce mature lncRNA transcripts. After 
RNase P cleavage, the mature lncRNA has an RNA triple helix at the 3' end (similar to a polyA tail) that 
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increases its stability. Additionally, both mRNAs and lncRNAs can be spliced, and some lncRNAs can be 
back-spliced and circularized (circular RNAs) (110).  
 
 LncRNA - Genomic location 
  
 One method of classifying lncRNAs is based on their location in the genome relative to protein-
coding genes. Based on this genomic location of a lncRNA, the functional role of the lncRNA can be better 
predicted. As shown in Figure 6, lncRNAs can be defined as sense, antisense, bidirectional or divergent, 
intronic, intergenic or intervening(111, 112). Importantly, lncRNAs can overlap protein-coding genes and 
be expressed in a similar pattern as the coding gene(113) (Figure 6, IIa and IIb). The V3.0 lncRNA 
classifications by Arraystar Incorporated shows their analysis of the number of each subgroup. The majority 
of lncRNAs are classified as lincRNAs (19,590) followed by intronic (4,409), antisense (3,691), sense 
overlapping (1,597), and bidirectional (1,299) lncRNAs (www.arraystar.com).  
 
 Sense lncRNAs are 
transcribed in the same 
direction as exons of 
protein-coding genes 
(Figure 6, Ia) and have been 
found to be non-coding 
variants of genes that can 
regulate gene expression. A 
lncRNA can also partially 
overlap a protein-coding 
gene on the same genomic 
strand, and both are 
transcribed in the same 
direction (Figure 6, IIa). 
These sense-overlapping 
lncRNAs can be transcript variants of protein-coding genes, and the majority of these lncRNAs lack a 
substantial ORF for protein translation.  
 
 Bidirectional, or divergent, lncRNAs are transcribed in the opposite direction as a protein-coding 
gene within the vicinity (within 1kb) (Figure 6, III). There is similarity in expression patterns between some 
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lncRNA and its protein-coding counterpart such they may be regulated by similar mechanisms, but this is 
does not hold true for all bidirectional lncRNAs.  Bidirectional expression of lncRNA-protein-coding gene 
pairs are prevalent in cancer.  
  
 Antisense lncRNAs are transcribed from the antisense strand, in the opposite direction as a protein-
coding gene (Figure 6, Ib). A lncRNA can also partially overlap a protein-coding gene, and both are 
transcribed in the opposite direction (Figure 6, IIb). Antisense lncRNAs can share the same promoter as 
coding gene and their expressions can highly correlate(114). Antisense lncRNA may pair with a protein-
coding gene on the sense strand to regulate epigenetic silencing, transcription, and mRNA stability(115). 
As an example of how genomic location can aid in characterization of lncRNAs, mouse sense-antisense 
transcripts tend to be poly(A) negative and localized in the nucleus(116). Antisense lncRNA transcription 
of genes affects both the expression and splicing of sense genes(117). Natural antisense transcripts' (NATs) 
expression regulate tumor suppressors and oncogenes in cancer. OncoNAT is useful tool that catalogs 
cancer-related genes with significant antisense transcription.  
 
 Intergenic lncRNAs (lincRNAs) are transcribed between two protein-coding genes and are at least 
1kb away from the nearest protein-coding genes (Figure 6, IV). Very long intergenic ncRNAs (vlincRNAs) 
can range in size from 50 kilobases to 1 megabase. As of 2009, more than 1,000 lincRNAs were identified 
to be encoded by the mammalian genome and are clearly conserved across mammals. Some lincRNAs (e.g. 
HOTAIR) have been found to associate with chromatin modifying proteins and regulate gene 
expression(118). They have also been found to be important in a variety of cellular processes including 
apoptosis, cell-cycle progression, and cellular senescence. Intergenic lncRNAs can be subcategorized as 
being enhancer-associated (elncRNA) (present close to the promoter, in an enhancer region) or promoter-
associated (plncRNA). ElncRNAs are more tissue-specific, less highly expressed, and less well conserved 
during evolution(119) and have been found to be important in certain diseases(120).  
 
 Intronic lncRNAs are transcribed from an intronic region of a protein-coding gene (Figure 6, V). 
Intronic lncRNAs can be transcribed in the sense or antisense direction. Intronic lncRNAs are expressed in 
similar tissues as the corresponding protein-coding gene, and the lncRNA may regulate alternative splicing 
or stability(121). 
 
 Additionally, there are certain regions of the genome that are associated with diseases, and these 
regions contain lncRNAs. Thus, these lncRNAs could be critical regulators in these diseases.  
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 LncRNA - Excluding protein-coding potential 
  
 Classifying RNAs as non-coding and coding transcripts is not a straightforward process as mRNA 
and lncRNA exhibit similar structure, and a single RNA can function as an mRNA and also have a non-
coding function. This discernment is also difficult, as lncRNAs overlap protein-coding genes (Figure 6, IIa 
and IIb). Certain lncRNAs have already been identified to encode functional peptides(8) (7), while some 
RNAs currently classified as lncRNAs may indeed encode proteins if researched further. These 
aforementioned difficulties of differentiating between coding and non-coding RNA are comprehensively 
reviewed by Dinger et al.(122). 
 
 Protein-coding transcripts contain a long open reading frame (ORF) capable of translating a protein, 
which can separate mRNAs from lncRNAs in some instances. Solely using ORF size is not acceptable as 
some RNAs classified functionally as lncRNAs also contain long ORFs (e.g. H19 and Xist). On the other 
hand, some mRNAs contain shorter ORFs. If an RNA contains an ORF, the conservation of that ORF can 
be analyzed to indirectly guide towards discerning between mRNA and lncRNA; certain codons for amino 
acids show preservation of protein-coding potential(111).  
 
 Certain RNAs classified as lncRNAs can contain ORFs by chance, and they might instead function 
solely as a ncRNA. On the other hand, if a lncRNA is identified to code for a protein it does not eliminate 
the possibility that it also has a critical non-coding function. Interestingly, there are specific bifunctional 
RNA that can have both protein-coding and coding-independent functions(123, 124). There are certain 
mRNAs that have regulatory non-coding RNA elements; for example, oskar RNA can act as a scaffold, 
independent of Oska protein(125). 
 
 Research techniques (such as mass spectroscopy proteomics and in vitro translation assays) can be 
used to identify lncRNAs that encode functional peptides. Ribosome footprint profiling can be used to 
visually show the direct binding of transcripts to ribosomes, and this technique specifically can be used to 
analyze lncRNAs in mammalian cells(126, 127). Software tools, such as the Coding-Potential Assessment 
Tool (CPAT)(128), can be used to predict the likelihood that a transcript can encode for a protein by 
analyzing an ORF for the presence of known protein motifs.  
  
 LncRNA - Tissue specificity and evolutionary conservation 
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 LncRNAs are typically tissue- and cell-type specific, even more than protein-coding genes(129-
132). Since many lncRNAs are expressed in certain tissues, this could be such that they have critical 
functions in the development and maintenance of that specific tissue. Alternatively, in 2015, a group 
conducted a pan-cancer analysis of lncRNAs from multiple tumor tissues to their matched normal 
counterparts and found a class of lncRNAs that are altered in multiple cancers. They classified these as 
'onco-lncRNAs' that are predicted to have conserved oncogenic and/or tumor suppressive across multiple 
cancer types(133).  
 
 Many lncRNAs have poor evolutionary conservation across species(134), but it is intriguing to 
characterize lncRNAs that are conserved and thus speculated to be critical for biological functions. 
Additionally, there are specific human lncRNAs that lack evolutionary conservation in non-human species, 
but are still functionally relevant in humans and should be studied further(134). LncRNAs have been 
identified in a variety of species, including yeast, viruses, and humans, but to further determine conservation 
of the lncRNA, samples from multiple species could be further analyzed for lncRNA expression. Lack of 
conservation does pose certain challenges in determining the research model for studying lncRNAs as many 
lncRNAs identified in non-human models have not progressed towards applicability in humans.  LncRNAs 
can be spliced to produce multiple isoforms, which creates challenges in that a certain lncRNA could be 
spliced differently in a certain species, tissues, and under certain cellular stresses, thus making it difficult 
to determine the biologically functionally isoform.  
 
 LncRNAs tend to exhibit poorer primary sequence conservation than mRNAs(134). Certain 
lncRNAs consist of highly repetitive sequences. The repetition of these elements can contribute to 
identification of function. For example, certain lncRNAs with Alu repeats can bind to hnRNPK and localize 
in the nucleus(135).   
 
 Secondary and tertiary structure are highly conserved and analyzing RNA structure could also help 
identify functionally important lncRNAs and their binding partners. LncRNAs are complex, high molecular 
weight molecules, which therefore makes crystallization difficult. The structure of an RNA can be 
determined by various in vitro and in vivo technologies, including dimethyl sulfate-sequencing (DMS-seq) 
and selective 2'-hydroxyl acylation analyzed by primer extension-sequencing (SHAPE-seq) (136). The 
presence of certain structural motifs can lead to the interaction with certain binding partners. For example, 
a G-rich motif in the lncRNA Braveheart interacts with certain nucleic acid binding partners such as a zinc-
finger transcription factor (137).  
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 LncRNA - Size, expression level, and stability 
 
 The size cut off of lncRNAs (>200 nucleotides) is an arbitrary cutoff that is used to separate from 
distinctly small ncRNAs. When comparing lncRNAs to mRNAs, lncRNAs tend to be shorter than mRNAs 
and have fewer but longer exons. Most lncRNAs range in size from less than 1kb (73%), between 1kb and 
2kb (14%), and more than 2kb (13%)(138). Few lncRNAs are exceptions in that they can span 100 
kilobases. For example, the promoter for the an antisense lnRNA Air (antisense Igf2r RNA) lies 107,796 
base pairs away from the 3' end, in an intron flanking the Mas1 gene(139). Tol determine RNA size, 
Northern Blot analysis can be conducted.   
 
 There are a variety of cellular stresses that regulate lncRNA expression, including, but not limited 
to, DNA damage(140), viral infection(141), and serum starvation (quiescence)(142). LncRNA expression 
levels are dysregulated in many diseases and their expression can correlate with clinical parameters (e.g. 
overall survival). Many lncRNAs are expressed at low expression levels compared to protein-coding 
mRNAs(108). This poses research challenges and the debate about if lncRNAs are expressed at high enough 
levels to be functionally important. The stoichiometry of a lncRNA to its target gene can predict the 
likelihood of this interaction having a critical importance. To determine relative expression level of a 
lncRNA, quantitative reverse polymerase chain reaction (qRT-PCR) can be used, and if absolute expression 
is desired, in vitro transcription followed by qRT-PCR can be used.  
 
 In 2012, Clark et al. compared the stability of mouse lncRNAs and mRNAs. Based on half-lives, 
lncRNA stability is comparable to, but on average less than, mRNAs. Intergenic and antisense lncRNAs 
that act in cis are more stable than those derived from introns. Additionally, spliced lncRNAs are more 
stable than unspliced (single exon) lncRNAs. LncRNAs localized in the nucleus are more likely to be 
unstable(143). Comparing lncRNAs to mRNAs, mRNAs are primarily degraded by 5'-to-3' exonuclease 
digestion in the nucleus or decapping at their 5' end in the cytoplasm, while many unstable lncRNAs are 
degraded by the nuclear exosome or nonsense-mediated decay (NMD) in the cytoplasm(144).  
  
 LncRNA - Cellular localization 
 
 Comparing lncRNAs to mRNAs, mRNAs usually localize to ribosomes in the cytoplasm while 
lncRNAs can vary in their localization. LncRNAs are primarily localized in the nucleus but can also localize 
in the cytoplasm(131) (Figure 7). The localization of lncRNAs primarily in the nucleus is consistent with 
lncRNAs main function of contributing to epigenetic regulation of gene expression in the nucleus(129). 
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Many lncRNAs are exported from the nucleus to the cytoplasm through the canonical mRNA pathway, via 
the major export complex TREX and NXF1/NXT1 nuclear transport receptor(145).  
 
 The sequence of an RNA determines if it is a substrate for retention in the nucleus or exportation 
to the cytoplasm(145, 146). There are specialized cis-elements in RNAs that can promote retention in the 
nucleus. During splicing of an RNA, the spliceosome recruits export factors to the RNA that can promote 
exportation. There are splicing-independent factors that instigate nuclear export via association with the 
same exportation factors(145).  
  
 Certain lncRNAs are restricted to localization in the nucleus. For example, the most abundant and 
conserved lncRNA is MALAT1 (metastasis-associated lung adenocarcinoma transcript 1), also known as 
nuclear-enriched abundant transcripts 2 (NEAT2). NEAT1 is also restricted to the nucleus and both NEAT 
lncRNAs interact with nuclear speckles in human cells (147). 
  
 Common technique to determine lncRNA cellular localization are cellular fractionation and RNA 
fluorescence in situ hybridization (FISH).    
 
 Alterations in mRNA localization are associated with various diseases. Under cellular stresses, 
nucleocytoplasmic transport is disrupted by sequestering critical transport factors into stress granules to 
exacerbate neurodegeneration(148). Thus, it is considered that lncRNA mis-localization could also be 
related to diseases. 
 
 Knowledge of lncRNA localization provides insight into interactions and functions. Nuclear 
lncRNA can regulate transcription and chromatin remodeling in various ways, as shown in Figure 6. They 
can regulate transcription by acting as enhancer RNA (eRNA) (Figure 7A), or interacting with and 
recruiting chromatin modifying complexes (Figure 7B) or transcription factors (Figure 7C). LncRNA can 
also be the mediators to spatially bring chromosomes in close proximity (Figure 7D) and pre-mRNA 
splicing (Figure 7E). Cytoplasmic lncRNAs can regulate mRNA stability (Figure 7F) or mRNA translation 
(Figure 7G). Linear and circular RNAs can bind to and sponge miRNAs (Figure 7H). Some lncRNAs 
contain small ORFs that can be translated to small peptides (Figure 7I).  
 
 LncRNA -Biological function 
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 Studying lncRNA biological function is critical, as lncRNAs already have been found to be 
associated with developmental processes (149) and dysregulation of lncRNAs is associated with 
diseases(150). Additionally, lncRNAs have been found to be involved with many biological processes, 
including proliferation, apoptosis, and differentiation by regulating gene expression, interacting with 
epigenetic modifiers, mRNA splicing and many others. LncRNA location can give a hint towards the 
function of a lncRNA, and some known nuclear and cytoplasmic functions are summarized in Figure 7. 
Broadly, lncRNAs molecular functions are subdivided into four categories: signals (HOTAIR), guides (Evf-
2)(151), decoys (GAS5), and scaffolds (ANRIL) (Figure 3). LncRNA commonly form ribonuceloprotein 
(RNP) complexes to control the location of protein regulators (Figures 3 and 7).   
  
 LncRNAs can act in cis in the nucleus, where they modify chromatin and/or regulate nearby gene 
expression, or in trans, where they leave the site of their transcription to perform biological functions. It 
can be difficult to determine the function of cis-acting lncRNAs as their expression can be directly, 
indirectly, or not important for downstream biological effects. The capability to act in cis makes them 
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unique from mRNAs, and allows lncRNAs to be involved in transcriptional regulation and chromosome 
looping.  
 
  Enhancer lncRNA 
 
 Figure 7A and 7D visually represent enhancer activity by a lncRNA. Recently, Miao et al. identified 
an enhancer lncRNA-mediated transcriptional regulation. The LEENE (lncRNA that enhances eNOS 
expression) lncRNA transcripts (located on chromosome 14) associates with the eNOS (endothelial nitric 
oxide synthase) locus (located in chromosome 7). Both chromosomes are brought into close proximity to 
permit the association and modulate eNOS mRNA synthesis(152).  
 
 Chromatin Remodeling 
 
 LncRNA can act as guides to recruit chromatin modifying enzymes to DNA to increase gene 
expression (Figures 7B and 3III). A recent study found that out of 3,300 human lincRNAs analyzed, 20% 
were bound by chromatin-modifying complexes including Polycomb Repressive Complex 2 (PRC2)(118). 
Certain lncRNAs can mediate chromatin remodeling in cis, while others can regulate in trans. In cis, 
transcribed lncRNAs such as Air can recruit the transcriptional repressive histone methyltransferase G9a to 
interact with the promoter of one of its imprinted genes Slc22a3 and silence Slc22a3 expression(153). In-
trans, lncRNA such as HOTAIR can act as a scaffold and bind to key PRC2 components (Suz12 and Ezh2) 
and the LSD1-coREST complex to methylate gene histones and promote gene silencing(154). 
 
 Interaction with Transcription Factors 
 
 Nuclear lncRNA can bind to transcription factors (Figure 7C) and guide them to DNA (Figure 3III) 
or away from DNA (Figure 3II) to regulate transcription. LncRNAs have been found to activate 
transcription, while others suppress transcription. One example of a lncRNA contributing to transcriptional 
activation is Evf-2 that is transcribed from an ultra-conserved enhancer, forms a stable complex with Dlx-
2, which consequently activates Dlx-2 to enhance transcription of Dlx-5/6(151). LncRNAs can repress 
transcription by binding to and sequestering transcription factors. An example of a lncRNA contributing to 
transcriptional repression is PANDA, which associates with the transcription factor NF-YA to act as decoy 
to keep NF-YA away from target gene chromatin. Due to this, pro-apoptotic genes are not expressed by 
NF-YA(155).  
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 Splicing Regulation 
 
 As shown in Figure 7E, lncRNA can regulate splicing. More specifically, lncRNAs can regulate 
alternative splicing and interact with splicing factor as recently summarized (156). MALAT1 controls the 
activity of the SR protein family of splicing factors to regulate alternative splicing(157). 
 
 mRNA Stability 
 
 Figure 7F visually shows that lncRNA can regulate mRNA stability. For example, the lncRNA 
LAST (lncRNA-assisted stabilization of transcripts) stabilizes CCND1 mRNA. c-Myc regulates the 
lncRNA LAST, which in collaboration with CNBP binds to the 5' UTR of CCND1 mRNA to protect against 
possible targeting by nuclease(158). 
 
 mRNA Translation 
 
 As shown in Figure 7G, lncRNA can regulate mRNA translation. For example, lincRNA-p21 
associates with JunB and β-catenin mRNAs and selectively decreases their translation by diminishing their 
polysomes (159). A lncRNA antisense to, and overlapping, the Uchl1 protein-coding gene was found to be 
required for Uchl1 translation. Furthermore, this was shown to be due to an embedded repetitive sequence 
(short interspersed nuclear element/SINE) in the lncRNA that regulates recruitment of polysomes to the 
mRNA for translation(115).  
 
 miRNA Regulation  
  
 As shown in Figure 7H, lncRNAs can interact with and sequester miRNAs and act as competing 
endogenous RNAs (ceRNAs). Multiple studies have analyzed for lncRNAs acting as miRNA sponges(160, 
161). Targetscan (targetscan.org)(162) can be used to predict miRNA targets, while spongeScan 
(http://spongescan.rc.ufl.edu) (163) can be used to specifically identify miRNA binding elements in 
lncRNA sequences.     
 
 p53-regulated lncRNAs 
 
 Expression of the tumor suppressor p53 correlates with many host lncRNAs and these lncRNAs 
were induced in a p53-dependent manner(164). Alternatively, lncRNAs regulate p53 expression levels. For 
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example, the nuclear lncRNA PURPL (p53 upregulated regulator of p53 levels) associates with MYBBP1A 
(a protein that binds to and stabilizes p53) to decrease p53 stabilization, decrease p53 basal expression 
levels, and promote tumorigenicity in colorectal cancer(165).   
 
 Overall, lncRNAs lack a standard classification framework, which makes categorizing and 
analyzing lncRNAs difficult. Currently, in an attempt to standardize this process, lncRNAs are primarily 
classified by genomic location and function.  
 
C. Circular ncRNAs 
 
  Circular ncRNAs - Overview 
 
 Circular RNAs (CircRNAs) are produced when precursor mRNA back-splice and the head to tail 
region bind each other. Due to their circular structure, they are thought to be stable as they would be resistant 
to degradation by exonucleases that typically degrade linear RNA. CircRNAs are typically cell- and tissue-
specific, fairly conserved, and expressed at low levels(166). They are, however, expressed in high levels in 
brain, indicating they have neuronal functions. Additionally, circRNAs play a role in pathological 
conditions such as development of cancer and other diseases. For example, circRNAs are associated with 
EMT-related functions(167).   
 
 Circular ncRNAs - Functions 
 
 The functions of circRNAs are currently being researched. Specific techniques are required to 
identify circRNAs, such that large scale high-throughput sequencing of ncRNAs looking for linear, polyA+ 
RNAs would not detect circRNA expression. When desired, circRNA detection efficiency of RNA-seq with 
a specific microarray platform could be used to efficiently profile circRNAs by circRNA microarray. Using 
a specific microarray platform, thousands of circRNAs could be detected in cell-free plasma samples(168). 
Some known functions are sequestering miRNAs and proteins, modulating transcription, interfering with 
splicing, and translating proteins (Figure 8).  
 
 CircRNAs can function as miRNA sponges, thus preventing the miRNA from targeting mRNA and 
permitting translation (Figure 8A). One of the most well-known circRNAs is ciRS-7 (also known as 
CDR1as), which contains 70 binding sites for miR-7 and has been identified as a miRNA inhibitor. 
Consequently, this regulation is involved with many different cancers since miR-7 directly targets several 
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oncogenes(169). Additionally, many other circRNAs acts as miRNA sponges. A testis-specific circRNA 
known as sex-determining region Y (circSry) serves as a miR-138 sponge to regulate testes development 
(170).  
 
 Exon-intron circRNAs (EIcircRNAs) can enhance transcription of their parental genes. For 
example, after EIcircRNA formation, it can interact with RNA Pol II and U1 snRNP to enhance 
transcription (Figure 8B). 
 
 CircRNAs can also act as a protein scaffold (Figure 8C) or bind and sequester proteins (Figure 8D) 
to particular cellular locations to modulate protein interactions(171). For example, circMbl can bind to the 
muscleblind (MBL) protein to regulate MBL function(172). 
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 Hundreds of endogenous circRNAs containing an internal ribosome entry site (IRES) and AUG 
start codon can interact with ribosomes and have translation abilities(173) (Figure 8E). Using human 
embryonic kidney 293 cells and HPV-18 positive cervical cancer cells (HeLa), a group identified 
dependence of N6-methyladenosine (m6A) motifs is the sequence of these circRNA molecules capable of 
translating proteins(174).   
 
 As host cells produced circRNAs, certain viruses also produce circRNAs.  For example, Epstein 
Barr virus (EBV) encodes latent and lytic viral circRNAs, some of which are dysregulated in stomach 
cancer samples(175). Kaposi's sarcoma herpesvirus also can encode viral circRNAs that are up-regulated 
during the lytic phase of infection and alter cell growth(176).  
 
D. LncRNAs - Clinical Implications  
 
 Currently, cervical cancer screening is the combination of high-risk HPV DNA testing with 
cytological morphological assessment during Pap smear. In the case of cervical cancer, identification of 
biomarkers associated with oncogenic progression would be useful. It is proposed by some that panels of 
epigenetic biomarkers (e.g. high CpG methylation rates of DAPK(177), CDH1(178), CCNA1(179), and 
CADM1(180)) analyzed during cervical cancer screening could be more beneficial predicters of oncogenic 
progression than standard methods. Certain epigenetic markers suggested are expressed in plasma or serum 
and can detect stages less invasively (DAPK(177) and CDH1(178)), while others are expressed in the tissue 
specimen to distinguish between stage and duration of disease (CCNA1(179) and CADM1(180)). 
Epigenetic alterations related to ncRNAs (including lncRNAs) contribute to cervical cancer and are being 
evaluated to determine disease progression and potentially target them for therapeutic benefit(181). 
 
 LncRNAs are strikingly more tissue specific than protein coding genes(129-132). Clinically, this 
allows for the advantage that these specific lncRNAs can be targeted for therapy to alter solely the tissue it 
is expressed in to reduce off-target effects. LncRNAs could be potentially targeted by multiple methods, 
including RNAi (siRNA), antisense oligonucleotides (ASOs), and small molecules(182, 183). Additionally, 
lncRNAs are being researched as clinical biomarkers for cancer detection and prognosis.   
 
 There are various basic science and clinical research studies being conducted to analyze for clinical 
potential of lncRNAs. For example, inhibiting the oncogenic lncRNA HOTAIR in vitro can inhibit cancer 
invasiveness, especially in cells with high PRC2 activity(184). Certain groups are working to identify a 
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gene signature to predict prognosis of cancer patients. One group specifically identified a prognostic 15-
lncRNA signature for cervical squamous cell carcinoma (CSCC) that are associated with patient 
survival(185).  There is a Phase 2/3 clinical trial designed to validate a previously identified and 
independently validated prognostic and predictive mRNA-lncRNA signature for triple-negative breast 
cancer (TNBC), which could be used to classify TNBC patients into high- or low-risk of recurrence. This 
signature was used to identify high-risk TNBC patients, such that this decision could influence the decision 
of alternative therapeutic treatments on this set of high-risk patients compared to low-risk. This study is 
actively recruiting patients (NCT02641847). A recently completed clinical trial is analyzing expression of 
various ncRNAs (lncRNAs, snRNAs, snoRNAs, miRNAs) in radiation-induced fibrosis in breast cancer 
patients. In addition to ncRNA expression, they are also analyzing for alterations pre- and post-radiation in 
cellular localization. This study was completed in 2018 (NCT03000764). 
 
 The idea of collecting a patient's body fluid (e.g. urine and blood) to analyze for expression of 
circulating lncRNA(s) has become intriguing in the field. It could eliminate the current invasive diagnostic 
and prognostic method to biopsy patient tissue. As examples, lncRNA PVT1 is a potential serum biomarker 
for detection of cervical cancer(186), and GAS5 is proposed as a diagnostic biomarker in non-small cell 
lung cancer(187). Excitingly, detection of lncRNAs in body fluids of patients has translated to being 
valuable to detect cancer in human patients. The lncRNA prostate cancer antigen 3 (PCA3) is leading the 
field of lncRNAs commercially available for cancer detection. The urine test PROGENSA PCA3 was FDA-
approved in 2012 for use in men who are considering repeat biopsy after an initially negative result for 
prostate cancer. It is considered to be more specific and effective in identifying prostate cancer than the 
prostate-specific antigen (PSA) urine test.  Certain clinical trials being conducted, in addition to their 
primary objective, are collecting blood/serum samples at diagnosis and later stages (e.g. at time of surgery, 
pre- and post-surgery) to detect alterations in lncRNA biomarkers. For example, a Phase 2/3 clinical trial 
to treat hormone receptor positive and triple-negative breast cancer (TNBC) is additionally collecting 
samples to test patients for angiogenic serum markers (miRNA, lncRNA, and circRNA) measured at 
diagnosis and time of surgery. This study is active, but currently not recruiting patients (NCT02221999).  
HOTAIR, as a single oncogenic lncRNA, expression is monitored in the peripheral blood of thyroid cancer 
patients. This study is not yet recruiting patients (NCT03469544). Analysis of ncRNA expression in 
exosomes is currently an actively pursued direction of clinical research. One newly posted clinical trial is 
currently recruiting patients to analyze ncRNA expression via genetic sequencing of miRNA/lncRNA in 
the exosome of epithelia ovarian cancer patients to determine biomarkers for detection and prognosis of 
patients. This study is currently recruiting patients(NCT03738319). Unfortunately, there are no results 
posted on clinicaltrials.gov for any lncRNA studies at this time. 
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IV. Human Papillomavirus (HPV) 
 
A. HPV - Overview 
 
 Human papillomavirus (HPV) is now recognized as one of the most prevalent sexually transmitted 
infection in the world. It is a member of the Papillomaviridae family, which is a group of small, non-
enveloped viruses with double stranded DNA circular genomes that are ~8 kilobase pairs. More specifically, 
HPV is classified as a mucosal alpha-virus. In the 1980s, Harald zur Hausen's group discovered that cervical 
carcinoma samples contained DNA from certain strains of HPV, which suggested HPV as a etiological 
factor in cervical cancer(188). A schematic of the HPV-mediated progression to carcinogenesis is presented 
in Figure 9. Upon micro-abrasions in cutaneous and mucosal sites, the basal layer of stratified squamous 
epithelia is exposed and the virus can infect keratinocytes. Infected cells in this region have a highly 
organized process of tissue renewal that viruses utilize to replicate and produce virions to infect other cells. 
In early stages of HPV infection, the viral genome is maintained in an episomal state; as the infected cells 
differentiate, the viral genome replicates in the nucleus of the infected cells using the host cells replication 
machinery. As the virus-infected cells differentiate and progress towards the surface of the epithelium, the 
virus replicates alongside the 
host cell in a differentiation-
dependent manner. Once the 
surface of an infected cell 
reaches the surface of the 
epithelium, virions are 
assembled and released to 
infect other target cells.  
  
 There are more than 
100 HPV strains, which are 
divided into the two subtypes 
high-risk and low-risk, 
depending on the clinical 
prognosis of lesions after HPV 
infection. Low-risk HPVs (e.g. 
HPV-6 and -11) can cause 
benign epithelial lesions and 
31 
 
are associated with 90% of genital warts. There are fifteen strains associated with cancer, and these are 
classified as high-risk HPVs (e.g. HPV-16 and -18). Each of these high-risk strains encode for 6 genes in 
the early region (E1, E2, E4, E5, E6, E7) and two genes in the late region (L1 and L2).  The genes encoded 
by the early region are responsible for modulating the cellular environment for viral replication and immune 
evasion, while the genes from the late region produce capsid, structural proteins(189).  
 
 As stated above, the viral genome is maintained in an episomal state in early HPV infection. While 
the genome is episomal, the E2 gene can repress the expression of the E6 and E7 oncogenes. However, 
upon persistent infection, over many years, the virus can integrate into the host genome. When integration 
occurs, the E2 gene is disrupted such that it cannot repress the promoter of E6 and E7, and there is a robust 
increase in the expression of these oncogenes. Up-regulation of E6 and E7 adds to carcinogenic progression 
because they contribute to the degradation of two important tumor suppressors p53 and Rb, 
respectively(189) (Figure 9). The co-expression of the oncogenes immortalizes the cells(190). After many 
years of persistent HPV infection, other mutations in host genes occur that transform the cells and contribute 
to formation of a tumor(191). In addition to viral infection, genetic mutations as well as epigenetic 
alterations contribute to carcinogenesis(181).   
 
 HPV infections are asymptomatic and usually cure spontaneously by the immune system; however, 
persistent high-risk infection is an etiological agent in a variety of different cancers. In the United States, 
there are more than 42,000 HPV-associated cancers each year related to cervical (91%), vaginal (75%), 
vulvar (69%), penile (63%), anal (91%) and oropharynx (70%) cancers in the United States. In 2012, 
worldwide, 4.5% of all cancers worldwide (1.2 million) are related to HPV infection, with 73% of these 
cases related to the two strains HPV-16 and -18 combined(192).  
 
 There are currently three FDA-approved prophylactic vaccinations against HPV infection. Gardasil 
9 protects against HPV-16 and -18, low-risk HPV-6 and -11, as well as five additional high-risk strains 
HPV-31, -33, -45, -52, and -58. Gardasil 9 has now replaced Gardasil (protects against HPV-16 and -18, as 
well as low-risk strains HPV-6 and -11). Cervarix protects against the two most carcinogenic strains (HPV-
16 and -18). A review published in 2017 summarizes these prophylactic vaccines in more detail, describing 
that Gardasil and Cervarix approach 90% effectiveness in preventing HPV-16/-18 infections in women 
older than 25 years(193).  
 
B. HPV - Viral Oncoproteins 
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 Both E6 and E7 are small (18 and 13 kDa, respectively) and primarily localize in the nucleus(194). 
Both proteins lack enzymatic activities and function instead by binding to other cellular factors. High-risk 
E7 alone can immortalize human keratinocytes, while E6 alone is not sufficient alone to immortalize 
primary cells; immortalization efficiency was increased when E6 and E7 were co-expressed(190). The 
combination of E6 and E7 is not sufficient to transform cells; additional oncogenes are required to induce 
tumorigenesis(191). These oncoproteins contribute to carcinogenesis both individually, but also by 
synergizing with each other(195). 
 
 Notably, the E6 and E7 proteins are not conserved between strains. For example, there is variability 
in p53 degradation activities between different HPV strains(196).  
 
 Both of the 
oncoproteins are involved 
with epigenetic regulation. 
E6 upregulates DNMT1 by 
suppression of p53(197). E7 
binds to DMNT1 to induce its 
DNA methyltransferase 
activity(198). One effect of 
this interaction is suppression 
of E-cadherin, which 
consequently decreases 
adhesion between epithelial 
cells(199). E6 can also 
regulate E-cadherin 
expression(200). E7 may be 
able to activate transcription of DNMT1 through the pRB/E2F pathway(201).  
 
 The HPV E6 oncoprotein downstream regulators are presented in Figure 10. The most well-known 
E6 regulation is that it interacts with E6 associated protein (E6AP) ubiquitin ligase that in turn binds to and 
degrades p53(202). This results in inhibition of p53 tumor suppressive functions in regulating growth arrest 
and apoptosis in response to aberrant proliferation. E6 can also abrogate p53 function by targeting the p53 
co-activator CBP-p300(203, 204). Additionally, E6 regulates a plethora of other proteins both directly and 
indirectly to contribute to regulate apoptosis, proliferation and immortalization to contribute to 
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carcinogenesis. E6 interacts with many proteins to activate transcription of telomerase reverse transcription 
(TERT); combined with Rb inactivation by E7, this is an essential step to immortalization.  E6 also mediates 
degradation of PDZ proteins, which leads to loss of cell polarity and induces hyperplasia.   
  
 Some known downstream effectors of HPV E7 are shown in Figure 11. E7 is most well-known for 
being involved in the regulation of retinoblastoma (Rb) family of proteins, contributing to cell cycle 
activation and proliferation downstream. E7 mediates pRB and pRB-related proteins (p107 and p130) 
destabilization by a proteasome-dependent mechanism. When E7 binds Rb, this dissociates the transcription 
factor E2F-1 that is bound to Rb such that unbound E2F-1 is free to drive expression of S phase genes and 
induce cell cycle activation and proliferation. E7 abrogation of Rb function leads to increased expression 
of the tumor suppressor p53. Consequently, E6 has evolved to target p53. E7 can also regulate many other 
proteins to influence genomic instability, apoptosis, and proliferation and contribute to carcinogenesis.  
 
V. LncRNAs in cervical cancer 
 
A. Cervical Cancer - Overview 
 
 Cervical cancer is one of the most common gynecological cancers. Worldwide, it is responsible for 
the second highest number of deaths in female cancers (exceeded only by breast cancer), as 10-15% of all 
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female cancer-related deaths were due to cervical cancer(205). 80% of patients have already developed 
invasive cancer at the time of diagnosis.  
 
 A combination of radiation therapy and low-dose chemotherapy is often used to treat early stages 
of cervical cancer. Alternatively, radiation therapy alone or surgery could be used for a small, early-stage 
tumor. Patients at high risk for recurrence could be administered radiation therapy and chemotherapy after 
surgery. Recurrent cervical cancer or patients with metastasis will be administered a combination therapy 
of platinum-based chemotherapy with the targeted therapy bevacizumab (Avastin) 
(https://www.cancer.net/cancer-types/cervical-cancer/treatment-options).  
 
 Identifying biomarkers for early detection as well as for prognosis are desirable. Somatic mutations 
in PIK3CA, PTEN, TP53, and KRAS are involved with the pathogenesis of cervical cancer(205). In the 
future, to predict, diagnose, and treat cervical cancer, it is proposed that utilizing lncRNAs could be 
beneficial. 
 
B. Host lncRNAs are altered in cervical cancer 
 
 Unfortunately, The Cancer Genome Atlas (TCGA) does not directly include all of the human 
lncRNAs. However, due to the identification of lncRNAs role in cancer, many databases have been 
developed to summarize specific lncRNAs expression correlated with survival. MD Anderson developed 
TANRIC (The Atlas of non-coding RNA in Cancer), which extracted RNA sequencing data from TCGA 
and provided lncRNA expression correlative to survival in cancer patients. Currently, there are 307 cases 
of cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) available 
(https://portal.gdc.cancer.gov/projects/TCGA-CESC).  
 
 There have been multiple analyses of global differential expression of host lncRNAs in cervical 
cancer that have assisted in identifying specific lncRNAs playing a role in cervical cancer. Interestingly, a 
single lncRNA could be oncogenic in one tissue type, but tumor suppressive in another tissue lineage. 
Expression changes of lncRNAs in cancer versus normal samples as well as how altering lncRNA 
expression affects cancer phenotype (e.g. proliferation, migration, invasion, etc.) are useful; however, 
further elucidation of specific mechanisms of their regulation is critical for applicability and clinical 
potential from these lncRNA studies. 
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 Host lncRNAs are altered at the three pre-malignant stages of cervical dysplasia as well as in 
established cervical cancer samples compared to normal samples. One group conducted differential 
lncRNA expression profile analysis between mild (CIN1), moderate (CIN2), and severe (CIN3) cervical 
dysplasia compared to non-neoplastic cervical tissue. Out of the 1,056 lncRNAs analyzed, 13 were 
aberrantly expressed in all three CIN stages(206).RNA-seq was performed on HPV-16 positive cervical 
cancer samples and matched adjacent non-tumor samples to identify differential expression of lncRNAs, 
circRNAs, miRNAs, and mRNAs in human patients, including 3 novel lncRNAs and 44 novel circRNAs. 
Additionally, this study analyzed the ceRNA network to show that each miRNA targeted multiple lncRNAs 
and circRNAs(207). In HPV-18 positive cervical cancer samples, the differential expression of circular 
RNAs with and without radiation was analyzed by RNA-seq. Further, the mechanistic role of these circular 
RNAs was evaluated in radioresistance. Circular RNA functions and pathways were analyzed, and more 
specifically circRNA-miRNA target gene interaction network studies were conducted(208).A recent study 
provided 41 microarray datasets and 10 RNA-seq data sets that can be analyzed for circRNA expression in 
cervical cancer(168). Overall, this provides resources that show host lncRNA alterations, as well as 
provides resources to extract host lncRNAs potentially involved in cervical cancer initiation and 
progression.   
 
 Many specific lncRNAs have been found to be involved in cervical cancer, some of which are 
HOTAIR, MALAT1, CCHE1, and lncRNA-EBIC(209, 210) and a summary of cervical cancer-related 
lncRNAs can be seen in Figure 12 below.  
  
 HOTAIR (Hox transcript antisense RNA) 
 
 HOTAIR is one of the most studied lncRNAs in cervical cancer. It is an oncogenic lincRNA that, 
in comparison to normal tissue, is up-regulated in many human cancers, including breast, gastric, colorectal, 
and cervical cancer(211-213). It interacts with the PRC2 complex leads to epigenetic regulation of many 
different cellular pathways(213). 
 
 In the context of cervical cancer, increased HOTAIR expression correlates with lymph node 
metastasis(211) and tumor size(211), tumor stage(212), and depth of cervical invasion(212). HOTAIR 
expression has been shown as a prognostic factor as high HOTAIR expression significantly correlated with 
poor overall survival(212) and disease-free survival/recurrence (211, 212) in cervical cancer patients. 
Knockdown of HOTAIR expression reduced cell proliferation, migration, and invasion in cervical cancer 
cell lines. HOTAIR could be exerting these oncogenic effects by regulating vascular endothelial growth 
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factor (VEGF), matrix metalloproteinase-9 (MMP-9), and epithelial-to-mesenchymal transition (EMT)-
related genes(211) (Figure 12a). HOTAIR also enhances radio-resistance by inhibiting p21 in cervical 
cancer(214). Thus, HOTAIR could be used as a prognostic marker or therapeutic target in cervical cancer. 
 
 MALAT1 (Metastasis-associated lung adenocarcinoma transcript 1)  
 
 LncRNA MALAT1 [also known as nuclear-enriched transcript 2 (NEAT2)] is dysregulated in 
many cancers, including lung(215) and cervical cancer(216). Depending on the cancer type, it can be 
oncogenic or tumor suppressive.  
 
 In the context of cervical cancer, MALAT1 is up-regulated in tumor tissues compared to adjacent 
normal tissue, and this high expression correlates with tumor size, stage, invasion, lymph node metastasis, 
and poor overall survival(217). MALAT1 is involved with cervical cancer cell proliferation, cell cycle, and 
invasion and can regulate gene expression of apoptotic regulations (e.g. Bcl-2 and caspase-3)(216). 
Furthermore, MALAT1 regulates cancer cell growth and invasion at least in part by regulating miR-124 
and its downstream target RBG2(218) (Figure 12f).  MALAT1 could be a diagnostic or prognostic marker 
in cervical cancer.   
 
 LncRNA-EBIC (EZH2-binding lncRNA in cervical cancer) 
 
 Sun et al. conducted a microarray analysis of lncRNA and mRNA differentially expressed in 
cervical cancer and paired peritumoral tissues. They identified 708 up- and 836 down-regulated lncRNAs, 
including the up-regulated lncRNA EBIC (also known as lncRNA-TI17313). This lncRNA plays a role in 
migration and invasion in cervical cancer cells. Additionally, lncRNA-EBIC binds to EZH2 to regulate 
transcription in cervical cancer, and this interaction is required for the repression of E-cadherin (tumor 
suppressor that inhibits epithelial to mesenchymal transition (EMT) and prevent malignant 
progression)(219) (Figure 12e). 
 
 ANRIL (Antisense non-coding RNA in the INK4 locus) 
 
 ANRIL lncRNA plays an oncogenic role in many cancers, including melanoma, osteosarcoma, and 
cervical cancer(220).High ANRIL expression in cervical cancer patients correlated with tumor, lymph node 
metastasis, and poor overall survival(220). ANRIL plays a role in cell proliferation, migration, and invasion 
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in cervical cancer(220) (Figure 12g). ANRIL can also promote cervical cancer developing by sponging 
miR-186(221).  
 
 HOXA11-AS (Homeobox A11 antisense) 
 
 Microarray analysis has been used to identify differential expression of lncRNAs in human cervical 
cancer tissue samples(222, 223).  A specific microarray analysis of mRNAs and lncRNAs expression 
identified differential lncRNA expression, number of differentially up- or down-regulated lncRNAs and 
mRNAs in each chromosome, and types (sense, antisense, intronic, intergenic, or bidirectional) of lncRNAs 
up- and down-regulated in cervical cancer(222). A specific microarray analysis identified HOXA11-AS 
lncRNA alteration in cervical cancer compared to normal cervix. Further analysis of this lncRNAs showed 
that HOXA11-AS is a regulator of HOXA11 that contributes to cervical cancer(223).  
 
  SNHG1 (Small nucleolar host gene 1) 
 
 Another group sent three pairs of cervical cancer tissue samples and corresponding adjacent normal 
samples for lncRNA microarray identify differential expression of lncRNAs. From this analysis, they 
identified that lncRNA SNHG1 is up-regulated in cervical cancer, and knockdown of this lncRNA resulted 
in a decrease in cell proliferation, migration, and invasion in both HPV-positive and HPV-negative cervical 
cancer cell lines(224). A recent review summarized that SNHG1 expression is up-regulated in at least 11 
types of cancers and contributes to proliferation, migration, and invasion of cancer cells; therefore, it is 
proposed to consider SNHG1 as a prognostic marker and/or therapeutic target(225).   
  
 LncRNA CCHE1(Cervical carcinoma high-expressed 1) 
  
 In cervical cancer, increased CCHE1 expression is associated with tumor size, stage, and poor 
survival(226, 227). CCHE1 is involved with proliferation and physically associates with proliferating cell 
nuclear antigen (PCNA) mRNA to enhance the PCNA expression (Figure 12h). Thus, CCHE1 could 
potentially serve as a diagnostic or prognostic marker in cervical cancer(227). 
 
 LncRNA CRNDE (Colorectal neoplasia differentially expressed RNA) 
 
 LncRNA CRNDE (colorectal neoplasia differentially expressed RNA) is altered many cancers, 
including colorectal cancer(228), glioma(229) and expression correlates with patient prognosis(230). Up-
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regulation of CRNDE expression in cervical cancer was determined from a lncRNA microarray analysis of 
cervical cancer tissues compared to normal adjacent tissues. Knockdown of CRNDE is HPV-positive and 
-negative cervical cancer cell lines decreased cell proliferation, migration, and invasion(231). Recently, 
CRNDE was found to be associated with poor prognosis in cervical cancer patients, and it targets 
PI3K/AKT to promote cervical cancer cell proliferation and inhibition of apoptosis(232). 
 
 MEG 3 (Maternally expressed gene 3) 
 
 MEG3 is a tumor suppressor that mediates p53 signaling and inhibits cell proliferation. It has been 
found to be down-regulated in a variety of human cancers, including cervical.  The MEG3 is a tumor 
suppressor in cervical cancer, as it inhibits cervical cancer cell proliferation through induction of cell cycle 
arrest and apoptosis(233) by regulating miR-21-5p(234) (Figure 12i).  
 
 BCAR4 (Breast cancer anti-estrogen resistance 4) 
 
 The lncRNA BCAR4 has been shown to enhance cell proliferation and promote metastasis in breast 
cancer by activating the HER2/3 pathway(235). Due to this, in cervical cancer, lapatinib (EGFR/HER2 
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inhibitor) BCAR4 lncRNA has been found to be associated with response to lapatinib in human 
patients(236).  
 
 LncRNA Loc554202 
 
 LncRNA Loc554202 is the host gene of miR-31(237). It has been shown to be involved in the 
development of breast(238), colorectal(239), and cervical cancer(240). Loc554202 exhibits higher 
expression in cervical cancer tissues than adjacent non-cancer tissues. High expression of the lncRNA 
correlates with poor overall survival, tumor size, stage, and lymph node metastasis. Knockdown of 
Loc554202 inhibits cell proliferation and induces apoptosis in cervical cancer cell lines(240).   
 
 H19  
 
 H19 can be oncogenic(241) or tumor suppressive (242), depending on the tissue lineage. In cervical 
cancer, it has been shown to be oncogenic and regulate cell proliferation(243). Additionally, in cervical 
cancer, H19 can sponge miR-138-5p to regulate proliferation and apoptosis(244). 
 
 GAS5 (growth arrest-specific transcript 5)  
 
 GAS5 is down-regulated in cervical cancer tissues as well as many other cancer types (e.g. 
breast(245) and lung(246))(247). GAS5 is a tumor suppressor lncRNA that when knocked down in vitro 
led to increased cell proliferation, migration, and invasion in cervical cancer (Figure 12d). The decrease in 
GAS5 expression significantly correlated with advanced cancer progression(248), thus GAS5 is considered 
a potentially useful biomarker for cervical cancer patients.  
 
 TUSC8 (tumor suppressor candidate 8) 
 
 Another tumor suppressor lincRNA in cervical cancer is TUSC8 (also known as XLOC_010588). 
In cervical cancer, TUSC8 expression is dramatically reduced, and this lower expression correlates with 
tumor stage and tumor size. With low TUSC8 expression in cervical cancer, c-myc is up-regulated and 
cervical cancer cells exhibit increased proliferation. Mechanistically, TUSC8 interacts with c-myc to 
consequently down-regulate c-Myc expression, and exogenous expression of TUSC8 in cervical cancer 
cells revealed decreased c-myc expression and decreased proliferation(249) (Figure 12c). Therefore, 
TUSC8 could be a potential therapeutic target in cervical cancer.  
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 LncRNA LET  
  
 LncRNA LET is down-regulated in cervical cancer, as well as many other cancers (colorectal, 
hepatocellular, and lung), and low expression correlates with poor overall survival. Decreased expression 
of lncRNA LET correlates with tumor stage and lymph node metastasis(250) such that it might be a useful 
prognostic marker and therapeutic target for cervical cancer (Figure 12b).   
 
 AC017078.1 and XLOC_011152 
 
 Recently, a group analyzed systemic lncRNA expression in serum from cervical cancer patients via 
microarray analysis. Further validation discovered two potential candidate lncRNA biomarkers whose 
expression was down-regulated in cervical cancer (AC017078.1 and XLOC_011152)(251). Further 
elucidation of circulating lncRNAs that could be used as blood-based biomarkers in cervical cancer 
diagnosis could be beneficial.   
 
 hsa_circ_0018289 
 
 Microarray analysis was used to identify differentially expressed circRNAs in cervical cancer 
tissues and reveal up-regulation of hsa_circ_0018289. Further analysis of this specific lncRNA showed its 
role in proliferation, migration, and invasion of cervical cancer cells as well as binding and sponging miR-
497 to contribute to cervical cancer(252).   
 
 hsa_circ_0023404 
 
 Hsa_circ_0023404 was shown to be up-regulated in cervical cancer tissue compared to normal 
tissue, and high expression of this circRNA correlated with poor overall survival. Knockdown of 
hsa_circ_0023404 reduced proliferation, migration, and invasion in cervical cancer cells. This circRNA 
binds to and sponges miR-136 such that the miRNA cannot regulate its target TFCP2, which consequently 
leads to activation of YAP signaling and cervical cancer progression(253). 
 
 circRNA-000284 
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 Another group conducted microarray analysis of cervical cancer cells (HPV-16 positive, HPV-18 
positive, and HPV-negative) compared to normal cervical cell line to identify differential circRNA 
expressions and more specifically identify circRNA-000284 as significantly up-regulated in all cervical 
cancer cell lines analyzed. This specific circRNA binds to and sponges miR-506 to promote proliferation 
and invasion in cervical cancer(254). 
 
 CircRNA8924 
 
 Human circRNA microarray V2.0 was used to identify up-regulation of circRNA8924 expression 
in cervical cancer tissues. Further studies showed the involvement of the circRNA in proliferation, invasion, 
and migration by competitively binding to miR-518d-5p/miR-519a-5p family to modulate CBX8 
expression in cervical cancer(255). 
 
 CircPAIP2 
 
 An intron containing circRNA (EIciRNA) circPAIP2 was shown to regulates memory-related 
genes through PABP reactivation in human cervical cancer cells(256). 
 
VI. LncRNAs regulated by HPV 
 
A. HPV-regulated host lncRNAs  
 
 Many host lncRNAs are dysregulated upon HPV infection with the entire HPV genome. A 2016 
review summarized lncRNAs that were altered upon HPV status, including many well-studied lncRNAs 
(e.g. XIST, H19, and MEG3) (DOI: 10.4137/ATV.S29816). CDKN2B-AS, EGOT (Eosinophil granule 
ontogeny transcript), NCRNA00185, PRINS (Psoriasis Susceptibility-related RNA Gene Induced by 
Stress), TTTY14, TTTY15, XIST, and LINC00152 were all identified to have altered expression in HPV 
active versus HPV negative oral tumor samples(257). LncRNA CCHE1 expression is correlated with HPV 
status in cervical cancer(226). Microarray analysis of HPV-16 positive cervical cancer cells compared to 
HPV-negative cervical cancer cells was conducted and 4750 differentially expressed lncRNAs were 
identified(258). RNA-seq analysis of HPV-16 positive tumor tissues compared to normal adjacent tissues 
identified lncRNAs and circRNAs that are differentially expressed(207). Nohata et al. conducted RNA-seq 
analysis of HPV-positive versus HPV-negative HNSCC tumors and identified 140 lncRNAs significantly 
differentially expressed between the groups. Multiple other molecular changes occur between HPV-positive 
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and -negative HNSCC samples, however, it can be speculated that HPV is contributing to alterations in 
lncRNA expression profiles(259). 
 
 Additionally, many host lncRNAs are regulated specifically by the sole presence of both the HPV 
E6 and E7 oncoproteins. MEG3, PCNA-AS, and H19 were all differentially expressed in human foreskin 
keratinocytes expressing HPV-16E6/E7(260). HPV proteins can alter mitochondrial lncRNA expression to 
potentially regulate the cell cycle. More specifically, HPV proteins induces the expression of a sense 
mitochondrial ncRNA (SncmtRNA-2)(261).  
 
 Certain lncRNAs can be altered solely by the expression of the HPV E6 oncoprotein. For example, 
CCEPR (Cervical carcinoma expressed PCNA regulatory) lncRNA expression is regulated by HPV E6 
oncoprotein to alter cell proliferation(262). Differential expression of lncRNAs was determined in human 
foreskin keratinocytes with and without HPV-16 E6 expression. FAM83H-AS1 expression is regulated by 
HPV-16 E6 oncoprotein in a p53-independent, p300-dependent manner. FAM83H-AS1 up-regulation 
altered cell proliferation and migration in HPV-16 positive cervical cancer cells (Chapter 2). 
 
 Alternatively, certain lncRNAs can be altered by the sole expression of the HPV E7 oncoprotein. 
A group conducted a study in the HPV-18 positive HeLa cervical cancer cell line where they knockdown 
HPV-18 E7 with siRNA and conducted lncRNA microarray analysis. They identified LINC01101 and 
LINC00277 whose expression increased with HPV-18 E7 knockdown. Both of these lncRNAs exhibited 
decreased expression in pre-cancerous lesion and cervical cancer compared to control tissues in a patient 
cohort of HPV-16 and -18 positive status. Additionally, lncRNA LINC01101 and LINC00277 expressions 
were significantly decreased in high-risk HPV-positive samples compared to HPV-negative samples; these 
two lncRNAs are more drastically decreased in HPV-18 samples than HPV-16, but both follow the same 
trend(263). CircRNA expression changes altered by the high-risk HPV-16 E7 oncoprotein were analyzed 
in a cervical cancer cell line (CaSki). More specifically, CaSki cells with knockdown of endogenous HPV-
16 E7 underwent microarray analysis to identify 352 up-regulated and 174 down-regulated circRNAs at 
least 2-fold change compared to control(264). HOTAIR expression in down-regulated in HPV-16 positive 
cervical cancer samples compared to HPV-negative normal samples(265). In cervical cancer, HOTAIR 
directly interacts with HPV-16 E7 and is inactivated by the HPV protein.  
 
 MALAT1 has been the most extensively studied HPV-regulated lncRNA. MALAT1 expression is 
increased in HPV-16 and HPV-18 positive human cervical cancer samples compared to normal human 
cervical samples(141, 218). Additionally, separating HPV-positive and HPV-negative samples, increased 
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MALAT1 expression correlated with HPV-positive status. In cervical cancer cells, MALAT1 has been 
shown to be involved in the regulation of miRNAs to contribute to carcinogenesis(218, 266). One group 
specifically showed that in high-risk HPV cervical cancer, MALAT1 expression is higher in radioresistant 
than radiosensitive cancer cases and that MALAT1 sponges miR-145 to mediate this radioresistance(267). 
Decreasing MALAT1 expression in cervical cancer cells altered proliferation and invasion(216). 
Knockdown of HPV-16 E6/E7 led to decreased MALAT1 expression, showing a potential E6/E7 regulation 
of MALAT1(141). Additionally, MALAT1 is up-regulated in oral keratinocytes expressing HPV-16 
E6/E7(268).   
 
 Overall, host lncRNAs are altered by individual expression of each of the HPV oncoproteins, co-
expression of both oncoproteins, as well as expression of the entire HPV genome. As miRNAs are altered 
by HPV to regulate the viral life cycle and additionally cause alterations that contribute to cancer, it is 
speculated that many lncRNAs are being altered by HPV for similar functions. 
 
B. HPV regulation of lncRNAs in cancer - Clinical implications 
 
 A clinical trial sponsored in China is currently recruiting uterine cervical adenocarcinoma patients 
to analyze multi-omics results of patients with and without HPV infection, with the goal of revealing the 
role of HPV integration in molecular mechanism(s) of tumorigenesis and prognosis of patients. They will 
analyze for changes in transcriptomics (lncRNA, miRNA, mRNA), whole-exome (DNA), and 
metabolomics (NCT03742869).  
 
VII. Oncogenic lncRNA FAM83H-AS1 (also known as 'onco-lncRNA-3')  
 
 In 2014, LCAL7 (lung cancer associated long non-coding RNA 7), which contains at least part of 
FAM83H-AS1, ENST00000533004, ENST00000534398, and ENST00000435097 in the genome, was first 
identified as up-regulated in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) 
human tissues compared to controls. LCAL7 is located in chr8: 144,823,553-144,828,510 and a partial 
sequence of LCAL7 was identified by 5' and 3' RACE in a lung cancer cell line and can be found in 
GenBank (accession number: KF773847)(269).  Overall, LCAL7 (containing a portion of FAM83H-AS1) 
is up-regulated in lung cancer. 
 
 In 2015, 'onco-lncRNA-3' expression was further analyzed using publicly available TCGA RNA-
seq data from tumors and matched normal tissues. Onco-lncRNA-3 is up-regulated in breast invasive 
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carcinoma (BRCA), colorectal and rectal cancer (CRC), lung adenocarcinoma (LUAD), and lung squamous 
cell carcinoma (LUSC). Additionally, analysis showed 'outlier' expression in head and neck squamous cell 
carcinoma (HNSC); 'outlier' referred to subset of patients from the certain cancer type exhibiting consistent 
gene expression changes. Onco-lncRNA-3 was not found to be altered in bladder urothelial carcinoma 
(BLCA), kidney renal cell carcinoma (KIRC), or uterine corpus endometrial carcinoma (UCEC). 
Functionally, onco-lncRNA-3 exhibited a 'guilt by association' effect as it was co-expressed with many 
protein coding genes involved in cell cycle regulation, such that it was speculated that onco-lncRNA-3 
plays a role in cell cycle progression. Onco-lncRNA-3 was shown to play a role in S-phase cell cycle in 
cancer as knockdown of the lncRNA in color cancer and lung cancer cells resulted in decreased EdU 
incorporation compared to control(133). In this study, onco-lncRNA-3 was found to be up-regulated in 
breast cancer, colorectal cancer, and lung cancer and plays a role in cell cycle progression. 
 
 Yang et al. identified FAM83H-AS1 (family with sequence similarity 83 member H-antisense 1) 
as the most up-regulated lncRNA in their RNA-seq analysis of breast cancer tissues compared to normal 
tissues. Additionally, analysis of 626 breast cancer samples compared to 105 non-cancerous breast tissues 
showed a significantly higher FAM83H-AS1 RPKM value in the cancerous tissues. Analyzing TCGA data 
from luminal subtype breast cancer patients revealed higher expression of FAM83H-AS1 correlates with 
poorer overall survival. Analyzing a TCGA cohort of breast cancer patients (containing all subtypes) 
revealed high expression of FAM83H-AS1 correlated with poorer overall survival(270). Taken together, 
FAM83H-AS1 is an independent prognostic marker in breast cancer. 
 
 Analysis of multiple colorectal cancer microarrays for differential expression of lncRNAs showed 
FAM83H-AS1 was the top up-regulated lncRNA analyzed in colorectal cancer (CRC) tissues compared to 
adjacent normal tissues. Further analysis of human colorectal cancer cell lines confirmed expression of 
FAM83H-AS1 in all but one cell line analyzed. High FAM83H-AS1 expression in CRC patients correlated 
with poorer overall survival than those with low FAM83H-AS1 expression(271). FAM83H-AS1 could be 
a potential prognosis biomarker in colorectal cancer patients.  
 
 RNA-seq analysis of LUAD tissues compared to controls in TCGA showed increased FAM83H-
AS1. Further studies analyzing FAM83H-AS1 expression in tumor versus adjacent normal tissue of the 
same lineage revealed significant up-regulation of FAM83H-AS1 in LUAD, lung large cell carcinoma 
(LULC), LUSC, bladder cancer, breast cancer, gastric cancer, head and neck cancer, and prostate cancer 
while no significant differences in kidney cancer, liver cancer, or thyroid cancer was observed in their 
analysis(272). Notably, data from a different study showed gastric cancer patients in TCGA revealed no 
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consistent differential expression of FAM83H-AS1(273). In lung cancer clinical patients, high expression 
of FAM83H-AS1 correlated with poorer patient survival. Functionally, knockdown of FAM83H-AS1 
expression in lung cancer cell lines decreased proliferation, migration, and invasion as well as decreased 
percentage of cells in S-phase of the cell cycle. Notably, proliferation was affected in most EGFR-mutated 
lung cancer cells. FAM83H-AS1 is primarily localized in the nucleus of lung cancer cells. Mechanistically, 
knockdown of FAM83H-AS1 decreased protein expression of MET, EGFR and their downstream proteins 
AKT and ERK1/2 in lung cancer cell lines. Notably, knockdown of FAM83H-AS1 regulated MET at the 
transcriptional and translational level(272). In lung cancer, FAM83H-AS1 could potentially be used as a 
diagnostic and prognostic marker or a therapeutic target to impact MET/EGFR signaling involved with cell 
proliferation and invasion.   
 
 RNA-seq data in TCGA of pancreas-adenocarcinoma ductal type (PDA) was analyzed for 
differential lncRNA expression. Analyzing relative enrichment in the stroma or epithelium identified 
FAM83H-AS1 as one of the top epithelial lncRNAs altered in their study. FAM83H-AS1 and the nearby 
protein coding gene FAM83H likely share the same promoter region, but are transcribed in opposite 
directions. FAM83H-AS1 is located in a genomic region frequently amplified in PDA (8q23.3-8q24.3), and 
its expression does in fact correlate significantly with amplification. Analysis indicates that is has four 
exons, and is located in an actively transcribed region in a pancreatic cancer cell line. FAM83H-AS1 
expression is shown to be up-regulated in PDA lines as well as a breast cancer cell line. Clinically, high 
expression of FAM83H-AS1 correlates with poorer overall survival in PDA. Knockdown of FAM83H-AS1 
in a pancreatic cancer cell line by two different siRNAs revealed 719 genes differentially expressed in cells 
with siRNA1 and siRNA2. Regulatory network analysis predicted 146 target genes of FAM83H-AS1 (78 
positive/activated and 68 negative/inhibited). Of these target genes, the negatively regulated targets were 
more associated with benign processes while positively regulated targets are associated with more 
malignant processes(274). Thus, FAM83H-AS1 is involved with malignant progression in pancreatic 
cancer.  
 
 Bi et al. identified FAM83H-AS1 is up-regulated in glioma tissues and cell lines compared to 
controls. FAM83H-AS1 expression significantly correlates with tumor grade. Patients with high FAM83H-
AS1 expression were associated with worse overall survival in glioma. High-grade tumors FAM83H-AS1 
expression correlates with patients' prognosis. FAM83H-AS1 expression could be an independent 
prognostic factor in glioma. Functionally, for the first time, a group expressed FAM83H-AS1 to observe 
functional alterations in the cells. Over-expression of FAM83H-AS1 in glioma cells increased cell viability 
and colony formation. Knockdown of FAM83H-AS1 in glioma cells reduced cell viability, colony 
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formation, percentage of cells in S-phase of the cell cycle, and cyclin-dependent kinases (CDK2, CDK4, 
CDK6), while it increased cellular apoptosis in glioma cells.  Additionally, knockdown of FAM83H-AS1 
in glioma cells resulted in increased CDK inhibitors CDKN1A (also known as p21) mRNA expression. 
FAM83H-AS1 is primarily localized in the nucleus and contributes to epigenetic transcriptional regulation 
of p21 expression by binding to EZH2 in glioma cells. Decrease in p21 expression potentially contributes 
to FAM83H-AS1 oncogenic function(275). Together, FAM83H-AS1 could be a prognostic marker in 
glioma patients, and/or therapeutically targeting FAM83H-AS1 and in turn modulating its downstream 
targets might improve glioma patient outcome.  
 
 FAM83H-AS1 expression is up-regulated in colorectal cancer (CRC) tissues and cells. In CRC 
clinical patients, FAM83H-AS1 expression correlates with tumor stage and size and high expression of 
FAM83H-AS1 is associated with decreased overall survival. Functionally, knockdown of FAM83H-AS1 
in colorectal cancer cells with specific short-hairpin RNA (shRNA) led to decreased proliferation, colony 
formation, and migration as well as increased cell apoptosis. Additionally, knockdown of FAM83H-AS1 
led to a decrease in Notch1 mRNA expression. Treatment of colorectal cancer cells with a widely used 
gamma-secretase inhibitor (DAPT) that represses receptors and ligands in the Notch signaling pathway 
(including Notch1) decreased FAM83H-AS1 expression. These results are indicative that FAM83H-AS1 
regulates through the Notch pathway.(276) Overall, analysis of FAM83H-AS1 expression in colorectal 
cancer tissues can act as an independent prognostic factor in colorectal carcinoma. Therapeutically targeting 
FAM83H-AS1 to modulate downstream Notch signaling might be clinically useful as Notch signaling is 
involved with regulation of cell proliferation, differentiation, and death.  
 
 Our group identified FAM83H-AS1 expression is up-regulated in cervical cancer tissues and cells, 
and clinical patients with high FAM83H-AS1 expression exhibited a significantly worse overall survival 
than those with low FAM83H-AS1 expression. Notably, in both cervical and HNSCC cells, FAM83H-AS1 
expression was significantly higher in HPV-positive compared to HPV-negative samples. Mechanistically, 
FAM83H-AS1 expression is regulated in a p53-independent and at least partially by HPV-16 E6 expression 
and p300 in cervical cancer. In cervical cancer cells, FAM83H-AS1 expression is primarily localized in the 
nucleus and does not appear to regulate its nearby protein coding gene FAM83H. Knockdown of FAM83H-
AS1 expression in cervical cancer cells decreased proliferation (and increased percentage of cells in the S-
phase of cell cycle), migration as well as increased apoptosis (Chapter 2). Together, FAM83H-AS1 could 
be a potential prognostic marker in cervical cancer, further studies could reveal that FAM83H-AS1 could 
be a diagnostic marker for HPV infection progression to cervical cancer, and therapeutically targeting 
FAM83H-AS1 could improve patient outcome.   
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 Overall, FAM83H-AS1 is up-regulated in many lung(133, 269, 272), breast(133, 270, 272), 
colorectal(133, 271, 276), pancreatic(274), glioma brain(275), bladder(272), prostate(272), and cervical 
cancers (Figure 13 and Chapter 2). FAM83H-AS1 expression is upregulated in certain gastric cancer(272) 
and HNSCC(272) studies, while others show variable alterations in gastric(273) and HNSCC(133) tissues. 
Thus, FAM83H-AS1 could potentially be a diagnostic marker in those cancers. High expression of 
FAM83H-AS1 correlates with worse overall survival in breast(270), colorectal(271, 276), lung(272), 
pancreatic(274), glioma brain(275), and cervical cancers (Chapter 2); therefore, FAM83H-AS1 could 
potentially be a prognostic marker in those cancer types. FAM83H-AS1 is mainly localized in the 
epithelium in pancreatic cancer cells(274) and specifically in the nucleus in lung cancer(272), cervical 
cancer (Chapter 2), and glioma brain cancer(275) cells. FAM83H-AS1 expression is up-regulated at least 
in part by HPV-16 E6 and p300 in cervical cancer cells (Chapter 2). Downstream, FAM83H-AS1 regulates 
Notch signaling in colorectal cancer(276), MET/EGFR signaling in lung cancer(272), and p21 expression 
in glioma(275). Further studies need to be conducted to determine if these upstream and downstream targets 
involved with FAM83H-AS1 expression are consistent between cancer types, and novel upstream and 
downstream regulators of FAM83H-AS1 expression need to be elucidated to increase therapeutic potential 
of targeting FAM83H-AS1.  
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I. Abstract  
  
 High-risk human papillomavirus (HPV) infection is one of the first events in the process of 
carcinogenesis in cervical and head and neck cancers. The expression of the viral oncoproteins E6 and E7 
are essential in this process by inactivating the tumor suppressor proteins p53 and Rb, respectively, in 
addition to their interactions with other host proteins. Non-coding RNAs, such as long non-coding RNAs 
(lncRNAs) have been found to be dysregulated in several cancers, suggesting an important role in 
tumorigenesis. In order to identify host lncRNAs affected by HPV infection, we expressed the high-risk 
HPV-16 E6 oncoprotein in primary human keratinocytes and measured the global lncRNA expression 
profile by high-throughput sequencing (RNA-seq). We found several host lncRNAs differentially 
expressed by E6 including GAS5, H19, and FAM83H-AS1.  Interestingly, FAM83H-AS1 was found 
overexpressed in HPV-16 positive cervical cancer cell lines in an HPV-16 E6-dependent manner but 
independently of p53 regulation. Furthermore, FAM83H-AS1 was found to be regulated through E6-p300 
pathway. Knockdown of FAM83H-AS1 by siRNAs decreased cellular proliferation, migration and 
increased apoptosis. FAM83H-AS1 was also found to be altered in human cervical cancer tissues and 
high expression of this lncRNA was associated with worse overall survival, suggesting an important role 
in cervical carcinogenesis.  
 
II. Introduction 
 
 High-risk HPV infection (e.g. HPV-16) is one of the most common causes of cervical cancer(1-
3), as well as a subset of head and neck squamous cell carcinoma (HNSCC)(1). The HPV oncoproteins 
E6 and E7 have been shown to contribute to carcinogenesis by modulating the degradation of human 
proteins, such as the tumor suppressors p53(4) and Rb(5) as well as a plethora of other cellular proteins(2, 
3, 6-8). The HPV-16 E6 protein can abrogate p53 function by proteasomal degradation as it forms a 
complex with E6-associated protein (E6AP)(9), or by targeting the p53 coactivator CBP-p300(8, 10). 
Upon transmission, HPV infects the undifferentiated keratinocytes at the basal layer of the stratified 
epithelia and its genome remains episomal maintaining low copy numbers. During the course of cancer 
development, the viral genome frequently becomes integrated into the host cell DNA(11). 
 
 The recent discovery of different classes of non-coding RNAs (ncRNAs) expressed in human 
cells has opened a new chapter in the understanding of cellular processes, such as chromatin remodeling, 
transcriptional control, and post-transcriptional regulation. One of these classes of ncRNAs called long 
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non-coding RNAs (lncRNAs) are defined as RNAs larger than 200 nucleotides that are not translated into 
proteins. Recent findings indicate that lncRNAs are involved in gene regulation at the transcriptional level 
by functioning as signal, guide, decoy, or scaffold RNAs(12-14). Dysregulation of lncRNAs occurs in a 
variety of cancers, suggesting a potential use of these ncRNAs as biomarkers for diagnosis, prognosis, 
stage of cancer, and response to therapy(15-18). LncRNAs have been shown to be altered in cervical 
cancer(19-21), however, only a few publications have studied lncRNAs that are specifically regulated by 
the HPV E6 oncoprotein, such as MALAT1 and CCEPR(22, 23). These lncRNAs were found altered in 
cervical cancer but it is unknown if these alterations are part of the early events in cervical carcinogenesis. 
A few studies have looked at aberrant expression of lncRNAs in progression from pre-malignant cervical 
intraepithelial neoplasia (CIN) to cervical cancer(24, 25). For these reasons, it is important to understand 
if certain lncRNAs are important in the first stages of immortalization and transformation caused by HPV 
infections.  
 
 In this study, we demonstrated that the lncRNA FAM83H-AS1 (also known as onco-lncRNA-3) 
is up-regulated in primary keratinocytes expressing HPV-16 oncogene E6 as well as HPV-16 positive 
human cervical cancer cell lines and cervical tumor samples. We show that FAM83H-AS1 is regulated by 
HPV-16 E6 through the presence of p300 instead of the tumor suppressor p53. Finally, we show that 
FAM83H-AS1 is involved with cellular proliferation, migration, and apoptosis and is associated with 
worse overall survival in cervical cancer patients.  
 
III. Results 
 
A. High-risk HPV-16 E6 oncoprotein alters host long non-coding RNAs in primary keratinocytes. 
 
 As an initial screen to identify host lncRNAs that are regulated specifically by HPV-16 E6, we 
developed a system to look specifically at the effect of E6 expression alone in primary human foreskin 
keratinocytes (HEKa). HEKa were infected with a retroviral vector expressing HPV-16 E6 oncogene or 
GFP as a control. After puromycin selection and stable expression of HPV-16 E6 was confirmed by RT-
PCR (Fig. S1), RNA was extracted, and samples were analyzed by RNA high-throughput sequencing 
(RNA-seq) to determine gene expression alterations in long non-coding RNAs (lncRNAs). Following 
bioinformatics analysis, we found 151 up- and 100 down-regulated host lncRNAs altered greater than 1.5-
fold change when HPV-16 E6 was expressed in HEKa cells compared to GFP control (Fig. 1A, Table 
S1). From these host lncRNAs, we randomly chose 8 up- and 8 down-regulated host lncRNAs to validate 
our RNA-seq data by qRT-PCR. The expression of all the lncRNAs selected for validation followed the 
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same trend of up- or down-regulation found by RNA-seq (Fig. 1B). In order to determine the importance 
of these 251 lncRNAs in cervical carcinogenesis, a variety of filtering methods were utilized to reduce 
our scope (see Methods section). After filtering, we performed preliminary experiments with many 
lncRNAs, however, some of our top altered lncRNAs from our RNAseq analysis of foreskin 
keratinocytes (HEKa) were not altered in cervical cells (HCK) with HPV-16 E6 expression (e.g. 
SNHG15). This is not surprising, as lncRNAs are known to typically be tissue specific(26). We also 
found differences in the expression of some lncRNAs between pre-malignant and cancerous cervical cells 
CaSki and W12/201402 to HCK (e.g. miR205HG). One of the up-regulated lncRNAs in our RNA-seq 
dataset, FAM83H-AS1 was intriguing. Its expression recently was found to correlate with poor overall 
survival in a variety of human cancers(27-32) but had not previously been shown in the context of 
cervical cancer. In addition, it was recently shown to be involved in regulating cellular processes 
associated with the hallmarks of cancer (e.g. proliferation and migration)(28, 31, 32).  To ensure that 
expression of FAM83H-AS1 is comparable to lncRNAs with well-known functions, we utilized our 
RNAseq dataset to compare their RPKM values (Table S2).  
 
B. FAM83H-AS1 expression is higher in HPV-16+ pre-malignant and cancerous samples.   
 
 Because many lncRNAs are known to be tissue specific(26) and our RNA-seq screening was 
performed with foreskin keratinocytes expressing HPV-16 E6 oncogene, it was critical to confirm the 
expression changes of FAM83H-AS1 in epithelial keratinocytes of the cervix where HPV naturally 
infects(11). Additionally, we considered that the E6 and E7 oncogenes can be synergistic with each 
other(33), so we needed to develop a model that closely mimics HPV infection by using the entire HPV-
16 genome. Therefore, primary human cervical keratinocytes (HCK) were transfected with the entire 
HPV-16 genome (by releasing the viral genome from a plasmid construct and circularizing it by ligation 
before transfection), then passaged several times (around 10-15 divisions) for growth selection of HPV 
positive immortalized cells. HPV-16 E6 and E7 expression was confirmed by RT-PCR (Fig. S2A), as 
well as p53 degradation through the HPV-16 E6 pathway by Western Blot (Fig. S2B). After confirmation 
of HPV-16 oncogene expression in these cells, we named them JAMM-16. It was confirmed by qRT-PCR 
that FAM83H-AS1 is also up-regulated in JAMM-16 cervical keratinocytes expressing the entire HPV-16 
genome in comparison to the parental cervical keratinocytes (Fig. 2A). We then used HPV-16 positive 
low-grade cervical (W12/20863 [episomal HPV-16], W12/201402 [integrated HPV-16]) and carcinoma 
(CaSki [integrated HPV-16]) cell lines to investigate the expression of FAM83H-AS1. As shown in 
Figure 2B, we found higher expression of FAM83H-AS1 in all the HPV-16 positive cell lines in 
comparison to HCK cells. Interestingly, FAM83H-AS1 was expressed at lower levels in HPV-negative 
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cervical cancer C33A cells compared to HCK as well as HPV-16 positive cervical cells (Fig. 2B). 
Furthermore, HPV-16 positive and HPV-negative head and neck squamous cell carcinoma (HNSCC) cell 
lines were compared, and higher expression of FAM83H-AS1 was observed in the HPV-16 positive 
versus the HPV-negative HNSCC (Fig. 2C). Overall, we conclude that presence of HPV-16 correlates 
with elevated levels of FAM83H-AS1 expression in early stages of cervical carcinogenesis (newly 
immortalized JAMM-16 cells and cervical low-grade pre-malignant cell lines) as well as cervical cancer 
and HNSCC cell lines.  
 
C. FAM83H-AS1 expression is regulated by HPV-16 E6 in a p53-independent, p300-dependent manner.  
  
 As shown in Figure 1, foreskin keratinocytes (HEKa) expressing HPV-16 E6 up-regulated 
FAM83H-AS1 expression. To further confirm HPV-16 E6 regulation of FAM83H-AS1 in cervical cells, 
cervical keratinocytes (HCK) stably expressing HPV-16 E6 were developed (Fig. S3). To measure if 
FAM83H-AS1 regulation could be affected by HPV-16 E7 oncogene in synergistic or antagonistic 
manner, we generated HCK stable cell lines expressing HPV-16 E7 or co-expressing HPV-16 E6 and E7 
(Fig. S3). FAM83H-AS1 was up-regulated when cells expressed HPV-16 E6 or HPV-16 E6 and E7, but 
not when they expressed HPV-16E7 alone (Fig. 3A) suggesting a specific regulation by E6. To further 
confirm these findings, HPV-16 E6 was knocked down in CaSki (Fig. 3B, Fig. S4A) and W12/201402 
(Fig. 3C, Fig. S4B) cell lines by two different siRNAs against HPV-16 E6-E7. FAM83H-AS1 expression 
was down-regulated after the reduction of HPV-16 E6 expression confirming the regulation of this 
lncRNA by HPV-16 E6. It is well known that one of the major HPV E6 targets is the tumor suppressor 
p53(34), which is involved in the regulation of cell proliferation, DNA repair, and apoptosis(35). 
Interestingly, when we knocked down p53 in HCK by using two different siRNAs, we observed that 
FAM83H-AS1 expression did not change (Fig. 3D, Fig. S4C), suggesting a regulation by HPV-16 E6 in a 
p53-independent manner. It is also known that HPV-16 E6 is able to regulate the expression of other 
important genes in carcinogenesis such as hTERT through the regulation of transcriptional coactivators 
such as p300(36). By using the UCSC Genome Browser (https://genome.ucsc.edu/) to investigate 
potential p300 binding site in the promoter region of FAM83H-AS1, we found three predicted p300 
binding sites (Fig. 3E). In order to measure the potential regulation of FAM83H-AS1 by p300, we used 
two siRNAs against p300 and quantified FAM83H-AS1 expression. When p300 was knocked down in 
primary cervical keratinocytes, FAM83H-AS1 expression was also reduced (Fig. 3F, Fig. S4D) 
suggesting direct and/or indirect p300 regulation of FAM83H-AS1. Previous publications have shown a 
greater affinity of HPV-16 E6 to interact with p300 in comparison with other high-risk HPV E6 such as 
HPV-18 E6(37). Interestingly, FAM83H-AS1 expression was found to be up-regulated in HPV-16 
68 
 
positive cell lines (Fig. 2), but down-regulated in HPV-18 positive HeLa cells and HPV-31b positive 
CIN-612 cells (Fig. S4E).  Altogether, we found that FAM83H-AS1 is regulated by HPV-16 E6 
independently of p53 but influenced by the presence of p300.  
 
D. FAM83H-AS1 is localized to the nucleus and does not regulate transcription of nearby FAM83H. 
  
 The cellular localization of lncRNAs can provide information on their potential function. Nuclear 
lncRNAs can regulate at the transcriptional level by interacting with critical epigenetic regulators and 
enhancing chromatin looping, as well as interact with splicing factors to regulate splicing(38). Meanwhile 
cytoplasmic lncRNAs have been found to function at the post-transcriptional level as competing 
endogenous RNAs by acting as microRNA sponges and binding to mRNAs leading to the recruitment of 
RNA binding proteins that promote decay, suppress translation, or factors that initiate translation(39). For 
this reason, we investigated the cellular localization of FAM83H-AS1 in two HPV-16 positive cervical 
cell lines by cellular fractionation. We used U6 as a nuclear RNA control and β-actin mature mRNA as a 
cytoplasmic RNA control. We found significantly higher amplification of FAM83H-AS1 in the nuclear 
fractions in comparison to the cytoplasmic fractions by qRT-PCR in CaSki (Fig. 4A) and W12/201402 
(Fig. 4B) cells, suggesting that FAM83H-AS1 is a nuclear lncRNA. Because many nuclear lncRNAs can 
act in cis(38), we hypothesized that FAM83H-AS1 could regulate its nearby protein coding gene 
FAM83H. The lncRNA FAM83H-AS1 and protein coding gene FAM83H share a promoter region but 
are transcribed in opposite directions(27) (Fig. 3E, Fig. S5). FAM83H is required for the organization of 
the keratin cytoskeleton in epithelial cells(40) and has been shown over-expressed in different tumor 
samples compared to their matching normal tissues(41). Interestingly, we found increased expression of 
FAM83H in HCK expressing HPV-16 E6 in comparison to parental HCK cells (Fig. S5B), but when we 
transfected an siRNA against FAM83H-AS1 in HPV-16 positive CaSki cells, we were unable to detect 
changes in FAM83H expression (Fig. S5C), suggesting that FAM83H-AS1 is not involved in regulation 
of FAM83H expression.  
 
E. FAM83H-AS1 knockdown in cervical cancer cells causes reduced cellular proliferation and migration, 
as well as induction of apoptosis.  
 
 To understand the significance of FAM83H-AS1 in cervical cancer cells, we analyzed the effects 
on cellular proliferation when FAM83H-AS1 was knocked down by siRNA in CaSki and W12/201402 
cervical cells. First, knockdown efficiency of a pool of 4 individual siRNAs (SMARTpool), as well as 
each of the individual siRNAs, was evaluated by qRT-PCR. Knockdown of FAM83H-AS1 in CaSki with 
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the siRNA SMARTpool was maintained over a time-course from 24 to 120 hours, which was sufficient 
for all functional assays conducted (Fig. S6). All of the individual siRNAs, as well as the SMARTpool 
showed greater than 51% knockdown of FAM83H-AS1 in CaSki (Fig. 5A) and greater than 49% in 
W12/201402 cells (Fig. S7A). Therefore, we decided to randomly choose two of the individual siRNAs 
and SMARTpool to knockdown FAM83H-AS1 and monitor cellular functional changes. Two siRNAs 
against FAM83H-AS1 were transfected independently into CaSki and W12/201402 cells, cultured for 48 
hours, and replated to measure cell proliferation by cell counting. In both CaSki and W12/201402 cells, 
we observed a decrease (≥48%) in cell number with knockdown of FAM83H-AS1 compared to control 
(Fig. 5B, Fig. S7B). Cellular proliferation assay (CCK-8) showed that there was a decrease in cellular 
proliferation when FAM83H-AS1 is knocked down in CaSki cells and W12/201402 as monitored from 
48 hours to 96 hours after replating. We found significantly less proliferation in CaSki (64% decrease) 
and W12/201402 (73% decrease) , in the siRNA FAM83H-AS1 knockdown compared to siRNA control 
cells at the 96-hour time point (Fig. 5C, Fig. S7C). We observed similar functional changes between the 
two individual siRNAs and the SMARTpool so for future functional assays we only used the siRNA 
SMARTpool. In order to identify changes in cell cycle that could explain the differences found in cellular 
proliferation after FAM83H-AS1 knockdown, we performed cell cycle flow cytometry analysis. CaSki 
and W12/201402 cells had a significant reduction (43% and 56%, respectively) of cells in S-phase when 
FAM83H-AS1 was knocked down in comparison to control suggesting that FAM83H-AS1 is important 
in the G2/S-phase transition (Fig. 5D, Fig. S7D). Other important hallmarks of cancer such as migration 
and resistance to apoptosis were measured after FAM83H-AS1 knockdown. We found that cellular 
migration was significantly decreased in CaSki and W12/201402 after siRNA knockdown of FAM83H-
AS1 compared to siRNA control  (Fig. 5E, Fig. S7E). Also, we measured a significant increase in early 
and late apoptosis in CaSki and W12/201402 cells with knockdown of FAM83H-AS1 compared to 
control cells by using Annexin V/PI staining and flow cytometry (Fig. 5F, Fig. S7F and S7G-H). 
W12/201402 cells with knockdown of FAM83H-AS1 showed a significant increase in necrosis (Fig. 
S7F), while only a slight increase in necrosis was observed in CaSki cells (Fig. 5F, Fig. S7H). Altogether, 
we observed significant alterations in cellular proliferation, cell cycle, migration, and apoptosis by the 
absence of FAM83H-AS1, suggesting an important role in cervical carcinogenesis.   
 
F. FAM83H-AS1 expression is increased in cervical cancer human tissues & is associated with worse 
overall survival.  
 
 In order to extrapolate our findings into a more clinically relevant setting, we extracted RNA 
from pre-malignant and cervical cancer patient samples and analyzed the expression of FAM83H-AS1 by 
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qRT-PCR. We found high expression of FAM83H-AS1 in the pre-malignant sample (CIN3) as well as 
the cervical cancer (CaCx) samples in comparison to normal cervix tissue (Fig. 6A). These findings 
corroborate our in vitro data suggesting an importance of FAM83H-AS1 in clinical tumor samples at 
different stages of carcinogenesis. We also took advantage of the cervical cancer samples deposit in the 
TCGA database to compare the expression of FAM83H-AS1 between normal cervix and cervical cancer 
samples obtained from different cancer stages (120 Stage I, 35 Stage II, 30 Stage III, 7 Stage IV, 4 Stage 
unavailable). The TCGA data showed elevated expression of FAM83H-AS1 (RPKM values) in cervical 
cancer patients compared to normal cervix control (Fig. 6B). This coincides with our previous 
observations of FAM83H-AS1 expression being higher in cervical cancer cells lines (Fig. 2B). Finally, 
we used the TCGA data set from the TANRIC database to divide cervical cancer patients into high versus 
low expression groups and measured overall survival based on FAM83H-AS1 expression. Interestingly, 
we found that patients with higher FAM83H-AS1 expression yielded a worse overall survival than 
patients with lower FAM83H-AS1 expression suggesting a biological importance of this lncRNA in 
cervical cancer reflected in patients' clinical outcomes (Fig. 6C). Overall, we conclude that FAM83H-
AS1 expression is elevated in cervical cancer patients and high expression correlates with overall poor 
survival. 
 
IV. Discussion 
 
 4.5% of all cancers worldwide are attributable to HPV infection. Almost all cervical cancers and 
a substantial amount of other anogenital and oropharyngeal cancers have been found to be infected by 
high-risk HPVs. HPV-16 and -18 contribute to 73% of HPV-associated cancers(42), implying a higher 
ability to induce tumorigenesis in comparison to other types of HPVs. Although the prevalence of HPV-
associated cancers has decreased due to development of the preventative vaccine and early detection 
screening methods(2), there is still a great need for prognostic and therapeutic options specially to people 
already infected with HPV as well as those affected in less developed countries where the access to the 
vaccine is limited.  
 
 Long noncoding RNAS (lncRNAs) have been shown to regulate a variety of critical cellular 
processes, including transcription and chromosome remodeling(12-14). Dysregulation of lncRNAs has 
been shown to be associated with the development and progression of many cancers(15-17), and 
interestingly they are commonly tissue specific(26) and only altered in one cancer type(32). Therefore, 
lncRNAs are currently being studied in the context of biomarkers for diagnosis and prognosis of cancer, 
as well as therapeutic targets(15-18).  
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 Previous studies have shown that the high-risk HPV E6 protein expressed is clearly involved in 
the progression of carcinogenesis. HPV E6-regulation of non-coding RNAs such as microRNAs has been 
well studied(43), however long non-coding RNA regulation by high-risk HPV E6 needs to be studied 
further; there are only a couple lncRNAs shown to be specifically HPV-16 E6 regulated, including 
MALAT1 and CCEPR(22, 23). To add to this field of study, we sought out to identify an HPV-16 E6 
regulated gene that was altered from the early stages of HPV infection until carcinogenesis and therefore 
we considered to be important in both the development and progression of carcinogenesis. Thus, we 
developed a new HPV-16 positive cell line referred to as JAMM-16 to represent early infection, but also 
analyzed expression in established HPV-16 positive cervical cell lines such as CaSki and W12 cells as 
well as pre-malignant and malignant cervical tumor samples. We found FAM83H-AS1 overexpression in 
W12/20863 and W12/201402 (which came from a CIN2 tumor) similar to CaSki cells (cervical 
carcinoma). Additionally, in Figure 6A, the CIN3 (considered Stage 0 cervical carcinoma) patient sample 
shows similar expression to later stage cervical carcinoma (CaCx) samples. For this reason, we believe 
that FAM83H-AS1 up-regulation in pre-malignant cervical samples could be linked to the expression of 
viral oncogenes in early HPV infection.  
 
 From the host lncRNAs altered by HPV-16 E6 in our RNA-seq analysis (Fig. 1), we found 
several of these lncRNAs previously described to be altered in cervical cancers, confirming that our data 
aligned with former studies. For example, it was previously found that decreased expression of GAS5 is 
associated with poor prognosis of cervical cancer patients(44, 45) as well as is tumor suppressive in other 
types of cancer such as breast cancer(46, 47) and prostate cancer(47). Furthermore, GAS5 expression was 
also found altered in vitro in HPV-16 positive CaSki cells(44) and HPV-18 positive HeLa cells(45). 
Another lncRNAs affected in our study was H19. It was shown previously that DNA methylation 
alterations at the IGF2/H19 imprinted domain may mediate the association between HPV and invasive 
cervical cancer(48) and high H19 expression has also been shown to be predictive of poor prognosis in 
cervical cancer(49) as well as in a variety of other human cancers, including HNSCC(50) and breast 
cancer(51).  
 
 A class of lncRNAs known as onco-lncRNAs were also interesting to us because, as the majority 
of lncRNAs are tissue specific(26), this group of lncRNAs exhibit differential expression across multiple 
cancers and are hypothesized to have conserved oncogenic or tumor suppressive functions. One such 
onco-lncRNA which was found in our RNA sequencing analysis of an E6-regulated lncRNA is onco-
lncRNA-3, referred to as FAM83H-AS1. This lncRNA is transcribed from chromosome 8 and its function 
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in normal cells is unknown. It was first characterized in 2015(32), and as of now multiple publications 
have shown increased expression of FAM83H-AS1 in breast(29, 32), lung(31, 32), colorectal(28, 30, 32), 
kidney(32), bladder(32), and pancreatic cancers(27) and increased expression correlates with worse 
overall survival in most of these cancers(27, 29-31).  Our findings show for the first time that FAM83H-
AS1 is overexpressed in human cervical cancer (CESC) tissues and high expression in patients correlates 
with poor overall survival (Fig. 6).  
 
 According to previous studies, FAM83H-AS1 is an epithelial lncRNA(27) supporting our data 
obtained from foreskin and cervical keratinocytes. Determining the localization of a lncRNA can predict 
functionality of the lncRNA; our findings that FAM83H-AS1 is localized in the nucleus of cervical 
cancer cells (Fig. 4) is consistent with previous findings of its nuclear localization in lung cancer cells14. 
Functionally, it has been found to be co-expressed with protein coding genes that were enriched for cell 
cycle-related genes(32), and knockdown of FAM83H-AS1 altered cell cycle(31, 32), proliferation(28, 
31), migration(28, 31), invasion(31), and apoptosis(28) in certain cancers. Our group shows here that in 
the context of cervical cancer, FAM83H-AS1 is involved in cell cycle, proliferation, migration, and 
apoptosis (Fig. 5). It is unknown if FAM83H-AS1 elicits its functions in cis or trans, but our findings 
suggest that FAM83H-AS1 does not elicit cis regulation on the nearby protein coding gene FAM83H 
(Fig. S5), which is up-regulated in a variety of human cancers. For this reason, it will be interesting in 
future studies to identify the protein, RNA, and/or DNA interactions of FAM83H-AS1 in cervical 
cancers.  
 
 Previously, it was shown that FAM83H-AS1 regulates MET/EGFR signaling in lung cancer 
cells(31) and that when FAM83H-AS1 was downregulated it exhibited an anti-proliferative role by 
suppressing the Notch signaling pathway in colorectal cancer(28). To elucidate additional downstream 
targets of FAM83H-AS1, a group recently conducted RNA-seq on a pancreatic cancer cell line with 
siRNA knockdown of FAM83H-AS1 compared to control and identified gene alterations (78 activated 
and 68 inhibited targets)(27). Our group plans to determine if these downstream regulators are also 
involved in FAM83H-AS1 mediated functional changes observed in cervical cancer cells.  
 
 HPV-16 E6 and -18 E6 are well known to contribute to the degradation of p53, however, it is 
important to note that HPV-16 and HPV-18 vary in their interactions with other proteins to regulate 
carcinogenesis. For example, previous studies have shown that HPV-16 E6 directly interacts with 
CBP/p300(8, 10, 37), but HPV-18 E6 appears to be unable to interact with p300(37). This could be a 
possible explanation for variation in FAM83H-AS1 expression between HPV-16 and -18 positive cancers 
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observed in our study (Fig. 2, Fig. S4E). Supporting our data, another publication previously showed low 
expression of FAM83H-AS1 in HeLa (HPV-18 positive) cells(27). This information led us to elucidate 
the mechanism of FAM83H-AS1 up-regulation by E6 in a p53-independent and p300-dependent manner 
(Fig. 3, Fig. S4). This regulation is interesting because the majority of E6 regulation of several coding and 
non-coding genes is primarily through the p53 pathway. Interestingly, a previous study showed that 
overexpression of cyclooxygenase (COX-2) gene was the result of the recruitment of p300 to its promoter 
region via the overexpression of HPV-16 E6 protein in CaSki cells as well as the exogenous expression of 
HPV-16 E6 in HPV-negative C-33A cells(52). Recently, p300 inhibitors such as C646 have been shown 
to be good candidates as anti-cervical cancer drugs, demonstrating the importance of p300 not only in the 
regulation of host genes but also of HPV viral genes(53). 
 
 In summary, the identification of FAM83H-AS1 up-regulation in the early stages of cervical 
carcinogenesis, correlation with overall survival in cervical cancer, and involvement in different 
hallmarks of cancer contributes further evidence of the importance of this lncRNA in cancer. Further 
studies on this lncRNA could enhance the use of FAM83H-AS1 as a potential biomarker or therapeutic 
target in multiple cancers.  
 
V. Methods 
 
 Detailed experimental protocols are described in the Supplementary Methods section. All 
experiments were performed in compliance with the Institutional Biosafety Committee at West Virginia 
University, number 15-03-03.  
 
A. Cells 
 
 The following cell lines were used: human primary foreskin keratinocytes (HEKa) (Invitrogen, C-
005-5C); human primary cervical keratinocytes (HCK) and J2-3T3 murine fibroblast feeder cells 
(obtained from Dr. Alison McBride's laboratory, NIH, Bethesda, MD); 3T3M murine fibroblast feeder 
cells, as well as CaSki (HPV-16 positive), HeLa (HPV-18 positive), and C-33A (HPV negative) cervical 
carcinoma cells (obtained from Dr. Daniel DiMaio's laboratory, Yale University, New Haven, CT); 
W12/201402 (HPV-16 positive) and W12/20863 (HPV-16 positive) pre-malignant cervical cells 
(obtained from Paul F. Lambert, University of Wisconsin-Madison, Madison, WI); CIN-612 (HPV-31b 
positive) (obtained from Dr. Laimonis A. Laimins' laboratory, Northwestern University, Chicago, IL); 
UMSCC-1 (HPV negative), UMSCC-47 (HPV-16 positive), and UMSCC-104 (HPV-16 positive) head 
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and neck squamous cell carcinoma (HNSCC) cell lines (obtained from Dr. Scott A. Weed's laboratory, 
West Virginia University, Morgantown, WV). Further details are in the Supplementary Methods section.  
 
B. High-throughput RNA sequencing 
  
 Three replicates each of human foreskin keratinocytes (HEKa) stably expressing HPV-16 E6 or 
GFP were sent for RNA high-throughput sequencing (Illumina). FASTQ files were subsequently 
imported into Strand NGS suites for analysis. Reads were aligned to the human hg19 reference genomes 
using the Bowtie algorithm. These were then quantified against Ensemble transcript and including small 
and lncRNA annotations. Any lncRNA that were detected in human subjects were used for further 
analysis. Raw lncRNA counts were then normalized to the total number of lncRNA reads per sample and 
expression values calculated against the control samples. Further Mapping rate visualization done using 
Strand NGS software. In order to determine the importance of the lncRNAs obtained from the RNA-seq 
analysis, we used the following filtering strategy: First, only lncRNAs with reasonable expression 
(RPKM greater than 1) were analyzed further. Then, we used The Atlas of Noncoding RNAs in Cancer 
(TANRIC, MD Anderson Cancer Center)(54), which contains 297 sequenced human cervical squamous 
cell carcinoma and endocervical adenocarcinoma (CESC) patient data from The Cancer Genome Atlas 
(TCGA), to analyze the expression and clinical outcomes of these lncRNAs in patient samples. Finally, 
we searched previous publications to identify lncRNAs altered in other types of cancer and/or involved in 
hallmarks of cancer. To increase our novelty, we eliminated lncRNAs that were previously shown to be 
involved specifically in cervical cancer (e.g. H19).  
 
C. Functional Analysis  
 
 For cell counting experiments, CaSki cells were transiently transfected with Lincode Human 
FAM83H-AS1 siRNA SMARTpool (Dharmacon, R-188909-00-000), Individual: Lincode FAM83H-AS1 
siRNA (N-188909-02-0002 and N-188909-04-0002), or Lincode Non-targeting siRNA #1 (Dharmacon, 
D-001320-01-05) using Lipofectamine® RNAiMAX according to manufacturer's instructions 
(Invitrogen). 
 
 CaSki cells were cultured with siRNA-containing media for 48 hours, re-plated in equal cell 
numbers (200,000 cells/well of 6-well), cultured for another 48 hours, and attached cells were re-counted 
with a hemacytometer.  
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 For all other functional assays (CCK-8 cell proliferation, FACS cell cycle, transwell migration, 
annexin V-FITC/PI apoptosis), CaSki cells were transiently transfected with Lincode Human FAM83H-
AS1 siRNA SMARTpool or Lincode Non-targeting siRNA #1 (Dharmacon, D-001320-01-05) using 
Lipofectamine® RNAiMAX according to manufacturer's instructions (Invitrogen). Cells were incubated 
with siRNA-containing media for 24 hours then re-plated in equal cell numbers for to initiate 
experiments described below. To monitor cell proliferation, transfected cells were plated in 96-well 
plates and after 24, 48, 72, and 96 hours analyzed with CCK-8 kit (Sigma-Aldrich) according to 
manufacturer's protocol. Alterations in cell cycle were determined by flow cytometry propidium 
iodide DNA staining. Transfected cells were plated in media containing 10% fetal bovine serum 
(FBS). Cells were allowed to attach and then were serum-starved for 24 hours. Samples were then 
fixed with ethanol, stained with propidium iodide, and analyzed by flow cytometry (Fortessa S10). For 
transwell migration assay, transfected cells were seeded onto upper chambers of transwell inserts 
(8µm pore size) with 20% FBS chemoattractant in the lower chamber of 24-well plate. After 48 hours, 
migrated cells located on the underside of the transwell insert were stained with 0.5% crystal violet in 
methanol. Migrated cells were quantified using ImageJ software. To monitor apoptosis, transfected 
cells were plated and incubated 24, 48, and 72 hours. At desired time point, attached and floating cells 
were pelleted and co-stained with annexin V-FITC and propidium iodine and immediately analyzed by 
flow cytometry (Fortessa S10).  
 
VI. Data Availability 
 
 The RNA-seq raw data generated during and/or analyzed during the current study are available in 
the Gene Expression Omnibus (GEO-NCBI) repository, accession number: GSE115334. 
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XI. Figure Legends:  
 
Figure 1: Differential expression of host lncRNAs after expression of HPV-16 E6 in primary foreskin 
keratinocytes. (A) Waterfall plot of host lncRNAs altered 1.5-fold or greater in primary foreskin 
keratinocytes (HEKa) expressing HPV-16 E6 compared to uninfected HEKa by high-throughput RNA 
sequencing (RNA-seq) analysis. Triplicates for each sample were sent for RNA-seq. (B) qRT-PCR 
validation of representative differentially expressed host lncRNAs found by RNA-seq analysis. Red bars 
represent the lncRNAs up-regulated with HPV-16 E6 expression, and green bars represent the lncRNAs 
down-regulated with HPV-16 E6 expression. GAPDH mRNA was used to normalize the qRT-PCR 
analyses, which are shown relative to uninfected HEKa (grey bars).  
 
Figure 2: Increased FAM83H-AS1 expression in primary cervical keratinocytes containing the HPV-16 
genome as well as in HPV-16 positive cervical cancer and head and neck squamous cell carcinoma cell 
lines. (A) qRT-PCR analysis showing the increase of FAM83H-AS1 expression in newly immortalized 
cervical keratinocytes expressing entire HPV-16 genome (JAMM-16) compared to uninfected primary 
cervical keratinocytes (HCK). (B) qRT-PCR analysis showing the increase of FAM83H-AS1 expression 
in HPV-16 positive cervical cell lines (CaSki, W12/20863, W12/201402) and decrease of FAM83H-AS1 
in HPV negative cervical cancer cell line (C-33A) compared to uninfected cervical keratinocytes (HCK). 
(C) qRT-PCR analysis showing the increase of FAM83H-AS1 expression in HPV-16 positive head and 
neck squamous cell carcinoma (HNSCC) cell lines (UMSCC-47 and UMSCC-104) compared to HPV 
negative HNSCC cell line (UMSCC-1). All graphs in the figure show the average of two individual 
experiments. Similar results were obtained in at least three independent experiments. GAPDH mRNA 
was used to normalize the qRT-PCR analyses. Two-tailed t test results are indicted as ** p ≤ 0.01. 
 
Figure 3: Regulation of FAM83H-AS1 expression by HPV-16 E6 in a p53-independent, p300-dependent 
manner. (A) FAM83H-AS1 expression by qRT-PCR analysis in cervical keratinocytes (HCK) stably 
individually expressing HPV-16 E6 or E7, or co-expressing E6/E7 compared to GFP control. (B-C) qRT-
PCR analysis of HPV-16 E6 and FAM83H-AS1 expression in HPV-16 positive CaSki (B) and 
W12/201402 (C) cervical cell lines transfected with an siRNA against HPV-16E6 compared to siRNA 
control. (D) qRT-PCR analysis of p53 and FAM83H-AS1 expression in HCK transfected with an siRNA 
against p53 compared to siRNA control. (E) Genome representative image showing location of FAM83H, 
FAM83H-AS1, and three predictive p300 binding sites in FAM83H-AS1 promoter region. (F) p300 and 
FAM83H-AS1 expression in HCK transfected with an siRNA against p300 compared to siRNA control. 
All graphs in the figure show the average of two individual experiments. Similar results were obtained in 
at least three independent experiments. GAPDH mRNA was used to normalize the qRT-PCR analyses. 
Two-tailed t test results are indicted as * p ≤ 0.05 and ** p ≤ 0.01. CTRL, control.  
 
Figure 4: FAM83H-AS1 is localized in the nucleus in cervical pre-malignant and cancerous cell lines. 
(A) qRT-PCR of FAM83H-AS1 expression in fractionated HPV-16 positive cervical cancer CaSki (A) 
and pre-malignant W12/201402 (B) cell lines. U6 small nuclear RNA (snRNA) was used as a nuclear 
control RNA and mature Beta Actin was used as a cytoplasmic control RNA. Representative images; 
similar results were obtained in at least three independent experiments. Normalization was done using C. 
Elegans total RNA as an exogenous spike for the amplification of worm-specific ama-1 gene. Two-tailed 
t test results are indicted as ** p ≤ 0.01. 
 
Figure 5: FAM83H-AS1 knockdown altered cell proliferation, migration, and apoptosis in CaSki cells. 
(A) Knockdown efficiency of individual and SMARTpool siRNA against FAM83H-AS1 in HPV-16 
positive CaSki cell line, measured by qRT-PCR analysis. Because of variations in the expression of 
GAPDH after the knockdown of FAM83H-AS1, we used UBC mRNA to normalize the qRT-PCR 
analyses. The graph shows average of two individual experiments. (B) CaSki cells were transfected with 
individual siRNAs against FAM83H-AS1, siRNA SMARTpool against FAM83H-AS1, or siRNA control 
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for 48 hours. Cells were then re-plated in equal numbers (200,000 cells/well, represented by dashed line 
in graph) and cultured another 48 hours prior to re-counting attached cells. Data were obtained in 
triplicate, and the graph shows the average of two individual experiments. (C) CaSki cells were 
transfected with individual siRNAs against FAM83H-AS1, siRNA SMARTpool against FAM83H-AS1, 
or siRNA control for 24 hours then plated in equal numbers. Transfected cells were analyzed for cellular 
proliferation assessment by CCK-8 assay at 48, 72, and 96 hours post-plating.  The graph shows the 
average of two individual experiments; similar results were obtained in three independent experiments. 
(D-F) CaSki cells were transfected with siRNA SMARTpool against FAM83H-AS1 or siRNA control for 
24 hours then plated in equal numbers for experiments. (D) Transfected cells were analyzed for cell cycle 
alterations by FACS analysis. CaSki cells with knockdown of FAM83H-AS1 exhibit less cells in S-phase 
of cell cycle compared to control cells. The graph shows the average of two individual experiments; 
similar results were obtained in three independent experiments. (E) Transwell migration of transfected 
cells was analyzed 48 hours post-plating in upper chamber with chemoattractant in lower chamber. The 
graph shows the average of three individual experiments. (F) Transfected CaSki cells were collected at 1, 
2, and 3 days post-plating, stained with Annexin V/PI, and analyzed by flow cytometry to show 
alterations in apoptosis compared to siRNA control. The graph shows the average of three individual 
experiments. Two-tailed t test results are indicted as * p ≤ 0.05 and ** p ≤ 0.01. 
 
Figure 6: FAM83H-AS1 expression is increased in human cervical cancer tissues and correlates with 
poor overall survival. (A) Increased FAM83H-AS1 expression in human cervical cancer and cervical 
intraepithelial neoplasia (CIN) stage 3 patient samples compared to non-cancerous cervical tissue as 
measured by qRT-PCR analysis. (B) The Cancer Genome Atlas (TCGA) analysis of FAM83H-AS1 
RPKM values in cervical cancer tissues (n=196) compared to non-cancerous tissues (n=3). (C) Survival 
plot of cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) patient data mined 
from TCGA with low (n=22) vs. high (n=174) expression of FAM83H-AS1. High expression of 
FAM83H-AS1 expression correlates with worse overall survival in CESC patients.  
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XII. Supplementary Tables  
 
Table S1: Host lncRNAs altered after expression of HPV-16 E6 in primary foreskin keratinocytes.  
 
Table shows details for each host lncRNA that was altered 1.5-fold or greater in primary foreskin keratinocytes (HEKa) 
expressing HPV-16 E6 compared to uninfected HEKa. Triplicates for each sample were sent for high-throughput RNA 
sequencing analysis. 
 
Gene ID Fold 
Change 
([HPV 
16E6 ] vs 
[Control]) 
Gene Symbol Chro
moso
me 
Start End Strand RPKM 
GFP 
Control
-1 
RPKM 
GFP 
Control
-2 
RPKM 
GFP 
Control
-3 
RPKM 
HPV-
16 E6-
1 
RPKM 
HPV-
16 E6-
2 
RPKM 
HPV-
16 E6-
3 
ENSG00000130600 4.99 H19 chr11 2016406 2022700 - 2.12904
93 
2.1426
256 
5.6363
993 
19.22
9809 
10.78
3182 
15.41
4708 
ENSG00000254236 3.54 KB-1639H6.2 chr8 104032415 104033656 - 0 0 0.2873
624 
3.250
996 
3.968
86 
3.449
8966 
ENSG00000244528 3.31 AC134873.1 chr2 243064438 243064620 + 1.27679
34 
2.8750
565 
2.7582
934 
6.186
408 
6.602
485 
9.019
768 
ENSG00000273413 3.07 RP11-
96C23.15 
chr10 88729994 88730583 - 8.39354
6 
0 0 4.790
1816 
7.013
6943 
7.246
6874 
ENSG00000228626 3.06 RP11-
495P10.9 
chr1 147760107 147761057 - 2.02880
84 
0.8839
2633 
2.2444
494 
6.981
7734 
5.038
5094 
3.696
5914 
ENSG00000230937 2.94 MIR205HG chr1 209602165 209606183 + 61.5482
64 
49.323
284 
62.656
292 
218.4
987 
181.1
5729 
121.9
17755 
ENSG00000254860 2.73 TMEM9B-AS1 chr11 8986222 8999074 + 0.80623
74 
1.7021
289 
0.6363
604 
4.052
271 
3.137
7754 
2.730
444 
ENSG00000249641 2.69 HOXC-AS5 chr12 54329112 54333427 - 0.95938
82 
1.8041
867 
0.9305
784 
3.716
362 
3.758
8704 
2.516
7224 
ENSG00000270168 2.56 LA16c-
380H5.4 
chr16 3051301 3052017 + 6.47689
87 
0.8551
222 
4.0893
016 
9.194
51 
7.053
4296 
6.857
7585 
ENSG00000235314 2.53 LINC00957 chr7 44078770 44081905 + 0.35596
678 
0.7332
8674 
0.7004
4947 
1.938
0348 
2.741
936 
3.045
2104 
ENSG00000230409 2.50 TCEA1P2 chr3 37317087 37318089 + 7.46950
8 
9.5921
29 
10.218
497 
22.00
8438 
24.91
3902 
20.84
6043 
ENSG00000233223 2.45 AC113189.5 chr17 7485282 7487390 - 1.45960
63 
2.9885
232 
2.0333
843 
3.720
071 
5.512
9123 
6.323
3705 
ENSG00000254192 2.36 CTC-558O2.2 chr5 168081518 168094766 + 1.23549
65 
0.9035
5885 
1.6458
715 
3.684
764 
2.919
8492 
2.477
2859 
ENSG00000251580 2.35 RP11-
539L10.3 
chr4 6672452 6675557 - 0.83309 1.3336
157 
1.0557
044 
2.159
164 
2.004
1137 
4.219
327 
ENSG00000220804 2.29 AC093642.5 chr2 243030784 243102304 + 1.02285
7 
1.6583
912 
2.8178
344 
4.230
8583 
2.589
8807 
5.207
1075 
ENSG00000201428 2.28 RN7SKP71 chr12 112704881 112705198 + 0.05682
099 
0.2640
6604 
0.3352
5583 
0.033
64112
6 
0.464
84584 
11.79
032 
ENSG00000238107 2.27 RP11-
495P10.5 
chr1 147767287 147769663 + 1.19644
03 
0.5992
599 
0.7781
85 
3.452
5478 
1.896
4818 
2.127
1327 
ENSG00000228463 2.25 AP006222.2 chr1 227615 267253 - 0.92179
984 
1.8147
042 
2.4698
875 
3.840
908 
3.520
3686 
3.766
3238 
ENSG00000263934 2.22 SNORD3A chr17 19091329 19092027 + 56.5595
66 
96.541
93 
87.400
215 
115.8
12065 
101.6
3637 
442.5
1657 
ENSG00000267984 2.21 CTD-
2616J11.9 
chr19 51848423 51856547 + 0.03900
8502 
0 0 0.093
65486 
0 10.77
701 
ENSG00000200488 2.18 RN7SKP203 chr2 76672205 76672536 - 0.39458
07 
2.4766
135 
0.8919
96 
1.181
4926 
0.604
2596 
21.76
185 
ENSG00000255717 2.13 SNHG1 chr11 62619460 62623386 - 7.09001
87 
3.8827
178 
5.6702
17 
13.07
7036 
11.90
0302 
9.669
952 
ENSG00000259001 2.12 RPPH1 chr14 20811207 20811844 - 15.0019
23 
52.592
74 
31.222
376 
27.47
0306 
36.77
239 
231.4
2776 
ENSG00000234741 2.10 GAS5 chr1 173833038 173838020 - 75.5498 34.682 63.601 141.4 116.2 93.72
99 
 
6 1 818 7461 6347 997 
ENSG00000215039 2.08 CD27-AS1 chr12 6548167 6560733 - 0.66829
19 
0.8538
55 
0.8496
1987 
3.074
375 
1.768
162 
1.665
7759 
ENSG00000259970 2.06 AC099668.5 chr3 49721913 49722416 - 0.57804
507 
1.3075
932 
0.8779
387 
2.843
681 
2.354
5742 
1.696
4713 
ENSG00000254578 2.04 CTD-
2517M22.16 
chr8 145689200 145690484 + 2.56431
48 
1.6997
473 
2.1004
875 
4.821
358 
4.543
132 
3.554
0457 
ENSG00000202198 2.04 RN7SK chr6 52860418 52860748 + 77.7898
2 
202.92
421 
175.02
835 
174.8
5051 
183.0
6963 
733.0
992 
ENSG00000255831 2.04 AL139385.1 chr13 111291555 111292340 + 0 2.5623
991 
0 0 5.166
7576 
4.200
331 
ENSG00000271992 2.02 RP11-42O15.3 chr1 70910754 70911219 + 0.34897
357 
0.0900
998 
0.8007
2904 
2.295
6822 
1.722
0101 
2.083
4737 
ENSG00000227195 2.01 MIR663A chr20 26167556 26232162 - 0.89503
71 
1.0255
735 
1.4251
992 
1.545
9784 
1.247
556 
6.125
4115 
ENSG00000239002 1.98 SCARNA10 chr12 6619388 6619717 + 0.54754
776 
1.9084
775 
1.3999
47 
1.167
0413 
2.879
6296 
6.134
6283 
ENSG00000263917 1.97 RP11-53I6.2 chr18 29598792 29691742 + 1.69259
02 
0.7714
8676 
1.5012
345 
1.865
241 
3.775
4347 
2.767
804 
ENSG00000266929 1.96 RP11-
400F19.8 
chr17 40688528 40714080 + 2.64025
28 
2.2248
166 
2.0022
075 
4.118
1316 
4.623
1112 
4.685
91 
ENSG00000223891 1.96 OSER1-AS1 chr20 42839600 42854667 + 0.42706
716 
1.3540
938 
1.7394
654 
2.074
9772 
3.062
2957 
2.806
612 
ENSG00000244879 1.96 GABPB1-AS1 chr15 50647525 50659636 + 1.49664
08 
1.0193
752 
1.1708
221 
2.835
0017 
2.036
269 
2.337
8665 
ENSG00000225976 1.96 RP11-
192N10.2 
chr10 29986832 29987157 + 4.10156
9 
1.4167
225 
3.0522
678 
4.856
7057 
5.441
2627 
5.069
306 
ENSG00000259827 1.95 RP11-
343H19.2 
chr16 56716382 56721719 + 3.48532
18 
2.4112
535 
2.5835
383 
3.920
711 
3.862
1109 
10.60
9867 
ENSG00000235499 1.95 AC073046.25 chr2 74212259 74213470 + 4.49410
3 
3.1759
024 
2.5058
224 
6.528
4495 
5.577
129 
7.256
5813 
ENSG00000258377 1.94 RP11-649E7.5 chr14 50087533 50090198 - 0 3.7360
387 
4.1599
88 
5.070
155 
4.762
3515 
4.735
923 
ENSG00000233825 1.94 RP11-
135A24.4 
chr10 32635427 32636107 + 2.00523
7 
0.9287
9003 
1.8029
468 
2.122
1492 
3.477
26 
3.551
1832 
ENSG00000269926 1.93 RP11-
442H21.2 
chr10 74034673 74035738 - 37.1678
16 
17.135
89 
27.302
435 
56.37
6045 
53.58
8455 
41.68
311 
ENSG00000261824 1.91 LINC00662 chr19 28175488 28284848 - 1.77218
08 
0.9460
5726 
1.4761
61 
3.744
9877 
2.442
1446 
1.996
9538 
ENSG00000267317 1.90 CTB-25B13.12 chr19 1457664 1462764 - 0.77052
76 
2.7577
708 
2.0533
23 
3.240
5212 
3.709
7907 
3.223
024 
ENSG00000179859 1.89 AC025335.1 chr17 7816642 7819271 - 2.48756
43 
3.6358
418 
4.2272
625 
7.583
128 
6.336
298 
5.399
1914 
ENSG00000257653 1.87 RP11-579D7.2 chr12 49159977 49161106 + 0.70771
77 
1.0421
093 
1.3791
414 
2.705
9877 
1.943
5432 
1.797
2413 
ENSG00000238271 1.87 IFNWP19 chr9 21455483 21456048 + 6.09118
27 
4.1468
25 
6.1276
43 
10.78
6538 
8.897
233 
10.57
8037 
ENSG00000224032 1.87 EPB41L4A-AS1 chr5 111496223 111499973 + 7.39583
83 
3.9629
142 
7.1221
61 
9.977
508 
12.22
6742 
11.20
5975 
ENSG00000257270 1.87 RP11-
521B24.5 
chr14 105934130 105936954 - 6.40190
6 
3.2108
22 
3.5815
47 
8.843
35 
7.365
5524 
7.390
7046 
ENSG00000257084 1.86 U47924.27 chr12 7072409 7073610 + 31.198 36.405
44 
20.322
99 
53.07
6824 
61.99
1566 
44.91
036 
ENSG00000225377 1.85 RP5-1103G7.4 chr20 300957 328868 - 2.56064
6 
3.4069
042 
5.1782
656 
6.993
363 
5.695
6306 
7.200
583 
ENSG00000239470 1.84 RP11-16F15.2 chr11 9681946 9682503 + 6.97289
23 
3.0191
91 
4.1343
21 
10.61
4801 
8.628
567 
5.930
6784 
ENSG00000198496 1.84 NBR2 chr17 41277627 41305688 + 0.83190
143 
1.0633
509 
1.4072
425 
2.247
7791 
2.288
2934 
1.808
5096 
ENSG00000203499 1.84 FAM83H-AS1 chr8 144816310 144828507 + 9.59697
8 
3.3299
105 
4.7020
435 
12.95
5384 
9.471
8895 
7.570
58 
ENSG00000177410 1.83 ZFAS1 chr20 47894715 47905797 + 211.102
16 
139.73
38 
252.70
905 
418.7
3697 
367.0
7626 
297.5
4745 
100 
 
ENSG00000224891 1.83 AC007899.3 chr2 37375673 37376447 + 4.01025
72 
2.9299
183 
3.7727
127 
6.872
386 
6.110
306 
6.431
074 
ENSG00000214293 1.82 RSBN1L-AS1 chr7 77286977 77325582 - 1.88850
9 
1.6980
832 
1.8871
909 
3.833
9822 
3.262
9604 
2.897
0351 
ENSG00000250902 1.81 RP11-
301H24.4 
chr4 146435767 146438270 - 6.98976
66 
3.0939
543 
5.3921
43 
10.33
7118 
8.141
412 
8.172
936 
ENSG00000259375 1.81 RP11-
815J21.2 
chr15 86122277 86123409 - 1.83370
24 
1.1494
807 
1.1902
504 
1.597
2154 
2.884
9528 
3.210
236 
ENSG00000012171 1.80 SEMA3B chr3 50304990 50314977 + 0.94935
43 
0.3429
1044 
1.0639
977 
2.247
6633 
1.790
5937 
1.540
2615 
ENSG00000273344 1.79 PAXIP1-AS1 chr7 154795158 154797413 + 1.07325
18 
2.6334
62 
2.4573
538 
3.006
4073 
3.060
8828 
4.358
569 
ENSG00000260552 1.79 RP11-49I11.1 chr18 33759959 33767411 - 1.30548
33 
2.1372
445 
4.7266
11 
3.969
9843 
6.068
1834 
3.154
5815 
ENSG00000243004 1.79 AC005062.2 chr7 19958604 20180076 - 4.87558
13 
7.2985
44 
3.9218
314 
6.931
1867 
14.13
0893 
8.209
532 
ENSG00000196756 1.78 SNHG17 chr20 37049235 37063996 - 2.54244
57 
1.8823
376 
4.6329
513 
4.370
9865 
5.745
9593 
5.005
6214 
ENSG00000272906 1.78 RP11-
533E19.7 
chr1 179850742 179851730 - 0.29894
31 
1.2788
76 
1.0368
878 
1.577
8978 
1.703
776 
2.794
0536 
ENSG00000261771 1.78 DYX1C1-
CCPG1 
chr15 55647446 55790558 - 2.09689
38 
2.6955
016 
2.8982
72 
5.290
535 
4.608
052 
3.804
3263 
ENSG00000204054 1.78 LINC00963 chr9 132245730 132275947 + 1.01223
13 
0.8181
0194 
0.7509
8056 
2.690
7895 
1.890
5445 
1.125
3008 
ENSG00000269893 1.78 SNHG8 chr4 119199864 119200978 + 95.6830
75 
85.640
51 
110.78
4874 
193.3
1099 
208.9
9217 
126.6
07704 
ENSG00000269900 1.78 RMRP chr9 35657748 35658015 - 61.7190
86 
117.54
486 
105.27
629 
99.84
465 
121.5
6224 
352.0
1825 
ENSG00000265735 1.76 RN7SL5P chr9 9442060 9442347 + 89.3426
7 
171.01
642 
175.36
769 
146.4
969 
160.5
5365 
623.5
067 
ENSG00000229413 1.75 AC018638.1 chr7 128293740 128293989 - 2.08112
76 
0.8533
8426 
0.6139
542 
2.203
358 
1.459
3241 
3.445
703 
ENSG00000250299 1.74 MRPS31P4 chr13 53191693 53211581 + 0.99767
58 
0.6966
341 
0.8349
367 
2.199
7466 
1.885
6709 
1.279
5835 
ENSG00000226419 1.74 RP11-31F15.1 chr1 113499037 113542118 + 3.05203
82 
2.3166
275 
2.4479
396 
5.745
393 
4.417
4857 
3.588
944 
ENSG00000245060 1.74 LINC00847 chr5 180257957 180262726 + 2.51798
3 
1.9512
683 
1.9726
743 
3.667
7196 
3.663
7437 
3.780
457 
ENSG00000110811 1.73 LEPREL2 chr12 6937572 6949018 + 1.43181
74 
1.6433
642 
1.4975
213 
3.065
626 
2.159
1876 
2.762
544 
ENSG00000262160 1.73 RP11-96D1.11 chr16 68259872 68263048 - 1.01642
31 
1.7172
104 
1.3368
715 
2.896
4238 
2.114
6343 
1.976
8672 
ENSG00000250251 1.73 PKD1P6 chr16 15219099 15248421 - 4.10675
76 
2.8266
087 
4.4332
04 
4.759
571 
5.149
509 
10.82
3436 
ENSG00000203512 1.72 AL353662.2 chr9 34195642 34195883 + 1.73161
97 
0.8091
1475 
1.1475
528 
3.164
7897 
1.525
1368 
2.108
7782 
ENSG00000227615 1.72 RP11-864N7.2 chr11 74456761 74457159 - 6.18152
57 
1.2890
593 
4.9579
773 
6.729
743 
6.448
0925 
4.633
6823 
ENSG00000257086 1.72 RP11-
783K16.13 
chr11 64014411 64016966 - 1.58257
52 
1.1539
651 
1.8851
668 
3.347
7898 
2.183
432 
2.384
6471 
ENSG00000230795 1.72 HLA-K chr6 29894236 29897009 + 0.61804
247 
1.1913
046 
1.5108
755 
1.330
7873 
2.285
3572 
2.992
5754 
ENSG00000180672 1.71 AC007362.1 chr2 206642540 206644433 + 1.37003
06 
0.6789
9704 
1.1776
617 
3.312
5985 
1.914
6636 
1.281
505 
ENSG00000254682 1.71 RP11-
660L16.2 
chr11 71159720 71163203 + 1.14260
32 
0.7100
659 
0.4964
7444 
1.667
6105 
1.925
3993 
1.792
3354 
ENSG00000267023 1.71 LRRC37A16P chr17 66121918 66148609 - 1.45405
14 
1.6921
17 
1.4601
423 
2.523
746 
2.944
7954 
2.423
118 
ENSG00000227081 1.71 RP11-
543P15.1 
chr12 3320775 3321096 - 7.24820
5 
1.5755
806 
5.4170
194 
7.375
556 
8.514
681 
4.918
4346 
ENSG00000223745 1.71 RP4-717I23.3 chr1 93727743 93811582 - 0.95840
377 
1.4749
708 
1.4199
601 
2.833
7555 
1.944
4739 
1.893
2604 
ENSG00000226752 1.70 PSMD5-AS1 chr9 123587106 123616651 + 0.90399 0.6311 1.0164 2.319 1.464 1.481
101 
 
02 066 516 7796 0397 2256 
ENSG00000227632 1.70 AC018804.6 chr2 130959885 130970201 + 1.50575
63 
2.2844
598 
2.4223
318 
2.553
2963 
4.621
544 
3.451
2596 
ENSG00000228327 1.69 RP11-
206L10.2 
chr1 700237 714006 - 3.12584
38 
1.0653
372 
3.5199
823 
3.532
1116 
3.393
6765 
4.746
0814 
ENSG00000228638 1.69 FCF1P2 chr3 48332283 48332865 - 0.71284
515 
0.7201
8015 
0.2133
4462 
2.789
1552 
1.738
6442 
0.814
9583 
ENSG00000258186 1.69 SLC7A5P2 chr16 21531151 21531686 - 8.26003 6.4758
79 
14.699
861 
13.65
3822 
13.00
4153 
21.40
1606 
ENSG00000225648 1.68 SBDSP1 chr7 72300004 72307909 + 10.7959
62 
11.587
327 
13.133
697 
19.68
8213 
19.81
655 
19.96
0356 
ENSG00000272711 1.68 RP11-
259N19.1 
chr2 75059782 75061114 - 1.45040
58 
1.1969
146 
1.6662
19 
3.884
3012 
2.328
7628 
1.503
2032 
ENSG00000256462 1.67 RP11-116G8.5 chr10 5566939 5567705 - 3.94108
49 
0 0 3.097
3866 
5.978
923 
0 
ENSG00000236439 1.67 RP11-175B9.3 chr1 202440937 202441258 - 6.70856
76 
3.0561
595 
4.4550
18 
7.306
8976 
8.068
728 
7.226
4347 
ENSG00000233016 1.67 SNHG7 chr9 139615818 139622636 - 3.80191
66 
2.5988
54 
3.9963
634 
4.894
757 
6.888
8636 
5.446
209 
ENSG00000234975 1.67 FTH1P2 chr1 228823162 228823574 + 2.36462
16 
8.7332
3 
5.5768
6 
7.877
958 
8.395
835 
8.092
968 
ENSG00000228998 1.66 RP11-697E2.7 chr15 90818266 90820841 + 1.66241
1 
1.0105
448 
1.4692
17 
2.458
5187 
2.098
612 
2.181
2184 
ENSG00000251022 1.66 THAP9-AS1 chr4 83814162 83822113 - 2.55584
17 
2.0884
433 
4.3881
38 
5.688
368 
4.508
133 
4.144
217 
ENSG00000256633 1.64 RP11-169D4.2 chr11 72295616 72299023 + 0.36736
822 
0.2219
0487 
0.2809
7868 
0.585
01613 
1.582
57 
2.773
093 
ENSG00000266754 1.64 RN7SL524P chr10 105734277 105734572 - 0.67657
28 
0.7092
3144 
1.0905
253 
2.662
4227 
0.618
2988 
1.791
2405 
ENSG00000260269 1.63 CTD-
2323K18.1 
chr15 75819491 75893546 - 1.65046
27 
0.9741
242 
0.6995
654 
3.534
106 
1.676
849 
1.202
5416 
ENSG00000260088 1.62 RP11-92G12.3 chr1 200638635 200663378 + 1.84138
01 
1.6593
088 
3.4227
7 
4.249
6977 
2.985
226 
3.536
2139 
ENSG00000267519 1.62 MIR24-2 chr19 13945330 13947173 - 4.72304
44 
4.5993
896 
8.6144
75 
9.827
661 
7.844
5435 
10.23
9091 
ENSG00000254681 1.61 PKD1P5 chr16 18458147 18495797 - 1.31439
34 
1.0079
812 
1.4375
087 
1.722
2397 
2.123
2183 
2.183
325 
ENSG00000197989 1.61 SNHG12 chr1 28905050 28909495 - 3.87161
02 
2.7489
998 
4.3954
32 
5.069
179 
5.840
756 
6.601
1386 
ENSG00000247315 1.61 AL034548.1 chr20 278214 280961 + 3.02354
24 
2.0685
76 
2.8194
673 
4.320
936 
4.353
7407 
3.915
0994 
ENSG00000251260 1.61 WDFY3-AS1 chr4 85724411 85731544 + 1.00389
2 
1.4533
712 
2.2153
144 
3.214
5927 
1.323
8585 
3.147
409 
ENSG00000250182 1.60 EEF1A1P13 chr5 14652047 14653438 - 9.46529 6.2075
24 
6.9742
58 
12.66
7569 
11.56
31275 
11.53
3177 
ENSG00000251143 1.60 RP11-849H4.4 chr11 71725337 71731956 + 3.97319
3 
6.8831
76 
5.2716
713 
9.131
103 
7.891
925 
8.129
692 
ENSG00000272888 1.59 AC013394.2 chr15 93425937 93441975 + 0.84985
04 
1.4388
658 
1.8384
619 
2.750
0532 
2.498
7977 
1.538
8129 
ENSG00000173295 1.58 FAM86B3P chr8 8086117 8102387 + 0.99347
425 
0.8375
4015 
1.0657
19 
1.652
3628 
1.481
0578 
1.727
7136 
ENSG00000271581 1.58 XXbac-
BPG248L24.12 
chr6 31324424 31325414 + 10.9642
39 
42.648
693 
30.244
503 
26.87
288 
45.12
537 
46.04
9137 
ENSG00000234694 1.58 RP1-92O14.3 chr1 43820355 43824329 - 1.44880
64 
2.5090
265 
1.8279
302 
3.333
9834 
4.057
3297 
1.937
6101 
ENSG00000231970 1.58 RP11-
452K12.7 
chr10 99160872 99179281 + 4.40716
4 
1.8063
688 
1.6439
916 
2.576
6385 
4.841
898 
4.122
6187 
ENSG00000258824 1.58 CTD-
2555O16.2 
chr14 64889653 64915275 - 0.54871
875 
0.3577
88 
0.8857
678 
2.461
6747 
1.143
732 
1.395
1521 
ENSG00000224886 1.58 BEND3P3 chr10 81444250 81444739 - 0.14750
265 
1.2424
577 
0.5076
731 
1.309
9444 
0.603
35094 
3.709
9042 
ENSG00000259623 1.57 RP11-156E6.1 chr17 40004770 40007699 - 1.19021
55 
0.7809
776 
1.3159
648 
2.417
0635 
1.441
4529 
1.755
5282 
102 
 
ENSG00000214184 1.57 AC012487.2 chr2 109123971 109150652 - 1.13318
16 
1.5004
897 
1.6879
808 
2.188
2014 
1.909
4998 
2.645
182 
ENSG00000231864 1.57 RP11-
229P13.23 
chr9 139957987 139959033 + 2.14776
64 
0.5192
181 
1.6303
065 
3.468
3156 
2.224
2556 
1.746
7672 
ENSG00000259948 1.56 RP11-
326A19.5 
chr15 89744322 89744999 - 0 0 0 0 2.250
7296 
1.690
6314 
ENSG00000203875 1.56 SNHG5 chr6 86370710 86388451 - 102.081
635 
49.028
21 
72.932
594 
136.5
7454 
115.0
8786 
87.77
891 
ENSG00000262944 1.56 RP11-473I1.9 chr16 9198705 9200618 + 4.37061
83 
3.5058
978 
5.2434
583 
9.294
138 
6.550
2 
4.981
1077 
ENSG00000223361 1.56 FTH1P10 chr5 17353804 17354733 - 1.12084
73 
1.9096
965 
3.1168
904 
3.494
8602 
3.568
4345 
2.014
9157 
ENSG00000234797 1.55 RPS3AP6 chr15 60060543 60061347 + 8.03755
8 
4.6485
057 
6.0571
284 
10.87
507 
9.480
915 
8.230
892 
ENSG00000186831 1.55 KRT17P2 chr17 18330175 18335162 + 2.67693
57 
5.9414
525 
8.2313
9 
8.073
757 
7.960
8884 
7.615
3316 
ENSG00000235298 1.55 RP11-575L7.8 chr9 86587148 86590692 + 0.99603
415 
0.1577
4745 
1.2684
056 
1.084
6498 
1.106
6335 
3.923
4712 
ENSG00000244398 1.55 RP11-
466H18.1 
chr11 16996240 16996560 - 210.415
99 
118.90
0734 
159.80
867 
323.5
744 
266.5
1407 
171.5
4987 
ENSG00000232956 1.54 SNHG15 chr7 45022622 45026560 - 4.96357
63 
4.2213
054 
6.0738
254 
7.899
4136 
7.568
8367 
7.776
898 
ENSG00000265688 1.54 MAFG-AS1 chr17 79885705 79888629 + 2.63169
65 
1.0524
323 
1.6549
61 
2.523
4575 
3.253
9558 
2.027
5886 
ENSG00000205746 1.54 RP11-
1212A22.1 
chr16 18428257 18488396 - 2.70093
97 
1.9503
261 
2.9362
893 
3.497
657 
3.365
603 
4.758
7376 
ENSG00000205763 1.53 RP9P chr7 32956427 32982788 - 1.58876
7 
2.6736 4.2468
457 
3.486
325 
3.794
6262 
4.901
2694 
ENSG00000260107 1.53 AC005606.15 chr16 2047655 2048375 + 9.51927
2 
5.6106
744 
7.2765
503 
8.348
566 
12.49
4355 
13.30
5827 
ENSG00000232445 1.53 RP11-132A1.4 chr7 100951627 100954266 + 6.63814
2 
1.0719
961 
3.6041
183 
4.977
168 
4.163
5494 
4.395
196 
ENSG00000204194 1.52 RPL12P1 chr6 33367836 33368333 - 8.81644
3 
4.4001
51 
10.382
515 
8.702
698 
12.67
3401 
12.93
3394 
ENSG00000254473 1.52 RP11-522I20.3 chr9 86322509 86328293 + 0.62335
21 
0.6170
2996 
0.9024
317 
2.064
1985 
1.439
8504 
1.178
33 
ENSG00000261971 1.52 RP11-
473M20.7 
chr16 3101992 3109371 - 0.38817
36 
0.9558
703 
1.3753
506 
1.559
6504 
1.193
0581 
2.581
4805 
ENSG00000235725 1.51 AC007389.3 chr2 65816700 65867311 - 0.91346
866 
0.7893
489 
1.0001
628 
1.792
3195 
1.434
173 
1.351
0778 
ENSG00000229212 1.51 RP11-561C5.4 chr15 85747141 85778026 - 1.54617
49 
2.1187
642 
2.2953
222 
2.896
4856 
2.832
387 
3.181
3629 
ENSG00000259328 1.51 RP11-
152F13.7 
chr15 82944773 82974312 + 1.00161
61 
1.3405
782 
1.1754
336 
1.238
5976 
1.825
4333 
2.403
051 
ENSG00000223396 1.51 RPS10P7 chr1 201487831 201499602 + 3.12924
72 
1.9355
738 
2.9419
267 
4.337
2602 
4.088
839 
3.454
8473 
ENSG00000269032 1.51 AC016629.7 chr19 59097525 59097723 + 0.32712
79 
0.8532
135 
0.6416
285 
0 2.120
2471 
1.611
3639 
ENSG00000203394 1.51 RP5-930J4.4 chr1 21069480 21070455 + 4.33596
37 
2.2852
726 
2.7163
084 
5.946
6834 
4.018
1866 
3.844
3263 
ENSG00000225151 1.50 AC103965.1 chr15 84867600 84898888 - 7.19354
3 
9.0674
305 
8.6491
41 
13.35
8168 
12.31
3677 
11.67
2823 
ENSG00000244257 1.50 PKD1P1 chr16 16404198 16428047 + 2.76064
6 
1.8415
892 
2.8608
568 
3.244
7884 
3.438
1177 
4.434
0997 
ENSG00000267580 1.50 CTD-
2540B15.11 
chr19 33790840 33792074 + 1.09239
59 
2.0792
82 
1.7315
762 
2.528
3904 
2.831
5682 
1.866
6612 
ENSG00000267151 1.50 MIR2117 chr17 41522075 41528568 + 1.46409
5 
1.9914
546 
1.7382
286 
2.071
921 
3.630
837 
2.286
1967 
ENSG00000270055 1.50 CTD-
3092A11.2 
chr15 30780166 30782516 + 1.17078
79 
0.9375
974 
1.4183
607 
2.055
2423 
1.595
0989 
1.714
8618 
ENSG00000228989 1.50 AC133528.2 chr2 242629829 242633704 + 1.82867
69 
1.5681
707 
0.6850
529 
3.815
1476 
2.544
251 
0.348
43844 
ENSG00000262791 1.50 RP11- chr17 1629042 1641879 - 0.61560 0.1723 0.3134 1.525 0.680 2.214
103 
 
961A15.1 89 9359 515 6633 255 0858 
ENSG00000248092 1.50 NNT-AS1 chr5 43571696 43603332 - 2.29409
2 
2.9645
55 
2.8210
022 
4.673
5754 
3.726
381 
3.718
8199 
ENSG00000270232 -1.51 RP11-475J5.7 chr5 99381632 99382078 - 14.4310
055 
8.3597
29 
7.1948
752 
7.179
785 
5.739
9325 
6.123
285 
ENSG00000255125 -1.51 RP11-
685M7.5 
chr11 10804860 10823172 + 2.00767
5 
1.9517
535 
4.4939
42 
1.263
7898 
0.861
9299 
4.028
4314 
ENSG00000265415 -1.52 CTD-2510F5.4 chr17 57280038 57281190 - 2.19017
36 
1.3541
911 
1.1740
087 
0.709
3079 
0.546
59224 
0.912
0858 
ENSG00000232358 -1.52 RP5-
955M13.4 
chr20 49615907 49626556 + 10.9595
83 
13.578
551 
15.932
661 
5.993
6986 
10.71
9287 
10.58
0886 
ENSG00000231298 -1.52 LINC00704 chr10 4692377 4720346 - 3.50088
14 
0.8419
1686 
0.5089
952 
0.122
57986
5 
0 0.204
42243 
ENSG00000269834 -1.52 CTD-
3018O17.3 
chr19 52892095 52901019 - 0.42566
574 
3.0581
512 
1.1532
478 
0.938
63595 
0.609
15244 
0.861
5535 
ENSG00000228649 -1.53 AC005682.5 chr7 22893797 22901021 + 2.84680
3 
1.1739
081 
1.4650
004 
1.375
8489 
0.801
59485 
0.919
04426 
ENSG00000250234 -1.53 CTD-
2024P10.1 
chr5 34656517 34657355 - 2.84991
8 
3.6838
043 
2.7612
894 
1.368
9165 
1.759
3302 
3.366
3306 
ENSG00000260549 -1.53 MT1L chr16 56651388 56652730 + 32.0605
55 
7.0488
276 
13.661
485 
8.433
363 
8.580
506 
11.88
6822 
ENSG00000269983 -1.53 RP11-
497H16.9 
chr5 69745463 69746180 + 2.89407
18 
2.6753
237 
1.4972
115 
1.057
8682 
2.014
671 
1.510
466 
ENSG00000232656 -1.54 IDI2-AS1 chr10 1068606 1090138 + 8.97962 2.5590
303 
4.5844
545 
4.037
7965 
2.612
7467 
2.731
6613 
ENSG00000273132 -1.54 RP11-
350J20.12 
chr6 150173598 150174328 + 4.93389
4 
3.8961
434 
1.3101
063 
0.214
81651 
2.748
0006 
2.503
8617 
ENSG00000262413 -1.54 RP11-498C9.3 chr17 79825597 79826428 + 131.380
23 
83.971
855 
65.720
39 
57.11
3407 
68.61
178 
50.39
401 
ENSG00000233144 -1.55 RP11-537A6.9 chr10 75141191 75143254 + 1.73480
49 
1.7642
145 
2.0247
85 
0.579
00864 
1.376
7893 
1.206
9995 
ENSG00000226963 -1.55 AC078883.4 chr2 173292502 173293331 - 3.65149 3.3694
608 
3.6925
917 
2.460
7828 
1.833
3695 
2.698
5145 
ENSG00000234327 -1.55 AC012146.7 chr17 5014763 5017674 + 1.95390
83 
2.4199
314 
1.5286
9 
0.984
7564 
1.408
148 
1.369
486 
ENSG00000259153 -1.56 RP6-65G23.3 chr14 71276922 71282120 + 1.99365
48 
2.7267
768 
1.2656
376 
1.045
882 
0.530
8814 
1.731
0688 
ENSG00000258791 -1.58 LINC00520 chr14 56247864 56263406 - 0.64874
68 
2.9121
616 
2.3695
24 
0.322
98782 
1.232
0567 
1.418
7404 
ENSG00000267776 -1.58 AC006116.24 chr19 56888073 56888653 - 2.15047
86 
3.7224
712 
2.8212
99 
1.832
4789 
1.608
6241 
1.933
2796 
ENSG00000257181 -1.58 RP11-611O2.5 chr12 69235068 69237017 - 5.82705
8 
7.4925
43 
6.0171
41 
4.169
096 
3.725
6134 
4.259
7303 
ENSG00000267774 -1.58 RP11-2N1.2 chr18 57363691 57364644 + 4.9585 2.7897
93 
5.2442
584 
1.467
508 
3.439
1992 
3.611
8386 
ENSG00000241749 -1.59 RPSAP52 chr12 66151800 66220754 - 3.20631
31 
1.0826
937 
1.4755
359 
0.093
51292 
0.572
23415 
1.282
0605 
ENSG00000268854 -1.59 CTD-
2545M3.2 
chr19 50983376 50986608 - 4.72710
04 
2.3693
736 
1.3470
087 
3.467
783 
1.066
7965 
1.013
8669 
ENSG00000224818 -1.59 RP11-134G8.8 chr1 201433511 201434274 - 3.14244
77 
7.4775
295 
3.8924
434 
2.826
5297 
2.930
994 
2.728
9903 
ENSG00000232815 -1.59 LINC00537 chr9 68413482 68414196 - 3.58854
34 
3.3276
02 
2.7501
92 
2.034
8413 
2.185
565 
1.820
1643 
ENSG00000241494 -1.61 RP11-796G6.1 chr14 102144280 102144717 + 3.58287
45 
1.8213
323 
2.3123
465 
1.848
1115 
1.181
2179 
1.666
4281 
ENSG00000258017 -1.62 RP11-
386G11.10 
chr12 49521565 49541652 + 27.8705
02 
18.402
964 
17.180
283 
12.05
1238 
12.65
8115 
13.56
6694 
ENSG00000034063 -1.62 UHRF1 chr19 4903092 4962165 + 6.74429
46 
1.2855
517 
2.7702
923 
2.075
5224 
1.767
3001 
1.536
0543 
ENSG00000254258 -1.62 RP11-398H6.1 chr8 140472305 140475259 - 4.54776
14 
7.7839
007 
6.3626
404 
3.925
3066 
3.584
0328 
3.740
049 
104 
 
ENSG00000213412 -1.64 HNRNPA1P33 chr10 47133338 47133898 - 14.4520
4 
8.3262
005 
6.1332
52 
8.466
77 
4.197
107 
4.750
102 
ENSG00000126005 -1.64 MMP24-AS1 chr20 33804265 33865934 - 9.15239
3 
7.7007
318 
6.1065
493 
5.459
143 
5.335
1436 
3.377
0957 
ENSG00000172965 -1.65 MIR4435-1HG chr2 111953927 112252677 - 3.55057
67 
3.3823
805 
3.6901
011 
1.780
8807 
2.279
2993 
2.452
1575 
ENSG00000253161 -1.65 RP11-
150O12.1 
chr8 37278859 37411701 - 11.0290
21 
12.441
466 
9.9816
79 
6.311
8887 
8.075
069 
6.012
6433 
ENSG00000261068 -1.65 RP11-7K24.3 chr6 42059976 42061997 - 1.63533
17 
8.6070
25 
3.6644
359 
1.894
0854 
2.506
5024 
2.411
0541 
ENSG00000187653 -1.66 TMSB4XP8 chr4 91759652 91760263 - 8.07511
6 
19.661
818 
14.503
13 
6.456
596 
7.568
5825 
10.31
9572 
ENSG00000226005 -1.66 RP11-
464C19.3 
chr10 3976711 3978005 + 1.07008
05 
1.8116
003 
2.9764
59 
0.289
62108 
0.678
89744 
1.258
3201 
ENSG00000250318 -1.67 CTA-963H5.5 chr22 31049864 31050801 - 1.83993
59 
2.2982
81 
1.8083
909 
0.734
8674 
0.672
6246 
1.651
6936 
ENSG00000240225 -1.67 ZNF542 chr19 56879468 56891197 + 2.40770
34 
2.6245
768 
2.5352
726 
1.434
9543 
1.558
2225 
1.541
5956 
ENSG00000240875 -1.68 LINC00886 chr3 156465135 156534851 - 8.04174
8 
2.8910
108 
2.4221
4 
2.591
8982 
2.259
8019 
2.029
531 
ENSG00000256663 -1.72 RP11-
424C20.2 
chr12 20704524 20705946 + 4.26013
66 
0.7228
8775 
1.1924
789 
0.947
2472 
0.934
9184 
0.820
1998 
ENSG00000241990 -1.72 RP6-109B7.3 chr22 46449585 46453090 + 7.39844
27 
3.9867
473 
4.8413
033 
3.091
525 
3.469
6312 
2.616
5955 
ENSG00000245112 -1.74 SMARCA5-AS1 chr4 144434625 144435788 - 0.00956
0357 
5.2469
225 
0 0 0.159
80777 
0 
ENSG00000259330 -1.74 LINC00984 chr15 40617417 40618916 + 4.89751 3.6402
433 
3.2306
47 
2.593
4253 
2.204
161 
1.912
7241 
ENSG00000235385 -1.75 GS1-600G8.5 chrX 13284167 13321571 - 4.73486
38 
22.813
477 
19.080
942 
3.339
2224 
14.33
58755 
8.066
61 
ENSG00000261065 -1.75 RP11-74C13.4 chr1 204100190 204101094 + 1.99908
89 
2.6730
783 
0.4170
3206 
0.414
32646 
0.868
4934 
0 
ENSG00000253618 -1.76 GRPEL2-AS1 chr5 148727679 148737205 - 1.68886
54 
3.2317
665 
0 0.215
5406 
0.803
7886 
0 
ENSG00000258232 -1.77 RP11-
161H23.5 
chr12 49658939 49667089 - 33.3097
57 
28.819
185 
28.912
59 
14.44
1423 
19.74
7879 
17.62
5807 
ENSG00000272734 -1.79 ADIRF-AS1 chr10 88725102 88731068 - 5.43516
25 
12.950
257 
11.457
844 
4.700
653 
5.038
381 
5.980
5155 
ENSG00000234546 -1.81 RP3-510D11.2 chr1 9242263 9252148 + 11.2780
56 
4.5766
697 
5.7239
7 
2.883
4605 
5.230
489 
3.284
4615 
ENSG00000258908 -1.82 RP11-
203M5.8 
chr14 20942948 20945248 - 7.68502
6 
3.8135
834 
4.4676
06 
2.660
3262 
2.985
3904 
2.748
8363 
ENSG00000272159 -1.83 RP11-
350N15.6 
chr8 38265566 38266260 - 7.30503
03 
2.4662
013 
2.9248
87 
1.585
6465 
2.061
9986 
2.634
9046 
ENSG00000226721 -1.84 EEF1DP2 chr9 95599108 95599950 - 0 6.2755
63 
0 0 0 0 
ENSG00000204556 -1.86 CTD-2514C3.1 chr20 25999468 26001320 + 3.08402
75 
2.3788
395 
1.0570
529 
1.181
9186 
0.448
66753 
1.024
0932 
ENSG00000197358 -1.86 BNIP3P1 chr14 28733596 28735180 + 4.02136
66 
6.1853
94 
4.5065
994 
2.335
3097 
2.544
7326 
2.919
4083 
ENSG00000235237 -1.88 RP1-151B14.6 chr22 37562797 37578890 + 5.69870
1 
5.5882
27 
3.9706
326 
2.796
2503 
2.296
2286 
2.966
6011 
ENSG00000237499 -1.89 RP11-356I2.4 chr6 138144810 138189370 - 2.07288
89 
2.8674
767 
2.2776
296 
0.910
7068 
1.268
385 
1.577
585 
ENSG00000235847 -1.89 LDHAP7 chr2 85004383 85005347 - 2.74156
7 
2.0703
194 
1.2152
584 
0.508
1032 
1.017
5685 
0.249
74425 
ENSG00000273038 -1.90 RP11-
479G22.8 
chr10 33176189 33178239 - 2.26414
06 
2.7482
634 
1.5507
42 
0.526
8092 
1.410
5644 
0.987
04404 
ENSG00000231991 -1.91 ANXA2P2 chr9 33624223 33625532 + 134.588
53 
110.10
068 
128.57
472 
52.56
764 
66.60
7285 
77.69
0636 
ENSG00000256929 -1.91 AC067852.1 chr17 40673736 40674065 + 3.25574 8.0733
17 
4.7597
175 
3.042
4023 
3.687
5687 
1.590
6979 
ENSG00000255959 -1.92 RP11- chr11 60603469 60610438 - 5.55156 2.3799 2.5062 1.125 1.753 2.367
105 
 
804A23.2 56 477 263 2497 554 571 
ENSG00000251292 -1.93 RP11-
380P13.2 
chr4 23724885 23735202 - 38.6029
8 
68.663
376 
43.137
657 
25.19
0517 
34.78
7884 
18.08
7368 
ENSG00000262410 -1.96 RP11-
388C12.8 
chr17 80702944 80703585 + 2.04051
07 
3.6950
738 
4.6220
4 
2.332
8707 
0.493
39446 
1.994
9535 
ENSG00000266088 -1.97 RP5-1028K7.2 chr17 38673278 38683254 + 4.31365
35 
1.3317
922 
1.3348
67 
0.232
17432 
0.229
15247 
0.586
2707 
ENSG00000255234 -1.98 RP11-
727A23.10 
chr11 82997171 83134559 + 74.2644
35 
131.67
998 
93.626
11 
40.38
3236 
64.51
9875 
45.11
061 
ENSG00000231826 -1.98 AC016735.2 chr2 43254992 43266686 - 16.923 4.0733
547 
5.2401
91 
4.893
341 
3.788
711 
2.493
266 
ENSG00000235823 -2.00 LINC00263 chr10 102133372 102143125 + 2.90408
5 
3.2670
798 
2.4657
273 
1.211
951 
1.841
8641 
1.311
8396 
ENSG00000265992 -2.00 ESRG chr3 54666149 54673884 - 233.581
45 
439.66
51 
314.18
79 
138.6
1157 
202.8
8977 
142.8
2372 
ENSG00000260834 -2.02 RP11-256I9.2 chr16 65224876 65268817 - 56.8772
7 
96.663
605 
70.333
88 
29.44
8397 
46.84
315 
33.75
8797 
ENSG00000256940 -2.06 RP11-
783K16.5 
chr11 64013436 64015689 + 13.2824
1 
9.2834
835 
8.4336
85 
6.031
071 
4.409
4415 
4.459
4874 
ENSG00000273387 -2.07 RP3-412A9.16 chr22 31478142 31479551 - 3.50702
29 
1.8962
02 
1.4603
726 
1.100
5665 
0.395
10265 
0.518
1117 
ENSG00000255021 -2.08 RP11-536I6.2 chr3 14313873 14345345 - 14.2297
64 
26.088
594 
15.773
34 
7.262
8064 
12.21
7939 
7.326
7016 
ENSG00000100181 -2.08 TPTEP1 chr22 17082777 17179632 + 20.2850
84 
40.960
05 
27.098
47 
11.95
8863 
17.23
5292 
12.10
646 
ENSG00000236673 -2.09 RP11-69I8.2 chr6 132223103 132241705 + 8.28539
9 
16.666
319 
10.295
293 
4.810
559 
6.592
9637 
4.929
272 
ENSG00000226792 -2.09 LINC00371 chr13 51656984 51746524 - 9.05261
9 
16.953
245 
10.620
668 
5.284
7075 
6.886
0707 
4.875
6647 
ENSG00000236824 -2.12 BCYRN1 chr2 47558199 47571656 + 12.5237
26 
24.176
477 
18.561
161 
5.118
2065 
7.327
3034 
15.67
111 
ENSG00000224081 -2.12 LINC01057 chr1 95104017 95285837 - 59.7651
8 
112.70
979 
71.806
335 
32.73
587 
50.64
0713 
30.50
0008 
ENSG00000225383 -2.15 SFTA1P chr10 10826400 10836943 - 33.8832
36 
11.625
587 
16.437
605 
5.999
579 
6.570
4207 
16.63
6505 
ENSG00000219445 -2.15 RP11-3B12.3 chr7 124869633 124904345 - 5.30390
45 
10.288
663 
7.6753
13 
3.506
465 
4.159
0476 
2.902
5939 
ENSG00000233218 -2.25 SNX18P16 chr1 142688379 142688925 - 1.71771
82 
2.6481
433 
3.3620
58 
0.430
26203 
1.351
1974 
0.339
88443 
ENSG00000233461 -2.25 RP11-
295G20.2 
chr1 231658134 231664302 - 4.34471
65 
5.2603
03 
4.8380
613 
0.901
0945 
2.709
4634 
3.601
3868 
ENSG00000269495 -2.34 CTB-147C22.8 chr19 51453441 51466905 + 4.91188
86 
14.511
923 
12.695
248 
1.724
4989 
4.951
8948 
8.315
971 
ENSG00000257219 -2.41 RP11-54A9.1 chr12 76653619 76698911 + 3.86657
3 
2.7792
904 
2.3597
717 
0.302
85415 
0.949
48655 
1.806
0194 
ENSG00000230439 -2.41 RP11-488P3.1 chr1 94218480 94241000 - 16.7174
1 
2.3367
712 
4.8807
71 
2.343
1618 
2.641
2401 
2.188
129 
ENSG00000214110 -2.44 LDHAP4 chr9 14921335 14922332 - 6.77137
7 
6.3298
79 
5.6765
62 
2.142
0772 
2.575
1235 
3.043
416 
ENSG00000267279 -2.45 RP11-
879F14.2 
chr18 59252979 59274149 - 6.17703
3 
1.2901
783 
1.8376
158 
0.892
23325 
0.914
65175 
0.947
58815 
ENSG00000254740 -2.63 RP11-334E6.3 chr11 119243416 119252323 + 1.65935
97 
5.2611
43 
5.3788
548 
1.041
0688 
1.639
0346 
1.514
5406 
ENSG00000268621 -2.68 AC006262.5 chr19 46692423 46706340 - 2.93583
7 
5.8567
724 
3.7140
47 
1.001
9716 
2.637
1474 
1.250
5352 
ENSG00000271573 -2.69 RP11-
96C23.12 
chr10 88786941 88787234 + 1.96670
2 
9.9967
87 
7.0107
24 
0.436
6481 
2.154
825 
3.302
377 
ENSG00000257042 -2.69 RP11-
993B23.3 
chr12 28111450 28122746 + 25.1891
9 
26.207
75 
21.461
538 
4.820
6534 
9.942
112 
15.11
63 
ENSG00000255198 -2.71 SNHG9 chr16 2014960 2015510 + 5.08295
3 
5.4102
4 
2.8378
108 
1.320
2466 
1.149
7614 
2.586
8635 
ENSG00000261780 -2.74 CTD-
2354A18.1 
chr18 70992176 71017113 + 7.45266
5 
13.354
17 
8.3805
11 
2.986
0015 
4.862
3896 
2.805
7775 
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ENSG00000258177 -2.75 RP11-394J1.2 chr12 96616575 96617751 - 11.3985
49 
7.2211
123 
5.6029
59 
1.443
8808 
3.685
8037 
4.163
6434 
ENSG00000255729 -2.78 AC005618.1 chr5 140699661 140700339 - 3.83701
63 
7.4735
03 
7.0763
206 
0.756
8286 
4.717
6375 
1.997
0802 
ENSG00000238266 -2.79 LINC00707 chr10 6821560 6884868 + 3.58438
56 
4.5337
21 
3.8257
384 
1.909
5888 
1.506
412 
0.787
2698 
ENSG00000239492 -2.98 FAM25HP chr10 47740330 47747200 + 15.1145
64 
31.412
348 
26.541
6 
5.972
542 
9.727
91 
8.178
021 
ENSG00000253746 -3.17 RP11-
527N22.2 
chr8 37262957 37264242 - 3.75136
5 
4.0315
757 
2.6437
647 
0.703
32074 
0.949
91237 
1.250
8819 
ENSG00000256288 -3.22 RP11-
277P12.10 
chr12 10485460 10490891 - 6.18079
3 
7.4155
67 
4.6269
43 
0.939
5672 
3.611
7387 
1.750
629 
ENSG00000242147 -4.40 RP13-
463N16.6 
chr10 5636954 5638081 - 18.6134
9 
1.4156
137 
3.2376
003 
0.521
8478 
0.030
29739
3 
0.474
20192 
ENSG00000229647 -4.79 AC007879.7 chr2 208104374 208110611 + 31.3377
27 
7.7880
12 
10.499
597 
3.835
9287 
3.087
454 
1.968
523 
 
 
 
 
 
 
 
Table S2: Comparison of FAM83H-AS1 RPKM (Reads Per Kilobase Million) with other previously 
published functional LncRNAs 
 
LncRNA ENSEMBL ID Avg. RPKM GFP Avg. RPKM 16E6 Known function 
FAM83H-AS1 ENSG00000203499 5.876310667 9.9992845  
XIST ENSG00000229807 8.137879 12.21193233 miRNA sponge in cervical cancer (Zhu et al 2018) 
HOTAIR ENSG00000228630 1.817852513 1.5785181 miRNA sponge in cervical cancer (Liu et al 2018) 
NEAT1 ENSG00000245532 34.23374033 27.70111733 miRNA sponge in cervical cancer (Han et al 2018) 
TINCR ENSG00000223573 16.26229083 16.07113433 miRNA sponge in gastric cancer (Chen et al 2017) and breast cancer (Liu et al 2018) 
H19 ENSG00000130600 3.3026914 15.14256633 miRNA sponge in cervical cancer (Ou et al 2018) 
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Table S3: Primers used in this study for qRT-PCR. 
 
Primers Sequence (5'-3') 
FAM83H-AS1 FWD TCCCAATAAACAGGGCAGAC 
FAM83H-AS1 REV CAAGATCACCACACCCCTCT 
Gapdh FWD CCACTCCTCCACCTTTGAC 
Gapdh REV ACCCTGTTGCTGTAGCCA 
UBC FWD GATTTGGGTCGCAGTTCTTG 
UBC REV CCTTATCTTGGATCTTTGCCTTG 
Beta-Actin FWD AGCACAGAGCCTCGCCTTT 
Beta-Actin REV CCACGATGGAGGGGAAGAC 
U6 FWD GTGCTCGCTTCGGCAGCACATAT 
U6 REV AAAAATATGGAACGCTTCACGAA 
C. Elegans ama-1 FWD GGAGCTCGAGTGGATCTTCG 
C. Elegans ama-1 REV GCGCAGAGAGTATCCTGGAC 
HPV-16E6 FWD AATGTTTCAGGACCCACAGG 
HPV-16E6 REV ACTGTTGCTTGCAGTACACACA 
HPV-16E7 FWD ACAAGCAGAACCGGACAGAG 
HPV-16E7 REV GCCCATTAACAGGTCTTCCA 
p53 FWD TTTGGGTCTTTGAACCCTTG 
p53 REV CCACAACAAAACACCAGTGC 
p300 FWD AGCGGCCTAAACTCTCATCTC 
p300 REV CACCATTGGTTAGTCCCAATTC 
FAM83H FWD CGACAAGTGCCGTGTCAACC 
FAM83H REV ACTTCCCAGTGCGGCAGTAG 
H19 FWD AGTGGACTTGGTGACGCTGTAT 
H19 REV CTCCTGAGAGCTCATTCACTCC 
MIR205HG FWD TCATTAAAGAGAGAAATCAACTATTCA 
MIR205HG REV TAAAGCACCCAGTTCAGCAG 
HOXC-AS5 FWD CTCCTTGGAGCAGTACACCTG 
HOXC-AS5 REV GTCCATTTGCTCTCCACTTGA 
GAS5 FWD CTTCTGGGCTCAAGTGATCCT 
GAS5 REV TTGTGCCATGAGACTCCATCAG 
LINC00963 FWD AACTGCCTTTGGAAGCAAGTAG 
LINC00963 REV ACTGCTCTAGTCCAGGAGTTCG 
SNHG15 FWD GCTGAGGTGACGGTCTCAAA 
SNHG15 REV GCCTCCCAGTTTCATGGACA 
MAFG-AS1 FWD AGGACTCGGGAGGAAGATAAAC 
MAFG-AS1 REV AACACCTTCAGCTCTCTGCTG 
RP6-65G23.3 FWD GAGATAGGAGGCCCATAATGTTTC 
RP6-65G23.3 REV CTGCAACCAGGTGGAAGTCA 
GS1-600G8.5 FWD ACTGTCCGGTTCACTGTGGG 
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GS1-600G8.5 REV CGGTGCCACTGGGTCATTTT 
RP3-510D11.2 FWD CCAGACCGACGGGACAGCG 
RP3-510D11.2 REV GCTTCCCTGTCCTCCTCCTA 
RP11-479G22.8 FWD TGGGAAACTAAAACCATTTAAGC 
RP11-479G22.8 REV GCTCAGAACATGGTTTTCTCTG 
LINC01057 FWD GTGAATTCCTTGGAAGATGAGG 
LINC01057 REV TCATTCACTCAACCACTGAACC 
SFTA1P FWD CAGCATTCCAGGTGGGCTTT 
SFTA1P REV CCTTGTTTGGCTTACTCGTGC 
RP13-463N16.6 FWD TTGGAAATCACTCCTTCCACTT 
RP13-463N16.6 REV CAGAGACAATTCAACTCCCACA 
AC007879.7 FWD ACAGGGAGCCAGGACACC 
AC007879.7 REV GGAACCAGCACCAGGAACC 
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XIII. Supplementary Methods 
 
A. Cell Culture 
 
 Primary human foreskin keratinocytes (HEKa) were cultured as described by supplier (EpiLife® 
Medium supplemented with Human Keratinocyte Growth Supplement (HKGS)). Primary human cervical 
keratinocytes (HCK) and J2-3T3 mouse fibroblast feeders were cultured as described by Alison 
McBride's laboratory (NIH, Bethesda, MD)1. HCK were maintained in F-media [3:1 F12:DMEM with 
5% Fetal Bovine Serum (FBS), 0.4ug/mL Hydrocortisone, 5ug/mL Insulin, 8.4ng/mL Cholera Toxin, 
10ng/mL Epidermal Growth Factor, 24ug/mL Adenine, 10U/mL Penicillin, 10ug/mL Streptomycin, 2mM 
L-Glutamine, Amphotericin B] containing 10uM Y-27632 ROCK Inhibitor (Tocris). HCK cells were co-
cultured with J2-3T3 feeder cells rendered mitotically inactive in 8ug/mL Mitomycin C for 3 hours; these 
growth-arrested feeder cells were replenished every 3-4 days. J2-3T3 stock cells were cultured in Feeder 
media [Dulbecco's Modified Eagles Medium (DMEM), high glucose, 10% Newborn Calf Serum, 2mM 
L-Glutamine, 10U/mL Penicillin, 10ug/mL Streptomycin, Amphotericin B]. J2-3T3 feeder cells are 
sensitive to trypsin; HCK, J2-3T3 stock, and growth-arrested J2-3T3 cells were centrifuged to remove the 
trypsin when passaged. HPV-16 positive CaSki cells were cultured in Roswell Park Memorial Institute 
(RPMI)-1640 medium containing 10% FBS, Streptomycin-Penicillin, HEPES Buffer, Amphotericin B. 
HPV-16 positive W12/20863 and W12/201402 and HPV-31b positive cervical (CIN-612) were co-
cultured in E-media (1:1 DMEM:Ham's Nutrient Mix F12 medium supplemented with 5% FBS, 10mM 
HEPES Buffer, Penicillin-Streptomycin, Amphotericin B, 0.02µM Triiodothyronine, 0.4µg/mL 
Hydrocortisone, 0.1µg/mL Cholera Toxin, 5µg/mL Transferrin, 180µM Adenine, 5µg/mL Insulin ) with 
murine 3T3 fibroblast cells (3T3M) that were rendered mitotically inactive with 4ug/mL Mitomycin C for 
at least 2 hours. HPV-negative cervical C33A cells, HPV-18 positive cervical (HeLa), HPV-16 positive 
HNSCC cell lines UMSCC-47 and -104, HPV negative HNSCC cell line UMSCC-1, HEK293T, and 
3T3M cells were all cultured in DMEM supplemented with 10% FBS, Penicillin-Streptomycin, HEPES 
Buffer, and Amphotericin B. To passage stock cells, 0.25% trypsin was utilized. Growth-arrested J2-3T3 
and 3T3M fibroblasts were removed with Versene solution and gently pipetting, prior to pelleting and 
when otherwise desired. Cells were cultured at 37°C in a humidified 5% CO2 cell culture incubator. 
 
B. Generation of stable cell lines  
 
 Plasmids MSCV-N-GFP (Plasmid #37855), MSCV-N-16E6 (Plasmid #37875), and MSCV-N-
16E7 (Plasmid #37881) were purchased from Addgene. For retroviral production, these plasmids were 
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co-transfected with packaging (pCL-ECO) and envelope (pVSV-GF) plasmids into HEK293T cells using 
calcium phosphate co-precipitation. 12-16 hours later, HEK293T media was replaced with fresh target 
cell media. After 48-hour incubation, retrovirus-containing target cell media was harvested, filtered 
(0.45µm), and mixed with polybrene (4µg/mL final concentration) to increase infection efficiency. 24 
hours before infection, co-cultured J2-3T3 fibroblasts were removed with Versene solution and gentle 
pipetting from HCK cells. HEKa and HCK cells were infected with recombinant retroviruses for 8 hours, 
virus was removed and replaced with fresh target cell media. Growth arrested J2-3T3 were added to 
infected HCK and replenished every 3 days. Cells were allowed to recover for 24 hours prior to 72-hour 
puromycin selection (HEKa-2.5µg/mL; HCK-3µg/mL).  Cells were allowed to recover and expression of 
exogenous HPV-16 E6 and E7, as desired, was confirmed by RT-PCR (Fig. S1, Fig. S3). 
 
C. Generation of HPV-16 positive cervical JAMM-16 cell line 
 
 According to Buck et al. protocol described previously2, the HPV-16 insert was cut out of 
pBR322 HPV-16 plasmid by performing a restriction digestion of two separate 25ug plasmid reactions in 
225uL each with the restriction enzyme BamHI (NEB) according to manufacturer's recommended 
conditions (37°C for 2 hours). Digested samples were then PCR purified by QIAquick® PCR Purification 
Kit (Qiagen) resuspended in 200uL Buffer TE. Purified samples were then ligated under dilute conditions 
(9mL total volume) by adding 1X Ligase Buffer and 6uL of high concentration (2m U/mL) T4 DNA 
Ligase (NEB) and incubated at 16°C overnight. <25ug in 9mL ligation reactions were conducted to avoid 
concatemer formation. The ligated samples were then treated with 4.5mL of 7.5M Ammonium acetate 
and mixed. 35mL of 95% ethanol was added to each, tubes were mixed, and incubated at 4°C overnight. 
The next day, the samples were brought back to room temperature and centrifuged at ~5,000 x g at room 
temperature for 1 hour. Pellets were washed with 70% ethanol, spun briefly, and washed again with 70% 
ethanol. The pellets were spun one last time to remove any residual ethanol, then air dried for several 
minutes. Pellets were resuspended in 100uL Buffer TE each, pellets were combined, and Nanodrop was 
used to calculate concentration retrieved. The entire product was run in 1% agarose gel for 3 hours. 
Desired band [expect to see supercoiled and relaxed circular bacterial backbone (~1.8 and ~3.2 kb) and 
supercoiled and relaxed circular (nicked) HPV genome (~6.2 and >16 kb)] was cut out and gel extracted 
with QIAquick® Gel Extraction Kit (Qiagen). Before transfection of the HPV-16 genomes, growth-
arrested J2-3T3 fibroblasts were removed by Versene solution and pipetting from co-cultured primary 
normal cervical keratinocytes (HCK). HCK were plated in a 6-well plate on day prior to transfecting 
according to manufacturer's protocol for Lipofectamine LTX (Invitrogen). On day of transfection, HCK 
were at about 70% confluency. Media was replenished on each well. For each well, 2.8ug of re-ligated 
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HPV-16 insert was diluted in 150uL Opti-MEM I Reduced Serum Media with 2.5uL PLUS Reagent, 
15uL Lipofectamine LTX was diluted in Opti-MEM I Reduced Serum Media. Diluted DNA and diluted 
Lipofectamine LTX/Plus complex were combined and incubated for 5 minutes at room temperature prior 
to adding to well. The transfected cells were passaged at least 10-15 times so HPV-16 immortalized cells 
could overgrowth the untransfected HCK cells prior to experimentation.  
 
D. RNA Extraction 
 
 Total RNA of cultured cell lines and human tissues was purified with TRIzol reagent (Invitrogen) 
and treated with Turbo DNA-free DNase (20 minutes at 37°C, Ambion) according to manufacturers' 
protocols. RNA concentration was determined with a Nanodrop 2000 Spectrophotometer (Thermo 
Scientific).  
 
E. cDNA synthesis, qualitative or quantitative RT-PCR  
 
 RNA was reverse transcribed to complementary DNA (cDNA) under standard iScript cDNA 
synthesis kit (Bio-Rad) instructions in T100TM Thermal Cycler (Bio-Rad). Exogenous spike of C. Elegans 
(70ng) was added for normalization of results if GAPDH mRNA levels were altered during processing 
(cellular fractionation). RT-PCR or qRT-PCR using SsoAdvancedTM Universal SYBR® Green enzyme 
was performed according to manufacturer's protocol (Bio-Rad) in CFX ConnectTM Real-Time System 
(Bio-Rad). The oligonucleotide primer sequences can be found in Supplementary Table S3. GAPDH was 
primarily used as housekeeping gene, however Ubiquitin C (UBC) or Glucuronidase Beta (GUSB) were 
used if GAPDH mRNA levels were altered with significant apoptosis (siRNA FAM83H-AS1 vs. siRNA-
CTRL) and ama-1 was used for cellular fractionation studies.  To validate cell fractionation efficiency, 
U6 snRNA was used as nuclear control and mature mRNA beta-actin as cytoplasmic control. Qualitative 
RT-PCR product was resolved by agarose gel electrophoresis to visualize or quantitative RT-PCR (qRT-
PCR) relative expression was calculated using the double delta CT method (relative expression = 2-∆CT; 
where ∆CT=CT (Target RNA) - CT (mRNA endogenous GAPDH/UBC control or C. Elegans mRNA 
Ama-1 was exogenous spike control). Fold changes were calculated relative to control siRNA or the mean 
value of normal samples. 
 
F. Western Blot analysis  
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 Cell lysates were boiled in sample buffer, separated by SDS-PAGE, and transferred onto 
Immobilon-Fl polyvinylidene difluoride membranes. After blocking for 1 hour with 5% milk-TBST 
buffer (5% non-fat dry milk, 25mM Tris-HCl pH 8.0, 125mM NaCl, 0.5% Tween-20), the membranes 
were incubated with primary antibodies against human p53 (Cell Signaling, #9282) or Actin (C-11) 
(Santa Cruz, sc-1615) overnight at 4°C. The membranes were then washed with TBST, incubated with 
appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies [anti-goat IgG (Santa Cruz, 
sc-2020); anti-mouse IgG (Thermo Scientific)] for 1 hour at room temperature, washed with TBST, and 
the proteins were detected on the membrane using Pierce SuperSignal West Pico or Femto Maximum 
Sensitivity Substrate (Thermo Scientific) chemiluminescence.  
 
G. Transient transfection 
 
 The following siRNAs were used to knock down FAM83H-AS1: Lincode Human FAM83H-AS1 
siRNA - Set of 4 (Dharmacon, RU-188909-00-0002), Lincode Human FAM83H-AS1 siRNA 
SMARTpool (Dharmacon, R-188909-00-000), Lincode Non-targeting siRNA #1 (Dharmacon, D-001320-
01-05). Two different siRNA against HPV-16E6: 5'-GAGGUAUAUGACUUUGCUUTT-3' (Dharmacon) 
and 5'-UCCAUAUGCUGUAUGUGAUTT-3' (siRNA 209, Dharmacon), two different siRNA against 
p53 (NEB, #2011S; Thermo Scientific Dharmacon®, J-003329-16), two different ONTARGETplus 
Human siRNA against p300 (Dharmacon, J-003486-11-0002; Dharmacon, J-003486-12-0002), and 
CTLsiRNA (Ambion, AM16104) were used. 
 
 HCK, CaSki, and W12/201402 cells were transiently transfected using standard Lipofectamine® 
RNAiMAX protocol (siRNA FAM83H-AS1 and siRNA HPV-16E6 #1).W12/201402 and CaSki cells 
were transfected with reverse transfection protocol (siRNA HPV-16 E6 #2 to improve transfection 
efficiency. For standard transfection, cells were plated at appropriate confluency to be about 70% 
confluent for transfection 24 hours post-plating. Growth-arrested J2-3T3 fibroblasts were co-cultured with 
HCK, and on day of transfection removed with Versene solution and gently pipetting . On day of CaSki, 
W12/201402, and HCK standard transfection, media was replenished on each well. For each well, Opti-
MEM I Reduced Serum Media was used to dilute Lipofectamine RNAiMAX (9uL per well of 6-well), as 
well as siRNA (40pmol per well of 6-well). Diluted RNAiMAX was combined with diluted siRNA, 
incubated 5 minutes at room temperature and added to each well. Cells were incubated 48 hours in media 
containing siRNA prior to harvesting, unless otherwise stated.   
 
H. Cellular fractionation  
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 Growth arrested 3T3M cells were removed by Versene solution and pipetting the day prior to 
fractionation for the W12/201402. Cellular fractionation protocol was modified from previous 
publication3. On ice, CaSki (~70% confluent) were washed two times with cold PBS, scraped, pelleted, 
and resuspended in RSB Buffer (10-1.25mM Tris, pH 7.4; 10-1.25mM NaCl; 3-0.38mM MgCl2), 
incubated on ice for 5 minutes, centrifuged (1500rpm for 4 minutes at 4°C). RSB Buffer was removed 
and swollen pellets were resuspended in RSB-G40 Buffer [2.5-0.63mM Tris, pH 7.4; 2.5-0.63mM NaCl; 
0.75-0.19mM MgCl2; 2.5-0.63% glycerol; 0.125-0.03% NP-40; 0.125-0.03mM DTT; 100U/mL RNasin 
Plus RNase Inhibitor (Promega)] in ≥ 4 times volume of pellet. Cells were disrupted with Dounce 
homogenizer; homogenate was centrifuged (4000 rpm, 4 minutes) to pellet nuclear fraction. The 
cytoplasmic fraction (supernatant) was collected. The pelleted nuclear fraction was resuspended in RSB-
G40 Buffer, 3.3% of sodium deoxycholate and 6.6% of Tween20 were added to the volume of RSB-G40 
(10% of final volume was sodium deoxycholate and 10% was Tween 20), samples were tapped to mix, 
incubated on ice for 5 minutes, and pelleted by centrifugation (7000rpm, 3 minutes). The supernatant was 
collected and combined with first cytoplasmic fraction, and nuclear pellet was washed two times with 
RSB-G40 Buffer, and then resuspended in RSB-G40 Buffer. Fractionated cells were Turbo DNase I-
treated, according to manufacturer's instructions (NEB), prior to RNA extraction to remove bound DNA 
and improve recovery of RNA. Total cell (second pellet), cytoplasmic, and nuclear RNA was extracted 
using TRIzol Reagent (Life Technologies) per manufacturer's instructions (Glycoblue was added during 
isopropanol precipitation step due to small amounts of RNA recovered from nuclear fraction) and treated 
with Turbo DNAfree DNase (Ambion) for 20 minutes at 37°C. qRT-PCR analysis was performed using 
cDNA generated using equal concentration of RNA with exogenous C. elegans RNA (70ng) added for 
normalization.  
 
I. Cell proliferation assay 
 
 Cell proliferation was monitored using Cell Counting Kit - 8 (CCK-8) (Sigma-Aldrich). 24 hours 
(CaSki) or 48 hours (201402) after transfection with FAM83H-AS1 siRNA, CaSki cells were detached 
with 0.05% trypsin and W12/201402 cells were detached with 0.25% trypsin. After cell detachment, 
trypsin was inactivated with trypsin neutralizer (CaSki) or E-media containing serum (201402), pelleted, 
resuspended in appropriate media containing serum, and plated at desired concentration (3E3 cells per 
well and of four separate 96-well plates; technical triplicates). In equal density per well, 3T3M fibroblasts 
treated with mitomycin C were added to the W12/201402 cells and fibroblast alone control wells were 
plated. At desired time (48, 72, or 96h post-plating), CCK-8 dye (100uL/well) was added to each well, 
114 
 
incubated for 2 hours (CaSki) or 3 hours (201402). Then, absorbance was read with a spectrophotometer 
(BioTek Synergy H1 Hybrid Reader) (OD450) according to manufacturers' protocols. Absorbances of 
feeders alone were subtracted from W12/201402 co-cultured with feeders. Biological replicate was 
conducted. 
 
J. Flow-cytometric analysis of cell cycle.  
 
 3T3M fibroblasts were stained with CellTraceTM Far Red Cell Proliferation Kit (Invitrogen) the 
day before plating transfected 201402 cells. 24 hours (CaSki) or 48 hours (201402) after transfection with 
FAM83H-AS1 siRNA, cells were detached with 0.05% trypsin (CaSki) or 0.25% trypsin (201402). After 
cell detachment, trypsin was inactivated with trypsin neutralizer (CaSki) or media containing serum 
(201402), and cells were plated at desired concentration (4E6 for CaSki and 2.3E6 for 201402) in 100mm 
dishes in media containing fetal bovine serum (FBS). Mitomycin C treated, far red stained 3T3M cells 
were added to the 201402 cells. Cells were allowed to attach (about 5 hours) then were washed 3 times 
with 1X D-PBS to remove residual FBS. Cells were then serum-starved for 24 hours. After incubation, 
cells were trypsinized with 0.25% trypsin, suspended in serum-free media (to avoid stimulation by 
serum), washed with 1X PBS, pelleted, and resuspended in PBS (200µL). Harvested cells were then fixed 
by adding 70% cold ethanol (1.8mL) while vortexing the cells and stored at 4°C until processing. Cells in 
ethanol were pelleted, washed with PBS, centrifuged, and resuspended in room temperature 0.2% Tween 
20 in PBS (300-1,000µL, depending on pellet size). 100uL of each sample was placed in a U-bottom 96-
well plate (3 wells/technical triplicates) and incubated 15 minutes at 37°C. PBS (100uL) was added to 
each well, cells were pelleted, resuspended in 10uL of RNase A-PBS (180ug/mL stock), tapped gently to 
mix, and incubated at room temperature for 15 minutes. After incubation, 20uL of PI-PBS (final 
concentration of 50µg/mL) was added to each well, pipetted to mix, and incubated for 15 minutes at room 
temperature. After incubation, the volume was brought up to 300uL and analyzed in the dark by flow 
cytometry (Fortessa S10). Gates were placed around 201402 population. Biological replicate was 
conducted.  
 
K. Transwell migration assay 
 
 24 hours (CaSki) or 48 hours (201402) after transfection with FAM83H-AS1 siRNA, cells were 
detached with 0.05% trypsin. After cell detachment, trypsin was inactivated with trypsin neutralizer, 
pelleted, resuspended in serum-free media, and cells were plated [1E5 (CaSki) or 0.75E5 (201402), 
200uL well, technical duplicates] in upper chambers of 24-well transwell (8mm pore size) with 800uL 
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serum-free media in lower chamber. In equal density per well, 3T3M fibroblasts treated with mitomycin 
C were added to the W12/201402 cells and fibroblast alone control wells were plated. Cells were then 
allowed to attach for ~3 hours prior to adding fetal bovine serum (final concentration of 20% for CaSki 
and 5% for W12/201402) to lower chamber. After 24 hours, media in upper chamber was replenished 
with appropriate fresh serum free media and lower chamber with appropriate fresh media containing with 
FBS chemoattractant. 48 hours after cells were plated, lower chamber/underside of transwell and upper 
chamber of transwell were washed with 25% D-PBS. D-PBS was removed and cells from the top of the 
upper chamber transwell membrane (non-migrated cells) were wiped away using a cotton swab. The 
lower chamber/underside of the transwell and upper chamber of transwell were washed again with 25% 
D-PBS and then the underside of the transwell (migrated cells) was fixed with 4% formaldehyde in 25% 
D-PBS in the lower chamber for 5 minutes at room temperature. The formaldehyde solution was removed 
and the lower chamber/underside of transwell and upper chamber of transwell were washed with 25% D-
PBS. The cells on the underside of the transwell were then stained using 0.5% crystal violet in 20% 
ethanol in water. The stain was added to the lower chamber, submerging the transwell for 20 minutes at 
room temperature. The stain was removed and the lower chamber/underside of the transwell and upper 
chamber of transwell washed 3 times with 25% D-PBS. The top of the upper chamber transwell 
membrane was then cleaned with a cotton swab. The transwells were allowed to dry overnight and then 
the underside of the transwell imaged with an Olympus MVX10 microscope. Migration was quantitated 
with ImageJ. Feeders alone were subtracted from W12/201402 co-cultured with feeders. Biological 
replicate was conducted.  
 
L. Flow-cytometric analysis of apoptosis 
 
 3T3M fibroblasts were stained with CellTraceTM Far Red Cell Proliferation Kit (Invitrogen) the 
day before plating transfected 201402 cells. 24 hours (CaSki) or 48 hours (201402) after transfection with 
FAM83H-AS1 siRNA, cells were detached with 0.05% trypsin (CaSki) or 0.25% trypsin (201402). After 
cell detachment, trypsin was inactivated with trypsin neutralizer (CaSki) or media containing serum 
(201402), pelleted, resuspended in appropriate media containing serum, and cells were plated in 100mm 
dishes at desired concentration (1.75E6 for CaSki and 1.1E6 for 201402). At 24, 48, and 72h later post-
plating, attached and floating cells were collected. On day of harvest, media containing dead cells was 
collected, PBS was added to the plates, collected, and added to the media. Attached cells were trypsinized 
with 0.25% tryspin, cells were pelleted (2 to 5E6) at 4°C, resuspended in PBS, and 100uL of each sample 
was aliquotted into 3 wells of a 96 well plate (technical triplicates). Cells were pelleted, PBS was 
removed, Annexin V Binding Buffer (100uL; diluted with autoclaved milliQ water) was added to each 
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tube, Annexin V-FITC (5uL) was added to each tube, and incubated in the dark at room temperature for 
10 minutes. After incubation, cold Binding buffer (200uL) was added to each tube, cells were pelleted, 
washed with cold Binding buffer two times, incubated on ice for 5 minutes in propidium iodine in 
Binding buffer (2ug/mL final concentration, 300uL), and analyzed by flow cytometry (Fortessa S10) 
immediately. Gates were placed around 201402 population. Biological replicate was conducted.  
 
M. Human cervical tissue specimen  
 
 10 human specimens were obtained from patients under the tissue collection protocol [Prognostic 
Marker (IRB0406147)] at the University of Pittsburgh. Patient samples were categorized as cervical 
intraepithelial neoplasia stage 3 (CIN3), invasive cervical cancer (CaCx), or non-cancerous.  
 
N. TCGA Analysis 
  
 The Cancer Genome Atlas (TCGA) (https://cancergenome.nih.gov/) contains patient survival and 
RNA sequencing data from 196 cervical squamous cell carcinoma and endocervical adenocarcinoma 
(CESC) human patient samples. TCGA-CESC reads per kilobase million (RPKM) data was extracted, 
and average RPKM for all patients combined was calculated. TCGA also contains RPKM data from 3 
individual non-cancerous cervical samples that were averaged together to compare to CESC RPKM 
values. The Atlas of non-coding RNA in Cancer (TANRIC) (MD Anderson Cancer Center)4 that utilizes 
TCGA-CESC dataset to characterize the expression profiles of long non-coding RNAs (lncRNAs) was 
used to extract FAM83H-AS1 expression in each of the TCGA-CESC patient samples. Classification and 
Regression Trees (CART) analysis was used to statistically define high/low lncRNA expression groups. 
The cut-off z score value was 3 to discern between high and low expression groups. Survival curves were 
estimated by the Kaplan-Meier method. The log-rank test was used to estimate statistical differences 
between survival curves. GraphPad software was used to make the survival plots.  
 
O. Statistics 
  
 Student's t-test was utilized to determine mean values differences between groups examined and 
significance was determined at p ≤ 0.05 (*) and p ≤ 0.01 (**). Scale bars represent Standard Deviations 
(SD).  
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I. Contribution to the Project 
 
 
 I assisted in numerous ways to progress the research presented in Chapter 3 to publication. I 
primarily conducted experiments that advanced the content in Figures 3-6. While obtaining data for these 
figures, I cultured cells (including human foreskin fibroblasts (HFFs) and human embryonic kidney 
(HEK293T)), and, on multiple occasions, I assisted with plating, inducing cellular quiescence (by serum 
starvation or confluency), transfecting, transducing, and pelleting cells, as needed (in experiments not 
described below). Additionally, I contributed to the development of several experiments stated below. 
 
 I conducted preliminary experiments in HFFs to optimize transfection conditions for future 
experiments. I determined optimal amounts of plasmid (GFP) and Lipofectamine for proliferating and 
quiescent cells (data not shown). 
 
 I conducted a preliminary experiment to determine how long microRNAs (miRNAs) could be 
expressed after knockdown of Exportin-1 (XPO1) followed by induction of quiescence for future 
experiments. To do this, I cultured and transfected HFF cells with Lipofectamine and siRNA against XPO1. 
Once cells were 100% confluent, I pelleted the cells at Day 0, 3, 6, 9, 12 for protein and RNA expression 
analysis. I conducted RNA extraction, cDNA synthesis, and qRT-PCR analysis to confirm knockdown of 
XPO1 and differential expression of other select genes (data not shown).  
 
 We analyzed downstream effects of individual knockdown of Exportin-5 (XPO5) (Fig. 3A, SI 
Appendix, Figs. S6A) and XPO1 (Figs. 3B-C, SI Appendix, Figs. S6B and S7A-E) in proliferating and 
quiescent HFFs using multiple siRNAs against XPO5 and XPO1, respectively. The Western Blot analysis 
I conducted were used in the manuscript for siRNA against XPO5 (Fig. 3A (right panel), SI Appendix Fig. 
S6A (middle panel)) and XPO1 (Fig. 3B (right panel), SI Appendix, Figs. S6B (middle panel) and S7D) as 
well as the samples I conducted RNA extraction, cDNA synthesis, and qRT-PCR analysis on to show RNA 
changes with individual siRNA against XPO5 (SI Appendix, Fig. S6A (left panel)) and individual siRNA 
against XPO1 (SI Appendix, Fig. S6B (left panel), S7A-C). Collaborators then used these samples for 
downstream experiments (Fig. 3C, SI Appendix, Figs. S6A-B (right panels), SI Appendix, Fig. S7E).  
 
 We exogenously expressed XPO1 in HFFs, immunoprecipitated XPO1, and discovered primary 
microRNAs (pri-miRNAs) that are bound to XPO1 (Fig. 3D, SI Appendix, Figs. S7F, S7G). To do this, we 
initially optimized transfection conditions (plasmid concentration and Lipofectamine volume) of an 
expression vector (not retroviral) (p3XFlag-XPO1). A collaborator transfected the cells. I then pelleted and 
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conducted RNA extraction, cDNA synthesis, and qRT-PCR analysis as well as protein extraction and 
Western Blot analysis to confirm XPO1 expression (data not shown). We were having difficulty 
exogenously expressing XPO1 with this construct, so I transformed and maxi-prepped to extract fresh 
plasmid. I performed a restriction digestion and ran the samples in an agarose gel to confirm the correct 
predicted size insert was digested (data not shown). To quickly determine if fresh plasmid solved the issues, 
I transfected the p3XFlag-XPO1 plasmid into HEK293T cells with Lipofectamine and performed Western 
Blot analysis (data not shown). A collaborator attempted to transfect the XPO1 expression constructs by 
nucleofection, and I performed Western Blot analysis to detect XPO1 protein knockdown (data not shown). 
Then, a collaborator transfected proliferating and serum-starved HFFs with p3X-Flag XPO1 and attempted 
multiple immunoprecipitations (IP) with an antibody against Flag. For this IP, I aided by crosslinking and 
conducting downstream RNA extraction, cDNA synthesis, and qRT-PCR analysis as well as protein 
extraction and Western Blot analysis (data not shown). Due to technical issues, a collaborator cloned XPO1 
into a retroviral vector (pBABE-Flag-XPO1). I transfected HEK293T with a calcium phosphate protocol 
to produce a retrovirus that was transduced into HFFs to successfully exogenously expressed XPO1 in 
HFFs. A collaborator serum-starved cells, then I crosslinked, immunoprecipitated with an antibody against 
Flag, performed Western Blot analysis (SI Appendix, Fig. S7F (left panel)) and initiated RNA extraction 
used for the figure in the manuscript to identify pri-miRNAs bound to XPO1 (Fig. 3D, SI Appendix, Fig. 
S7F (right panel), Fig. S7G). I performed replicates of this experiment. It was desired for potential future 
experiments to stably select a pool population and single cell clones of HFFs expressing XPO1. 
Unfortunately, after I transfected HEK293T (pBABE-Flag-XPO1), transduced HFFs, selected with 
antibiotics, and cultured the "stable" pool and single cell clones, they did not maintain exogenous expression 
of XPO1 after multiple passages (data not shown).  
  
 We knocked down TGS1 in proliferating and quiescent HFFs using siRNA against TGS1 (Fig. 4, 
SI Appendix, Figs. S8 and S9). Prior to my assistance, my collaborators were observing only moderate 
knockdown of TGS1 at the RNA level with siRNA against TGS1 in HFFs. To aid in improving TGS1 
knockdown, we performed optimization experiments. I varied the amount of siRNA against TGS1 (while 
a collaborator varied the amount of Lipofectamine concentration) transfected into proliferating and 
quiescent cells to determine the optimal conditions to observe TGS1 knockdown without toxicity to the 
cells. I conducted RNA extraction, cDNA synthesis, and qRT-PCR analysis as well as protein extraction 
and Western Blot analysis on all of our samples to optimize TGS1 knockdown efficiency in HFFs (data not 
shown). After optimization, I significantly aided in conducting multiple protein extraction and Western 
Blot analysis experiments as well as multiple RNA extraction, cDNA synthesis, and qRT-PCR analysis 
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using pellets provided by a collaborator who performed the upstream portion of experiments (Fig. 4, SI 
Appendix Figs. S8 and S9).  
 
 After we obtained results presented in Figure 4, we pursued the potential of Snurportin-1 in 
regulating localization of the TMG-capped pri-miRNAs induced during quiescence (data not shown). 
(Snurportin-1 is involved with recognizing a (m2,2,7G, TMG)-cap on certain small nucleolar RNAs 
(snRNAs) to import them to the nucleus from the cytoplasm(1)). I performed preliminary experiments to 
explore the regulation of Snurportin-1 in quiescent versus proliferating cells. To do this, I conducted 
Western Blot analysis of HFFs cells that were quiescent for 0, 1, 2, 3 days to analyze for protein expression 
changes in Snurportin-1 (data not shown). Additionally, I conducted Western Blot analysis on HFF cell 
pellets with siRNA against Snurportin-1 provided by a collaborator so I could detect knockdown of 
Snurportin-1 protein (data not shown). 
 
 We knocked down Drosha and XPO1 individually as well as together in proliferating and quiescent 
HFFs for downstream experiments (Fig. 5, SI Appendix, Figs. S10 and S12). I conducted Western Blot 
analysis to confirm Drosha and/or XPO1 knockdown (SI Appendix, Fig. S12 (top panel)) prior to a 
collaborator performing downstream experiments with these samples (Fig. 4, SI Appendix, Figs. S12 
(bottom panel), S10).  
 
 After we identified an increased expression of a short isoform of Drosha in quiescent cells (Fig. 
6A), we used a pool of three siRNAs to target Drosha mRNA in proliferating and quiescent cells and 
determined that these siRNAs were knocking down both isoforms of Drosha (SI Appendix, Fig. S13A). To 
do this experiment, a collaborator performed upstream knockdown experiments, and I processed the 
provided pellets through protein extraction and Western Blot analysis. The data I obtained was used in the 
manuscript (SI Appendix, Fig. S13A).   
 
 We performed cellular fractionation of quiescent and proliferating HFFs to determine localization 
of Drosha (Fig. 6B). While a collaborator was optimizing cellular fractionation conditions for proliferating 
and serum-starved HFFs, I processed multiple rounds of pellets for protein extraction and Western Blot 
analysis. Additionally, I obtained the data that was used in the manuscript (Fig. 6B). 
 
 Moreover, I proofread the manuscript prior to the initial submission and re-submission after 
revisions as well as proofread the comments to the reviewers upon re-submission.  
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 In summary, my experimental and writing contribution to this specific manuscript were substantial. 
The participation in this project helped me learn several molecular techniques as well as the process of 
submission and publication of its findings. 
 
1. Huber J, Cronshagen U, Kadokura M, Marshallsay C, Wada T, Sekine M, Luhrmann R. 
1998. Snurportin1, an m3G-cap-specific nuclear import receptor with a novel domain structure. 
Embo j 17:4114-4126. 
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II. Abstract  
 
 The reversible state of proliferative arrest known as cellular quiescence plays an important role in 
tissue homeostasis and stem cell biology. By analyzing the expression of microRNAs (miRNAs) and 
miRNA processing factors during quiescence in primary human fibroblasts, we identified a group of 
miRNAs that are induced during quiescence despite markedly reduced expression of Exportin-5, a protein 
required for canonical miRNA biogenesis. The biogenesis of these quiescence-induced miRNAs is 
independent of Exportin-5 and depends instead on Exportin-1.  Moreover, these quiescence-induced 
primary (pri)-miRNAs are modified with a 2,2,7-trimethylguanosine (TMG)-cap, which is known to bind 
Exportin-1, and knock-down of Exportin-1 or trimethylguanosine synthase 1, responsible for (TMG)-
capping, inhibits their biogenesis. Surprisingly, in quiescent cells Exportin-1-dependent pri-miR-34a is 
present in the cytoplasm together with a small isoform of Drosha, implying the existence of a different 
miRNA processing pathway in these cells. Our findings suggest that during quiescence, the canonical 
miRNA biogenesis pathway is down-regulated, and specific miRNAs are generated by an alternative 
pathway to regulate genes involved in cellular growth arrest. 
 
III. Significance 
 
 Quiescence is a growth-arrested cellular state where genes involved in this process are finely 
regulated by several factors including miRNAs. During miRNA biogenesis, Exportin-5 transports miRNA 
precursors from the nucleus to the cytoplasm. In this study, we demonstrated the existence of an alternative 
miRNA biogenesis pathway in quiescent primary human cells.  This pathway involves the repression of 
Exportin-5 expression by autophagy and miRNAs, and the (TMG)-cap modification of specific pri-
miRNAs, which signals their export to the cytoplasm by Exportin-1. We further showed that these pri-
miRNAs are rapidly processed in the cytoplasm by a small isoform of Drosha. Collectively, these results 
reveal a new mechanism of miRNA biogenesis that will expand our understanding of miRNA regulation in 
normal or disease-related cells. 
 
IV. Introduction 
 
Most metazoan cells enter a reversible cell cycle arrest known as cellular quiescence when they are 
exposed to anti-mitogenic signals or an environment unfavorable for proliferation (2, 3). In mammalian 
cells, quiescence (also known as G0 arrest) is characterized by reduced DNA replication, altered 
metabolism, increased autophagy, and increased expression of cyclin-dependent kinase inhibitors such as 
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p27Kip1 (4, 5). In vitro, quiescence can be induced in primary cells by serum starvation, contact inhibition, 
and loss of adhesion to a substrate (6). Quiescence is involved in important cellular processes including the 
balance between differentiation and self-renewal in different types of stem cells, and dysregulation of 
quiescence could favor carcinogenesis. However, the molecular mechanisms that regulate quiescence are 
poorly understood (7).  
 
MicroRNAs (miRNAs) are small non-coding RNAs ~22-nucleotides (nt) long that regulate the 
expression of protein-coding genes by base-pairing with the 3’ untranslated region (3’UTR) of messenger 
RNAs (mRNAs), repressing translation and/or inducing degradation of the target mRNA (8, 9). In canonical 
miRNA biogenesis in mammalian cells, miRNAs are transcribed by RNA polymerase II to produce 7-
methylguanosine-capped (m7G) primary miRNAs (pri-miRNAs) containing one or more bulged hairpin 
structures that are recognized by the nuclear microprocessor, which consists of the ribonuclease (RNase) 
III enzyme Drosha and the double-stranded RNA (dsRNA) binding protein DiGeorge syndrome critical 
region gene 8 (DGCR8) (10-13). Specific cleavage of the pri-miRNA by the nuclear microprocessor 
generates an ~70-nt stem-loop structure known as the precursor miRNA (pre-miRNA), which is recognized 
and transported to the cytoplasm by Exportin-5 (XPO5) (4, 11, 12, 14). Subsequently, pre-miRNA is 
cleaved by the cytoplasmic RNase III enzyme Dicer (15-18), generating a double-stranded mature miRNA. 
Finally, the guide miRNA strand is loaded into the RNA-induced silencing complex (RISC) containing one 
of four Argonaute proteins and GW182 protein at its core (19-21). 
 
Recent studies have identified alternative pathways of microRNA biogenesis in different cell and 
animal models: pre-miRNA/introns miRNAs (miRtrons), which are Drosha and DGCR8 independent (22); 
Drosha and DGCR8-independent viral miRNAs that use the Integrator complex to produce viral pre-
miRNAs (23); miRNAs independent of DGCR8, Exportin-5, Dicer and Argonaute 2 (AGO2) known as 
Simtrons (24), which are exported from the nucleus by an unknown mechanism; Dicer-independent 
miRNAs, such as miR-451, which are generated by the catalytic activity of AGO2 (25, 26); and cytoplasmic 
re-localization of Drosha by RNA viruses, with no changes in endogenous miRNA expression but robust 
synthesis of viral miRNAs (27). Recently, we reported a novel class of (m7G)-capped pre-miRNAs in 
human cells whose 5’ end corresponds to the transcription initiation site (28); these pre-miRNAs are 
exported from the nucleus by Exportin-1 rather than Exportin-5.  
 
Exportin-1 recognizes certain RNAs including viral mRNAs, cellular mRNAs, and small nuclear 
RNAs (snRNAs) and exports them from the nucleus to the cytoplasm (29). For example, precursors of 
snRNAs involved in mRNA processing such as U1, U2, U4, and U5 have a (m7G)-cap, which is recognized 
125 
 
by cap-binding complex (CBC) and the phosphorylated adaptor for RNA export (PHAX) in the nucleus to 
enable their export to the cytoplasm (30) by Exportin-1. These snRNAs are then recognized by Sm proteins 
in the cytoplasm and trimethylguanosine synthase 1 (TGS1) is recruited to hypermethylate the (m7G)-cap 
into a (m2,2,7G, TMG)-cap. This modification is recognized by Snuportin-1 in association with Importin-β 
and other factors to import the snRNAs back into the nucleus (31, 32).  Interestingly, Exportin-1 also has 
high affinity for the (TMG)-capped small nucleolar RNA (snoRNA) U3 in the nucleus and transports it 
from Cajal bodies to the nucleoli (33). Another study showed that TGS1 enhances Rev-dependent HIV-1 
RNA expression by (TMG)-capping viral mRNAs in the nucleus, thereby increasing recognition by 
Exportin-1 for transport to the cytoplasm (34).  
 
miRNAs play an important role in regulating cellular quiescence. For example, it has been shown 
that over-expression of miR-221 and miR-222, both of which target the 3’UTRs of p27 and p57 mRNA, 
induce S-phase entry in quiescent cells (35). Another study reported up-regulation of let-7 and miR-125 
and down-regulation of the miR-29 family in quiescent fibroblasts (36).  Furthermore, over-expression of 
miR-29 increased cell cycle re-entry in quiescent cells, whereas over-expression of let-7 and miR-125 
delayed cell cycle re-entry (36). Modulation of miR-29 can also influence senescence, an irreversible 
growth arrested state, by affecting B-myb expression (37). We also showed that during quiescence some 
miRNAs up-regulate translation of their target mRNAs (38). Finally, Exportin-5 protein expression is 
reduced during quiescence and promptly induced during cell cycle entry, causing a global increase in 
miRNA expression (39).  
 
Here, we report the existence of an alternative miRNA biogenesis pathway in primary human 
foreskin fibroblasts (HFFs) during quiescence. We confirmed that the level of Exportin-5 is substantially 
reduced during quiescence and that certain miRNAs are induced during quiescence despite this paucity of 
Exportin-5. We also demonstrate that the biogenesis of pri-miRNAs corresponding to these miRNAs is 
dependent not on Exportin-5, but rather Exportin-1.  Furthermore, the Exportin-1-dependent pri-miRNAs 
have a trimethylguanosine (m2,2,7G, TMG)-cap and are found in the cytoplasm during quiescence, as is a 
smaller isoform of Drosha. Together, our findings suggest that in quiescent cells, an alternative miRNA 
biogenesis pathway selectively processes and transports a specific set of miRNAs, which could be essential 
for reversible G0 arrest. 
 
V. Results  
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A. Differential expression of specific pri-miRNAs and their corresponding mature miRNAs during 
quiescence 
 
To examine global miRNA expression during quiescence, miRNA microarrays that interrogated 
1105 mature human miRNAs were used to compare proliferating HFFs and quiescent HFFs after 12, 48, 
and 72 h of serum starvation. We identified 88 up-regulated and 94 down-regulated miRNAs that changed 
1.5-fold or more for at least two time-points of serum starvation (Fig. 1A and SI Appendix, Tables S1, S2). 
As assessed by qRT-PCR, mature miR-26a-2, miR-34a, miR-126, miR-199b, miR-638, miR-1228*, and 
miR-3188 were induced two- to four-fold by serum starvation, and miR-17, miR-18a, miR-29b, miR-155, 
and miR-423-3p were repressed two- to three-fold, confirming the microarray data (Fig. 1B). There was a 
similar pattern of miRNA expression (with the exception of miR-26a-2 and miR-126) when quiescence was 
induced by confluency (SI Appendix, Fig. S1A). Northern blot analysis confirmed induction of 
representative miRNAs in quiescence induced by serum starvation or confluency (SI Appendix, Fig. S2). 
By using specific primers to amplify the pri-miRNAs of these differentially expressed miRNAs (SI 
Appendix, Table S3), we found that the mature miRNAs induced during quiescence are also induced at the 
pri-miRNA level (Fig. 1C and SI Appendix, Fig. S1B). In contrast, rather than being repressed, the levels 
of the pri-miRNAs corresponding to the repressed mature miRNAs miR-17, miR-18a, miR-29b, miR-155, 
and miR-423-3p were induced during quiescence (Fig. 1C and SI Appendix, Fig. S1B), suggesting that 
repression of these miRNAs is due to post-transcriptional regulation, presumably during their processing 
through the microRNA biogenesis pathway. 
 
B. Exportin-5 expression is down-regulated by autophagy and miR-34a during quiescence. 
 
To explore the mechanism of miRNA synthesis in quiescent cells, the abundance of proteins 
involved in miRNA biogenesis was examined in quiescent HFF. Confirming the previous findings of 
Iwasaki and collaborators (39), Exportin-5 protein levels were dramatically reduced (~30-fold) during 
quiescence induced by serum starvation (Fig. 2A, and SI Appendix, Fig. S3A) or contact inhibition (SI 
Appendix, Fig. S3B), as assessed by immunoblotting and immunofluorescence. Exportin-5 protein was also 
reduced in serum-starved HeLa (human cervical carcinoma) and C127 (murine mammary tumor) cell lines 
(SI Appendix, Fig. S3C). The level of Exportin-5 mRNA did not change during quiescence (SI Appendix, 
Fig. S3 D and E), indicating that Exportin-5 is regulated at the post-transcriptional level.  The level of 
Exportin-1, a protein involved in protein and RNA export (29), did not change during quiescence (Fig. 2A, 
and SI Appendix, Fig. S3B). The quiescence marker p27 was induced, as expected (40). 
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 To determine the basis for the reduction in Exportin-5 expression during quiescence, we blocked 
two major pathways of protein degradation, the proteasome and the autophagy pathways. Treatment of 
quiescent cells with the proteasome inhibitor, MG132, did not restore Exportin-5 expression, whereas the 
protein MDM2, which is known to be degraded by the proteasome, is maintained upon MG132 treatment, 
as expected (Fig. 2B, and SI Appendix, Fig. S4A). In fact, the level of Exportin-5 was further reduced in 
response to MG132 treatment, suggesting that a down-regulation pathway is induced by this drug (Fig. 2B). 
Treatment with 3-methyladenine (3-MA), an autophagy inhibitor, reduced the level of Exportin-5 in 
proliferating cells (Fig. 2C). Strikingly, treatment of quiescent HFFs with 3-MA restored the levels of 
Exportin-5 and of p62, a protein specifically degraded by autophagy (Fig. 2C and SI Appendix, Fig. S4B). 
These data suggest that the autophagy pathway is responsible for accelerated degradation of Exportin-5 
during quiescence.  
 
 We also tested whether Exportin-5 levels are modulated by miRNAs.  The 3’UTR of the Exportin-
5 mRNA contains a conserved predicted binding site for miR-34a (Fig. 2D and SI Appendix, Fig. S5), which 
as shown above is induced during quiescence (Fig. 1B and SI Appendix, Fig. S1A). To determine if miR-
34a affects expression of Exportin-5, we transfected synthetic miR-34a into proliferating HFF cells and 
examined the expression of Exportin-5 after 48 h. As shown in Figure 2E, transfected miR-34a reduced the 
amount of endogenous Exportin-5 protein but not Exportin-5 mRNA, suggesting translational repression 
of Exportin-5 by miR-34a. In contrast, there was no change in expression of Exportin-1, which does not 
contain a miR-34a binding site in its 3’UTR. To determine if there is a direct functional interaction between 
miR-34a and Exportin-5 mRNA, we cloned the complete 3’UTR of the Exportin-5 gene (1,537 nt) into a 
luciferase reporter vector and transfected quiescent HFF cells with the empty reporter vector, the reporter 
vector containing the Exportin-5 3’UTR, or a reporter vector containing the Exportin-5 3’UTR with three 
point mutations in the miR-34a seed sequence binding site (Fig. 2D). As shown in Figure 2F, luciferase 
activity from the vector containing the wild-type Exportin-5 3’UTR was reduced about two-fold during 
quiescence compared to the vector lacking the 3’UTR, and there was partial recovery of luciferase activity 
in response to the mutant 3’UTR.  These results suggest that regulation of Exportin-5 expression in 
quiescent cells is mediated in part by miR-34a. We also co-transfected proliferating HFFs with the 
Exportin-5 3’UTR luciferase reporter vectors and synthetic miR-34a or scrambled control miRNA. miR-
34a but not the control miRNA caused a reduction in luciferase activity from the wild-type Exportin-5 
3’UTR reporter but not from the miR-34a binding site mutant or empty vector (Fig. 2G).  Together these 
results demonstrate a functional interaction between Exportin-5 3’UTR and miR-34a. We conclude that 
Exportin-5 expression is regulated at two different levels during quiescence, at the protein level by 
autophagy and at the mRNA level by miR-34a. 
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C. Expression of quiescence-induced miRNAs is not dependent on Exportin-5.  
 
The increase in the levels of specific mature miRNAs in quiescent cells expressing little Exportin-
5 raised the possibility that these quiescence-induced miRNAs are generated by an Exportin-5-independent 
pathway. To investigate this possibility, we transiently transfected proliferating HFFs with an siRNA 
against Exportin-5 and 48 h later measured miRNA levels. Exportin-5 knock-down was confirmed by 
Western blot and qRT-PCR (Fig. 3A). As expected, Exportin-5 knock-down in proliferating cells lowered 
levels of mature miR-17, miR-18a, miR-29b, miR-155, and miR-423-3p, which are repressed during 
quiescence (Fig. 3A, dark gray bars). In contrast, levels of their corresponding primary miRNAs did not 
decline (Fig. 3A, light gray bars), consistent with Exportin-5 being required for maturation of these 
miRNAs, as it is for all canonically processed miRNAs. Strikingly, however, Exportin-5 knock-down did 
not repress the levels of several mature miRNAs and pri-miRNAs that are induced during quiescence, 
including miR-26a, miR-34a, miR-126, miR-199b, miR-638, and miR-3188 (Fig. 3A). Similar results were 
obtained with a second Exportin-5 siRNA in an independent experiment (SI Appendix, Fig. S6A). Although, 
we cannot exclude other possibilities such as a higher affinity for Exportin-5 by some quiescence-induced 
miRNAs (which can thus tolerate lower Exportin-5 levels), or differences in the stability of the mature 
miRNA (41), our findings suggest that the biogenesis of these miRNAs can proceed via an Exportin-5-
independent mechanism, even in proliferating cells.  
 
D. Exportin-1 is required for processing of quiescence-induced miRNAs.  
 
The results in the preceding section imply that an export factor other than Exportin-5 is required 
for the synthesis of mature miRNAs during quiescence.  Previous studies showed that Exportin-1, an 
essential transport factor for certain proteins and RNAs, supports pri-miRNA processing in C. elegans and 
Drosophila, as well as shuttling of mature miRNA from the cytoplasm to the nucleus (29, 42, 43).  Recently, 
we showed that Exportin-1 is involved in the nuclear export of a group of mammalian (m7G)-capped pre-
miRNAs in proliferating cells (28).    
 
To test whether Exportin-1 is involved in the biogenesis of the miRNAs induced in quiescent cells, 
we transiently transfected proliferating HFFs with an siRNA targeting Exportin-1 and confirmed siRNA-
mediated reduction of Exportin-1 but not Exportin-5 expression (Fig. 3B).  Strikingly, Exportin-1 knock-
down in proliferating cells inhibited the expression of several of the mature miRNAs that are induced during 
quiescence, namely miR-26a, miR-34a, miR-126, miR-199b, miR-638, miR-1228*, and miR-3188 (Fig. 
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3B, dark gray bars). Notably, the levels of the pri-miRNAs corresponding to these miRNAs did not decline 
(Fig. 3B, light gray bars); in fact, pri-miR-34a increased five- to nine-fold in the absence of Exportin-1. The 
levels of Exportin-5-dependent miRNAs miR-17, miR-18a, miR-29b, miR-155, and miR-423-3p were also 
reduced in proliferating cells by Exportin-1 knock-down (Fig. 3B, dark gray bars), but the corresponding 
primary miRNAs of these mature miRNAs were also decreased, suggesting a reduction of transcription or 
changes in pri-miRNA turnover in the absence of Exportin-1. Mature miR-155 and the Simtron miR-1228* 
but not their corresponding pri-miRNAs were reduced by both Exportin-5 and Exportin-1 knock-down (Fig. 
3 A and B, dark gray bars), suggesting that both exportins are involved in the biogenesis of these miRNAs. 
Similar results were obtained with a second Exportin-1 siRNA experiment (SI Appendix, Fig. S6B). 
 
To test the contribution of Exportin-1 to miRNA levels during quiescence, we knocked down 
Exportin-1 in serum-starved cells and measured the levels of mature miRNAs. Exportin-1 knock-down in 
quiescent cells did not affect the level of Exportin-5 or p27 mRNA or other proteins involved in miRNA 
biogenesis such as DGCR8, Drosha, Exportin-5, Dicer, and AGO2 (SI Appendix, Fig. S7A-D). 
Nevertheless, Exportin-1 knock-down prevented or attenuated the increase of the quiescence-induced 
miRNAs: miR-34a, miR-638, miR-3188, and miR-1288* (Fig. 3C). The Exportin-1-dependence of miR-
34a expression in quiescent cells was confirmed by Northern blot (Fig. 3C).  Because the expression of the 
other quiescence-induced miRNAs was difficult to detect by Northern blotting, we focused on miR-34a in 
subsequent experiments. Interestingly, Exportin-1 knock-down did not change the percentage of HFFs 
entering quiescence after 24 h of serum starvation but caused a two-fold decrease in the percentage of cells 
in S phase 24 h after the addition of serum, suggesting that Exportin-1-mediated miRNA biogenesis may 
be required for normal exit from quiescence (SI Appendix, Fig. S7E). 
 
We used protein-RNA crosslinking followed by Exportin-1 immunoprecipitation to determine if 
there is a physical interaction between Exportin-1 and pri-miR-34. For this experiment we stably expressed 
FLAG-tagged Exportin-1 and immunoprecipitated cell extracts with an antibody recognizing the FLAG 
epitope (SI Appendix, Fig. S7F). The control snoRNA U3, which is normally transported by Exportin-1 
(33), was co-immunoprecipitated as expected (Fig. 3D and SI Appendix, Fig. S7G).  Strikingly, the 
Exportin-1-dependent pri-miR-34a but not the Exportin-5-dependent pri-miR-423-3 was co-
immunoprecipitated from quiescent HFFs by anti-Flag-Exportin-1 (Fig. 3D, and SI Appendix, Fig. S7G). 
Together, these results suggest that Exportin-1 is required for the export and/or processing of miRNAs 
induced during quiescence and that this activity involves a physical association between these pri-miRNAs 
and Exportin-1.  
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E. Exportin-1-dependent pri-miRNAs have a (TMG)-cap during quiescence. 
 
Previous reports showed that Exportin-1 can bind to (TMG)-capped RNAs such as snoRNA U3 
and viral Rev-dependent HIV-1 RNAs (33, 34). Therefore, we investigated whether pri-miRNAs of the 
Exportin-1-dependent miRNAs contain a (TMG)-cap. We used an antibody against (TMG)-caps (which 
does not cross-react with the (m7G)-cap (44)) and non-immune rabbit serum to perform 
immunoprecipitation from extracts of proliferating or quiescent HFFs.  Specific immunoprecipitated pri-
miRNAs were detected by RT-PCR amplification followed by gel electrophoresis.  As shown in Figure 4A, 
top panel, the control (TMG)-capped U3 snoRNA was amplified following anti-(TMG)-cap pull-down from 
both proliferating and quiescent HFF, as expected.  Strikingly, pri-miR-34a and pri-miR-3188, two 
quiescence-induced miRNAs, were also detected in the anti-(TMG)-cap immunoprecipitate from quiescent 
and to a lower extent from proliferating HFFs.  qRT-PCR data from a replicate experiment confirmed that 
pri-miR-34a and pri-miR-3188 were immunoprecipitated by the anti-(TMG)-cap antibody during 
proliferation and quiescence (SI Appendix, Fig. S8 and SI Appendix, Table S4). In contrast, pri-miR-29b 
and pri-miR-423, which are repressed during quiescence, were not detectable in the anti-(TMG)-cap pull-
downs. These results indicate that some quiescence-induced pri-miRNAs are specifically modified with a 
(TMG)-cap.  
 
TGS1, the enzyme that catalyzes 5’-cap hypermethylation, has two active isoforms, a short isoform 
in the nucleus and a full-length isoform in the cytoplasm (45).  We found that the short form of TGS1 is 
induced during quiescence, suggesting it may be responsible for cap hypermethylation of Exportin-1-
dependent pri-miRNAs (SI Appendix, Fig. S9A). Indeed, the ability of the anti-TMG antibody to 
immunoprecipitate pri-miR-34a and pri-miR-3188 (as well as the control U3 RNA) was dramatically 
diminished by siRNA-mediated knock-down of TGS1 in proliferating and quiescent HFFs (Fig. 4A, 
compare siRNA CTRL anti-TMG IP lanes against siRNA TGS1 anti-TMG IP lanes, and SI Appendix, Fig. 
S8 and S9 B and C), arguing that this enzyme is required for cap hypermethylation of these miRNAs. 
 
To further test the model that TMG capping is required for miRNA biogenesis in quiescent cells, 
we examined levels of mature miRNAs after knock-down of TGS1 in quiescent HFFs.  As shown in Figure 
4B, TGS1 knock-down inhibited the induction of the quiescence-induced miR-34a and miR-3188 but did 
not affect the abundance of the quiescence-repressed miR-423-3p and miR-29b. The knock-down of TGS1 
did not affect the expression of DGCR8, Drosha, or Exportin-5, and actually increased the expression of 
Dicer and AGO2 (SI Appendix, Fig. S9D). To investigate whether the (TMG)-cap modification in 
quiescence-induced pri-miRNAs is important for the interaction with Exportin-1, we used protein-RNA 
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crosslinking followed by immunoprecipitation of FLAG-Exportin-1 in quiescent HFFs that had been treated 
with control scrambled siRNA or siRNA against TGS1. snoRNA U3, which contains a (TMG)-cap, showed 
a reduced level of co-immunoprecipitation from cells treated with siRNA against TGS1, as expected (Fig. 
4C). Notably, Exportin-1-dependent pri-miR-34a was also co-immunoprecipitated to a lesser extent in cells 
after TGS1 knock-down (Fig. 4C), whereas the Exportin-5-dependent pri-miR-423 was not co-
immunoprecipitated in the presence or absence of TGS-1, reaffirming the hypothesis that this pri-miRNA 
does not contain a modified cap.  
 
Taken together, these findings indicate that the pri-miRNAs of quiescence-induced miRNAs are 
modified with a specific hypermethylation in their 5’-cap by TGS1, a modification important for Exportin-
1 recognition (33). 
 
F. Pri-miR-34a is present in the cytoplasm of quiescent cells together with a small isoform of Drosha. 
 
To examine whether quiescence-induced pri-miRNAs are exported to the cytoplasm as a 
consequence of (TMG)-capping and interaction with Exportin-1, we prepared nuclear and cytoplasmic 
RNA from proliferating and quiescent HFFs pretreated with control siRNA or a pool of siRNAs against 
Drosha (in order to minimize possible rapid processing of these pri-miRNAs (SI Appendix, Fig. S10). As 
expected, Exportin-1-dependent pri-miR-34a and Exportin-5-dependent pri-miR-29b and pri-miR-423 
were detected in the nuclear fraction of both proliferating and quiescent HFFs (Fig. 5A).  These nuclear pri-
mRNAs accumulated in response to Drosha knock-down, supporting previous studies that showed their 
Drosha dependency (46, 47). Strikingly, we also detected pri-miR-34a in the cytoplasmic fraction of 
proliferating and quiescent HFFs following Drosha knock-down, whereas pri-miR-29b and pri-miR-423 
were not detectable in this cellular fraction (Fig. 5 A and B). These data suggest that pri-miR-34a and 
possibly other quiescence-induced pri-miRNAs are transported into the cytoplasm where they are processed 
by an uncharacterized cytoplasmic form of Drosha. We also observed a reduction of all the pri-miRNAs in 
the nuclear fraction of the quiescent cells (Fig. 5A and SI Appendix, Fig. S11).  
 
To determine if the presence of cytoplasmic pri-miR-34a required Exportin-1, we simultaneously 
knocked down Exportin-1 as well as Drosha in quiescent HFFs and determined the level of cytoplasmic 
pri-miRNAs compared to cells treated with control siRNA or Droshan siRNA alone (SI Appendix, Fig. 
S12). As shown in Figure 5C and D, knock-down of Exportin-1 expression in quiescent HFFs greatly 
attenuated the increased amount of cytoplasmic pri-miR-34a in the Drosha knockdown cells and caused the 
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accumulation of this pri-miRNA in the nuclear fraction, suggesting that Exportin-1 is involved in the 
transport of pri-miR34a from the nucleus to the cytoplasm.  
 
To further explore the processing of pri-miRNAs in quiescent HFFs, we analyzed Drosha protein 
during quiescence. Western blotting showed the presence of full-length Drosha (~160 kDa) in proliferating 
and quiescent cells (Fig. 6A). In addition, quiescent cells displayed induction of a smaller Drosha band 
(~130 kDa) (Fig. 6A). A pool of three siRNAs that target Drosha mRNA in different regions caused a 
reduction in both bands, suggesting that the smaller band is a distinct splicing isoform or cleavage product 
of Drosha (SI Appendix, Fig. S13 A and B). An earlier publication also detected a smaller form of Drosha 
(~145 kDa) in HEK-293 cells, which was observed in a different protein complex than full-length Drosha, 
suggesting that it associates with different binding partners (12).  
 
To investigate the localization of these two different forms of Drosha, we examined nuclear and 
cytoplasmic fractions from proliferating and quiescent HFFs. The short form of Drosha was found 
specifically in the cytoplasmic fraction of quiescent HFFs (Fig. 6B). In addition, immunofluorescent 
staining of Drosha in proliferating and quiescent HFFs revealed a cytoplasmic signal during quiescence 
(Fig. 6 C and D), which was reduced by siRNA against Drosha (SI Appendix, Fig. S13E). Because DGCR8 
is essential for Drosha activity, we analyzed the cytoplasmic fraction of proliferating and quiescent HFFs 
for DGCR8. We were unable to detect DGCR8 in the cytoplasmic fractions by direct Western blotting (Fig. 
6B) or by blotting after immunoprecipitation (SI Appendix, Fig. S14A), suggesting that Drosha may interact 
with a different dsRNA binding protein in the cytoplasm, as was previously suggested (27). It is noteworthy 
that two recent publications demonstrated that alternative splicing of Drosha could affect its subcellular 
localization, consistent with our finding that a specific Drosha isoform exists in the cytoplasm of quiescent 
cells (48, 49). Furthermore, siRNA against DGCR8 in quiescent HFFs did not affect the biogenesis of the 
quiescence-induced miR-34a but altered the processing of the quiescence-repressed miR-423-3p (SI 
Appendix, Fig. S14B), supporting the existence of functional cytoplasmic Drosha without DGCR8.  
 
To characterize the short form of Drosha in quiescent cells, we amplified the Drosha open reading 
frame mRNA by tiling RT-PCR (SI Appendix, Fig. S15). Cloning and sequencing identified two exon-
skipping events in the same transcript, occurring in the 5’ half Drosha mRNA, during quiescence.  These 
events disrupt the proline-rich (P-rich) region as well as the nuclear localization signal in the arginine and 
serine-rich (RS-rich) portion of Drosha (Fig. 6E), but leave intact the previously described minimal active 
fragment of the protein (18). To indirectly measure the activity of the short isoform of Drosha, we measured 
the levels of pri-miR-34a and pri-miR-423 after treating cells with siRNAs against both Drosha isoforms 
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(siRNA Drosha both) or an siRNA that specifically targets the exon 6 region that is present only in the full-
length Drosha but not in the short isoform (siRNA Drosha full-length) (SI Appendix, Fig. S13 C and D). 
siRNA against both forms of Drosha caused a marked increase in the level of pri-miR-34a and pri-miR423 
in quiescent cells, confirming that Drosha contributes to the processing of these miRNAs (Fig. 6F). Notably, 
siRNA specifically targeting full-length Drosha was much less effective in inducing pri-miR-34a or miR-
34a in quiescent cells than was siRNA in reducing both Drosha isoforms, implying that the short 
cytoplasmic form of Drosha was competent to process pri-miR-34a to mature miR-34a. In contrast, the 
short isoform of Drosha does not appear to be involved in processing pri-miR-423 because specific knock-
down of the full-length form was sufficient to cause pri-miR-423 accumulation. Similarly, siRNA against 
full-length Drosha allows partial induction of mature miR-34a but not miR-423 in quiescent cells (Fig. 6G), 
supporting the hypothesis that the short isoform of Drosha is able to process pri-miR-34a but not pri-miR-
423 during quiescence.  
 
VI. Discussion 
 
 When cells reversibly exit the cell cycle and enter quiescence, they remain in a non-proliferative 
state until they receive appropriate mitogenic signals, but must avoid irreversible states such as apoptosis, 
differentiation, and senescence. Because miRNAs regulate many cellular pathways, changes in miRNA 
biogenesis are likely to play an important role in controlling these important cellular processes. This study 
revealed a number of unique features of miRNA biogenesis in proliferating and quiescent cells.   
 
A. Exportin-5 levels are regulated during cellular quiescence by autophagy and miR-34a. 
 
We confirmed the findings of Iwasaki and collaborators (39) that the amount of Exportin-5 protein 
decreases during quiescence (Fig. 2A and SI Appendix, Fig. S3). We showed that at least two post-
transcriptional mechanisms contribute to the reduction of Exportin-5 expression during quiescence.  
Because a specific inhibitor of autophagy prevented the loss of Exportin-5, a major regulator of Exportin-
5 levels during quiescence appears to be protein degradation by autophagy. In fact, autophagy is induced 
during quiescence to protect cells from apoptosis mediated by the proteasome (50), and serum starvation 
or treatment with an mTOR inhibitor activates autophagy, resulting in the degradation of Dicer and AGO2 
(51). Together with our findings, these results indicate that several proteins involved in miRNA biogenesis 
are regulated by autophagy during quiescence to avoid induction of apoptosis. In addition, our studies 
suggest that miR-34a binds to an evolutionarily conserved binding site in the Exportin-5 mRNA 3’UTR 
and represses Exportin-5 expression (Fig. 2D-G). miR-34a-mediated repression of Exportin-5 appears to 
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act in conjunction with autophagy-mediated degradation to ensure low levels of Exportin-5 throughout 
quiescence. Consistent with this idea, miR-34a is induced relatively late after the onset of quiescence, when 
Exportin-5 levels are already low (Fig. 2A and SI Appendix, Fig. S3). Taken together, our data suggest that 
Exportin-1 contributes to Exportin-5 down-regulation during quiescence by supporting the synthesis of 
miR-34a, which binds to Exportin-5 mRNA and reinforces the block of Exportin-5 expression. An 
interesting topic for future studies will be to determine if the regulation of Exportin-5 is related exclusively 
to the induction of quiescence or rather to the absence of specific growth factors such as IGF-1, which have 
been shown to be important in the regulation of autophagy in HFFs (52). 
 
B. Exportin-1-dependent microRNA biogenesis occurs during cellular quiescence. 
 
Our major finding is the discovery of an alternative miRNA biogenesis pathway involving 
Exportin-1 (also known as CRM1) during quiescence. Exportin-1, the major factor responsible for the 
export of proteins from the nucleus, is also involved in the export of certain RNAs such as ribosomal RNAs, 
small nuclear RNAs, and mRNAs encoding some proteins involved in cell cycle regulation (29, 53). 
Previous studies in C. elegans and Drosophila showed that Exportin-1 is involved in pri-miRNA processing 
and biogenesis (42). Our findings demonstrate that Exportin-1 is also involved in the biogenesis of specific 
miRNAs in proliferating mammalian cells and that this activity is enhanced during quiescence. First, there 
is no change in Exportin-1 levels during quiescence (Fig. 2A and SI Appendix, Fig. S3B). Second, Exportin-
1 knock-down reduced the levels of specific quiescence-induced mature miRNAs in proliferating and 
quiescent HFFs (Fig. 3 B and C), although the effect was not as dramatic as the reduction of quiescence-
repressed miRNAs by Exportin-5 knock-down (Fig. 3A), Third, the Exportin-1-dependent pri-miR-34a but 
not the Exportin-5-dependent pri-miR-423 is found in a stable complex with Exportin-1 (Fig. 3D). Our data 
further demonstrate that some miRNAs, including miR-26a, miR-34a, miR-126, miR-199, miR-638, and 
miR-3188, can use an Exportin-5-independent biogenesis pathway in proliferating cells. We also identified 
miRNAs subject to complex regulation during quiescence. For example, siRNA-mediated knock-down of 
either Exportin-5 or Exportin-1 in proliferating HFFs reduced the expression of mature miR-1228* but did 
not affect levels of pri-miR-1228 (Fig. 3 A and B, and SI Appendix, Fig. S6 A and B). Thus, both Exportin-
5 and Exportin-1 are involved in the biogenesis of miR-1228*, which is considered a Simtron, a class of 
miRNAs that are produced in the absence of splicing and are independent of DGCR8, Dicer, Exportin-5, 
and Argonaute (24). Kim and collaborators (48) demonstrated that Exportin-5 knockout in the colorectal 
cancer cell line HCT116 only modestly affects the processing of several miRNAs, consistent with the 
existence of Exportin-5-independent miRNA maturation in these cells.  
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C. Quiescence-induced primary miRNAs contain a (TMG)-cap and bind Exportin-1. 
 
We discovered that the primary miRNAs of Exportin-1-dependent quiescence-induced miRNAs 
contain a (TMG)-cap, which may be a signal for recognition by Exportin-1, whereas this cap structure is 
absent from the Exportin-5-dependent pri-miRNAs (Fig. 4A, SI Appendix, Fig. S8, and SI Appendix, Table 
S4). We also found that a short nuclear isoform of TGS1 is up-regulated during quiescence (SI Appendix, 
Fig. S9A). Importantly, knocking down expression of TGS1 in HFFs reduced (TMG)-capping of 
quiescence-induced pri-miRNAs, diminished induction of the corresponding mature miRNAs during 
quiescence, and reduced the interaction of pri-miR-34a with Exportin-1 (Fig. 4). Because most RNAs need 
to be exported to the cytoplasm to be modified with a (TMG)-cap, we have not ruled out the possibility that 
some pri-miRNAs could be exported by Exportin-1 with a (m7G)-cap and then undergo cap 
hypermethylation in the cytoplasm. We recently described microprocessor-independent human and mouse 
pre-miRNAs that are specifically (m7G)-capped and transported by the PHAX-Exportin-1 pathway and 
cleaved by Dicer prior to loading into the RISC complex (28). The miRNAs described here are processed 
differently because TMG caps are added at the pri-miRNA level, indicating that human cells contain at 
least two alternative Exportin-1-dependent pathways of miRNA biogenesis.  
 
D. Discovery of primary miRNAs and a smaller Drosha isoform in the cytoplasm of quiescent cells. 
 
Another important discovery is finding pri-miR-34a in the cytoplasm. We detected cytoplasmic 
pri-miR-34a in proliferating and quiescent HFF only after knocking down Drosha, suggesting that this pri-
miRNA is rapidly processed once it leaves the nucleus (Fig. 5 A and B). We were unable to consistently 
detect other quiescence-induced pri-miRNAs in the cytoplasm, presumably because they are less abundant 
than pri-miR-34a. Drosha-mediated rapid cleavage of these cytoplasmic (TMG)-capped pri-miRNAs may 
prevent their recognition by Snuportin-1, which could potentially return the pri-miRNAs to the nucleus (31, 
32). Moreover, we observed a reduction in the amount of pri-miR-34a in the cytoplasmic fraction of cells 
knocked down for both Exportin-1 and Drosha (Fig. 5C). This observation, together with the discovery of 
an interaction between pri-miR-34a and Exportin-1 (Fig. 3D), suggests that Exportin-1 plays a role in 
transporting pri-miR-34a from the nucleus to the cytoplasm. Further studies are necessary to elucidate the 
mechanism involved in the transport of quiescence-induced pri-miRNAs to the cytoplasm, their (TMG)-
capping, and their cytoplasmic processing.  
 
We also discovered the preferential expression of a smaller, alternatively spliced cytoplasmic 
isoform of Drosha during quiescence (Fig. 6A-E). Recent studies demonstrated the existence of splicing 
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isoforms of Drosha found in the cytoplasm in several cell lines (48, 49). These Drosha isoforms contain 
deletions in the nuclear localization region (RS-rich) similar to the small isoform of Drosha found in 
quiescent HFFs. These data support the hypothesis that splicing of specific genes, such as Drosha, by the 
spliceosome machinery is important in the regulation of cell cycle progression (54). Importantly, our data 
expand the concept that a specific Drosha isoform can be found in the cytoplasm of normal human cells in 
a particular stress condition such as serum starvation. Another study showed that certain RNA viruses 
trigger Exportin-1-dependent translocation of Drosha to the cytoplasm, providing a potential antiviral 
mechanism that acts by cleaving viral genomic RNA (55). Consistent with this model, Exportin-1 knock-
down reduced the amount of cytoplasmic pri-miR-34a (Fig. 5C), and a short cytoplasmic isoform of Drosha 
appeared to be involved in pri-miR-34a processing during quiescence (Fig. 6 F and G). Our discovery of 
pri-miRNAs and a small isoform of Drosha in the cytoplasm suggest the existence of a new miRNA 
biogenesis pathway during quiescence.  
 
E. The contribution of quiescence-induced miRNAs to cellular growth arrest. 
 
Do the quiescence-induced miRNAs play a role in growth arrest? These miRNAs may be essential 
for the induction of quiescence, thereby necessitating the use of an alternative miRNA biogenesis pathway 
when the canonical pathway is repressed. For example, the p53-regulated miR-34a regulates cellular 
pathways such as cell cycle, differentiation, and apoptosis (56, 57); it is a master regulator of tumor 
suppression in different human cancers and is being evaluated as a miRNA therapeutic (58). Similarly, 
miR-638 up-regulation in vascular smooth muscle cells was recently reported to inhibit cell proliferation 
and migration by targeting the orphan nuclear receptor 1 (NOR1) and consequently affecting the expression 
of cyclin D1 mRNA (59). In addition, miR-1228* over-expression suppresses xenograft tumor formation 
by negatively regulating NF-KB activity (60). Finally, miR-3188 was found to reduce cell cycle transition 
and proliferation in nasopharyngeal carcinoma by targeting mTOR mRNA and regulating PI3K/AKT 
signaling pathway through FOXO1 (61). In addition, it is possible that impaired processing of specific 
miRNAs in certain growth conditions may contribute to embryonic lethality of TGS1 knock-out mice (62). 
 
The results of the cell cycle analysis in SI Appendix, Fig. S7E show that Exportin-1 regulated 
miRNAs are not required for entry into senescence.  However, the reduced number of cells in S phase 24 h 
after serum addition suggests that Exportin-1 is required for proper exit from quiescence.  We speculate 
that the Exportin-1-dependent, quiescence-induced miRNAs are important not to maintain growth arrest 
but rather to poise cells so that they can efficiently reenter the cell cycle when favorable growth conditions 
are restored. 
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Not only do miRNAs affect cell growth, but also cell growth state can affect miRNAs.  We reported 
previously that growth arrest can convert some miRNAs from repressors into activators of translation (38), 
and we show here that quiescence inhibits canonical miRNA biogenesis but stimulates an alternative 
miRNA biogenesis pathway.  Thus, the cellular growth state may globally affect miRNA synthesis and 
function, which in turn may profoundly influence cellular gene expression and phenotype. 
 
In summary, we have shown that a set of miRNAs is processed independently of the canonical 
miRNA pathway in quiescent cells via (TMG)-cap modification of their pri-miRNA, interaction with 
Exportin-1 and cytoplasmic processing by a novel isoform of Drosha (SI Appendix, Fig. S16). This pathway 
is constitutively active in proliferating cells, but its activity is enhanced during quiescence, presumably to 
regulate key processes involved in cellular growth arrest.  Conversely, in quiescent cells the canonical 
miRNA pathway is turned off, likely contributing to the quiescent state. Future investigation will be 
necessary to identify additional components of this miRNA Exportin-1-dependent pathway and its impact 
on cell physiology. 
 
VII. Materials and Methods 
 
 Detailed experimental protocols are described in the Supporting Information Appendix (p.175). 
 
A. Cell culture and reagents 
 
 Normal primary human foreskin fibroblasts, HeLa/E6-5K, 293T, and C127 cells were cultured in 
DMEM-10 at 37°C in the presence of 5% CO2. Further details are in the SI Appendix. 
 
B. Quiescence induced by serum starvation and confluency 
 
 HFFs, HeLa, and C127 cells were rinsed with DPBS, detached with 0.25% trypsin-EDTA and 
plated in serum-free DMEM at low density. For quiescence induced by confluency, we plated HFFs (2 X 
106 cells/100 mm plate) in DMEM-10. Further details are in the SI Appendix. 
 
C. Immunoprecipitation of tri-methylated capped RNA 
 
 HFFs were incubated for 72 h in serum-free DMEM to induce quiescence. RNA was extracted 
using Trizol Reagent and 10 µg of RNA was diluted in NET-2 buffer, pre-cleared and incubated with 
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Protein G Sepharose 4 Fast Flow beads loaded with 15 μL normal rabbit serum or 15 μL rabbit m3G-cap 
antibody. Beads were rinsed 5 times with NET-2 buffer and resuspended in G-50 buffer. RNA was extracted 
from the beads by phenol-chloroform-isoamyl alcohol extraction. Further details are in the SI Appendix. 
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IX. Figure Legends 
 
Figure 1. Differential expression of mature miRNAs and their corresponding pri-miRNAs during 
quiescence. (A) Heat map of mature miRNA microarray data comparing proliferating HFFs to HFFs serum-
starved (SS) for 24, 48, or 72 h. Only differentially expressed miRNAs during quiescence are shown. (B) 
qRT-PCR validation of representative differentially expressed mature miRNAs during quiescence. (C) 
qRT-PCR quantitation of pri-miRNAs corresponding to differentially expressed mature miRNAs (using 
primers that bind upstream and downstream of the miRNA stem loop). Red bars represent the miRNAs up-
regulated and the green bars represent the miRNAs down-regulated during quiescence by miRNA 
microarray analysis. Numbers refer to days of serum starvation. Black bars represent miRNAs in 
proliferating (P) cells. RNU43 and GAPDH mRNA were used to normalize the qRT-PCR analyses, which 
are shown relative to expression in proliferating cells. Similar results were obtained in three independent 
experiments. 
 
Figure 2. Regulation of Exportin-5 during quiescence by autophagy and miR-34a. (A) Western blot 
showing reduction of Exportin-5 but not Exportin-1 levels during the induction of quiescence by serum 
starvation. p27 was used as a marker of quiescence induction, and β-actin was used as a loading control. 
(B) Western blot showing Exportin-5 and MDM2 in proliferating and quiescent HFFs treated with 10 μM 
of the proteasome inhibitor, MG132. Mock indicates cells proliferating in the presence of serum; cells were 
serum-starved for 3, 6, or 12 h as indicated to induce quiescence. (C) Western blot of Exportin-5 and p62 
in proliferating and quiescent HFFs treated with 10 μM of the autophagy inhibitor, 3-MA. Similar results 
were obtained in three independent experiments. (D) The sequence of hsa-miR-34a and its putative wild-
type (WT) or mutant (mt) binding site in the Exportin-5 3′UTR are shown. Vertical lines indicate predicted 
base pairing between hsa-miR-34a and the Exportin-5 3’ UTR, and the dots indicate potential G-U base 
pairs. Point mutations in the Exportin-5 3’UTR are shown with asterisks. Numbers represent the nucleotide 
sequence of Exportin-5 3’UTR numbered from the beginning of the untranslated region. (E) miR-34a 
regulates the expression of Exportin-5.  Left panels, Western blot of Exportin-5 and Exportin-1 48 h after 
transfection of exogenous miR-34a. Right panel, qRT-PCR analysis of Exportin-5 mRNA 48 h after 
transfection of miR-34a. (F) Activity of the Exportin-5 3’UTR is regulated by cell growth state. Luciferase 
activity from the empty reporter vector (Control), the vector containing the wild-type Exportin-5 3’UTR 
(WT) or the Exportin-5 3’UTR containing a mutant miR-34a binding site (mt).  Assays were conducted in 
proliferating (P) or quiescent (Q) HFFs as described in the experimental procedures. (G) miR-34a regulates 
the Exportin-5 3’UTR. Luciferase activity from the reporter vectors described in panel (F) was measured 
in proliferating HFFs transfected with a scrambled miRNA control (miR-CTRL) or miR-34a. In panels (F) 
and (G) firefly luciferase activity was measured and normalized to Renilla luciferase activity expressed 
from the same plasmid (Relative luciferase units, RLUs). Data were obtained in triplicate, and the graph 
shows the average of two individual experiments. Two-tailed t-test results are indicated by * for P < 0.05 
and ** for P < 0.01. 
 
Figure 3. Biogenesis of quiescence-induced miRNAs requires Exportin-1 but not Exportin-5. (A) qRT-
PCR analysis showing relative expression of primary miRNAs (light gray bars) and their corresponding 
mature miRNAs (dark gray bars) in proliferating HFFs 48 h after transfection with an siRNA scrambled 
control (dashed line) or an siRNA targeting Exportin-5 (Dharmacon) (dark and light gray bars). Right panel 
shows Western blot analysis of Exportin-1 and Exportin-5 after siRNA transfection. (B) qRT-PCR analysis 
showing relative levels of primary miRNAs (light gray bars) and their corresponding mature miRNAs (dark 
gray bars) in proliferating HFFs 48 h after transfection with an siRNA scrambled control (dashed line) or 
an siRNA targeting Exportin-1 (ID s14937, Ambion) (dark and light gray bars). Two-tailed t-test results 
are indicated by * for P < 0.05 and ** for P < 0.01. Western blot analysis of Exportin-1 and Exportin-5 is 
also shown after siRNA transfection. (C) qRT-PCR analysis of quiescence-induced miRNAs and miR-34a 
Northern blot 48 h after transfection of an siRNA scrambled control (black bars) or an siRNA targeting 
Exportin-1 (ID s14937, Ambion) (gray bars) into proliferating HFFs in the presence of serum (P) or into 
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HFFs serum-starved (SS) for 24 or 72 h (24, 48, or 72 h for miR-34a Northern blot). Transfection of 
quiescent cells was done 24 h prior to serum starvation. (D) Exportin-1 physically associates with pri-miR-
34a in quiescent cells. qRT-PCR were used to detect U3 snoRNA, pri-miR-34a, or pri-miR-423 in control 
Flag-Vector (Flag, black bars) or Flag-Exportin-1 (Flag-XPO1, gray bars) immunoprecipitates from 
quiescent HFFs (expression data in Fig. S7E). Exogenous spike of C. elegans RNA was used for qRT-PCR 
normalization by amplifying Ama-1 mRNA. Similar results were obtained in two independent experiments.  
 
Figure 4. Quiescence-induced primary miRNAs are (TMG)-capped by TGS1. (A) Quiescence-induced pri-
miRNAs contain a TMG cap. Extracts were prepared from proliferating or serum starved quiescent HFFs 
transfected with control siRNA or siRNA targeting TGS1 (ID s41313, Ambion). siRNAs were transfected 
24 h prior to serum starvation. RNA was harvested 48 h after transfection of siRNAs in proliferating HFFs 
or 72 h after removal of serum. Extracts were then immunoprecipitated with control antibody or antibody 
recognizing the TMG cap, and immunoprecipitated U3 snoRNA and pri-miRNAs were amplified by RT-
PCR and visualized after gel electrophoresis. Labels: input (I), supernatant (S), immunoprecipitate (IP), 
control anti-rabbit serum (C), and anti-TMG antibody (T). (B) TGS1 knock-down inhibits expression of 
quiescence-induced miRNAs. HFFs were transfected with an siRNA scrambled control (black bars) or an 
siRNA targeting TGS1 (sc-45875, Santa Cruz) (gray bars). 24 h later, cells were serum starved (SS) for 24 
or 72 h, or maintained in serum (P). RNA was then prepared and quantified by qRT-PCR. (C) TGS1 knock-
down affects the binding of pri-miR-34a to Exportin-1 in quiescent cells. qRT-PCR was used to detect U3 
snoRNA, pri-miR-34a, or pri-miR-423 in immunoprecipitate samples of control Flag-Vector or Flag-
Exportin-1 in quiescent HFF cells. Cells were transfected with siRNA control (black bars) or siRNA against 
TGS1 (gray bars). Two-tailed t-test results are indicated by ** for P < 0.01. Similar results were obtained 
in two independent experiments. 
 
Figure 5. Detection of cytoplasmic pri-miR-34a is dependent on Exportin-1 expression. (A) Detection of 
pri-miR-34a in the cytoplasmic fraction of Drosha knock-down HFFs. Proliferating (P) and quiescent (Q) 
HFFs were transfected with control siRNA or siRNA targeting Drosha (sc-44080, Santa Cruz) and after 48 
h subjected to cytoplasmic and nuclear RNA fractionation. RT-PCR was used to detect pri-miR-34a, pri-
miR-29b, and pri-miR-423. U6 snRNA is a nuclear control and mitochondrial (mt) tRNA-val is a 
cytoplasmic marker. (B) qRT-PCR of cytoplasmic fractions as in Figure 5A was used to quantify the levels 
of pri-miR-34a. Two-tailed t-test results are indicated by ** for P < 0.01.  (C and D) Exportin-1 knock-
down affects the distribution of pri-miR-34a in quiescent HFFs. Cells were transfected with an siRNA 
scrambled control, an siRNA targeting Drosha (sc-44080, Santa Cruz), or siRNAs targeting Drosha (sc-
44080, Santa Cruz) and Exportin-1 (ID s14937, Ambion). 24 h later, cells were serum starved for 72 h. 
RNA was then prepared from the cytoplasmic (C) or nuclear (D) fraction for the quantification of pri-miR-
34a and pri-miR-423 by qRT-PCR. Normalization was done using C. elegans total RNA as an exogenous 
spike for the amplification of the worm-specific ama-1 gene. Similar results were obtained in two 
independent experiments. 
 
Figure 6. Detection of a small cytoplasmic isoform of Drosha during quiescence. (A) Western blot showing 
reduction of full-length Drosha and appearance of a more rapidly migrating form of Drosha (Droshashort) 
during the induction of quiescence by serum starvation. (B) A small form of Drosha (Droshashort) is found 
in the cytoplasmic fraction of quiescent cells. Western blot analysis of Drosha and DGCR8 in total, nuclear, 
and cytoplasmic fractions in proliferating (P) and quiescent (Q) HFFs. 10% of the total loading was used 
for the nuclear fraction in the Drosha Western blot. Histone deacetylase 1 (HDAC1) was used as nuclear 
marker and β-tubulin as cytoplasmic marker. (C) Cytoplasmic localization of Drosha in quiescent HFF 
cells. Immunofluorescence of Drosha (green) in proliferating and quiescent HFFs. Nuclear fluorescence 
(DAPI, blue) and cytoskeleton immunofluorescence (actin, red) were used to visualize the localization of 
Drosha. (D) Quantification of cytoplasmic Drosha immunofluorescence. Proliferating and quiescent HFF 
cells were incubated with digitonin (to selectively permeabilize only the plasma membrane) to diminish 
masking of cytoplasmic Drosha staining with nuclear Drosha signal. Confocal microscopy was used to 
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visualize the cells, and fluorescent images were used to obtain relative pixel area quantification using Image 
J software. Two-tailed t-test results are indicated by * for P < 0.05. Similar results were obtained in three 
independent experiments. (E) Drosha mRNA exon skipping during quiescence. Illustration and sequencing 
data show two alternative splicing events (red lines) between exon 3 and 4 and between exon 5 and 7 in 
Drosha mRNA and the affected regions in Drosha protein. Numbers represent the nucleotide sequence of 
Drosha mRNA. P-rich indicates the proline-rich region, RS-rich indicates the arginine and serine-rich 
region, RIIIDa and RIIIDb indicate RNase III domains a and b, respectively, and dsRBD indicates double-
stranded RNA-binding domain. (F) The short isoform of Drosha is responsible for processing of pri-miR-
34a. Quantitative RT-PCR of pri-miR-34a and pri-miR-423 was conducted in quiescent HFFs transfected 
with control siRNA or siRNA against the full-length Drosha (IDs26491, Ambion) or both Drosha isoforms 
(both) (sc-44080, Santa Cruz). Reduced accumulation of pri-miR-34a in cells treated with siRNA targeting 
full-length Drosha compared to siRNA against both Drosha isoforms (both) suggests the short Drosha 
isoform can process pri-miR-34a. (G) qRT-PCR of mature miR-34a and miR-423-3p was conducted from 
the same experiments shown in Figure 6F. Two-tailed t-test results are indicated by ** for P < 0.01. Similar 
results were obtained in two independent experiments. 
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XI. Supplementary Tables 
 
Table S1 
 
miRNA Name 12hrs SS vs 
mock 
48hrs SS vs 
mock 
72hrs SS vs 
mock 
hsa-let-7g-star_st 1.15 1.53 2.23 
hsa-miR-101_st 1.68 1.79 1.94 
hsa-miR-1208_st 2.10 1.55 1.46 
hsa-miR-1225-5p_st 3.21 2.13 1.70 
hsa-miR-1228-star_st 4.48 2.10 1.67 
hsa-miR-1231_st 5.31 2.61 2.47 
hsa-miR-1246_st 3.00 3.68 4.87 
hsa-miR-126_st 1.18 1.79 3.16 
hsa-miR-1281_st 2.04 2.05 1.37 
hsa-miR-133b_st 1.71 1.55 1.87 
hsa-miR-1469_st 5.39 3.37 2.54 
hsa-miR-149-star_st 3.90 1.78 1.46 
hsa-miR-150-star_st 2.62 1.90 1.53 
hsa-miR-154_st 1.39 1.71 2.74 
hsa-miR-1825_st 1.82 1.69 1.25 
hsa-miR-187-star_st 2.92 3.97 1.76 
hsa-miR-1908_st 4.59 2.49 2.21 
hsa-miR-1909_st 5.49 2.72 2.32 
hsa-miR-1909-star_st 1.92 1.92 1.50 
hsa-miR-1910_st 2.73 2.36 1.39 
hsa-miR-1915_st 4.59 3.64 2.58 
hsa-miR-194_st 2.04 2.05 3.50 
hsa-miR-195_st 1.15 1.50 1.83 
hsa-miR-199a-3p_st 1.34 1.66 2.33 
hsa-miR-199b-3p_st 1.35 1.78 2.54 
hsa-miR-199b-5p_st 1.21 2.42 4.31 
hsa-miR-224-star_st 1.05 1.74 1.71 
hsa-miR-2277_st 3.10 1.95 1.34 
hsa-miR-26a_st 1.09 1.55 1.57 
hsa-miR-26b_st 1.86 1.38 2.18 
hsa-miR-2861_st 7.14 4.60 3.70 
hsa-miR-2909_st 1.63 1.67 1.32 
hsa-miR-301a_st 1.78 1.74 1.66 
hsa-miR-302a_st 1.52 1.56 1.53 
hsa-miR-30b_st 1.13 1.64 2.13 
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hsa-miR-30d_st -1.05 1.54 2.34 
hsa-miR-30e-star_st 1.77 1.50 2.00 
hsa-miR-3144-5p_st 2.09 1.68 1.39 
hsa-miR-3154_st 1.65 1.32 1.51 
hsa-miR-3168_st 1.55 1.66 1.78 
hsa-miR-3178_st 3.79 2.50 2.12 
hsa-miR-3180-3p_st 4.44 2.24 2.13 
hsa-miR-3181_st 4.08 3.60 3.01 
hsa-miR-3185_st 7.28 4.50 3.59 
hsa-miR-3187_st 5.49 4.27 2.83 
hsa-miR-3188_st 8.77 5.21 4.93 
hsa-miR-3194_st 1.12 2.15 1.59 
hsa-miR-3195_st 6.20 4.79 3.22 
hsa-miR-3196_st 3.29 1.87 1.48 
hsa-miR-342-3p_st -1.05 1.55 1.61 
hsa-miR-346_st 3.20 2.69 2.15 
hsa-miR-34a_st 1.12 1.95 2.39 
hsa-miR-34a-star_st 1.01 1.55 2.44 
hsa-miR-378_st -1.04 1.82 1.58 
hsa-miR-422a_st 1.81 2.87 3.07 
hsa-miR-4259_st 1.64 1.49 1.61 
hsa-miR-4271_st 2.69 1.98 1.56 
hsa-miR-4281_st 5.29 2.70 2.32 
hsa-miR-4292_st 2.18 2.06 1.90 
hsa-miR-4320_st 1.58 1.67 1.59 
hsa-miR-4321_st 2.18 1.90 1.31 
hsa-miR-4322_st 3.43 2.57 2.47 
hsa-miR-455-5p_st 2.41 2.43 3.06 
hsa-miR-498_st 2.39 1.71 1.20 
hsa-miR-514_st 1.30 1.56 1.50 
hsa-miR-523_st -1.19 1.68 1.55 
hsa-miR-532-3p_st 1.33 1.81 1.99 
hsa-miR-557_st 1.89 1.22 1.54 
hsa-miR-564_st 2.44 2.30 1.79 
hsa-miR-566_st 1.70 1.25 1.55 
hsa-miR-572_st 3.60 2.18 1.21 
hsa-miR-575_st 1.57 1.66 1.53 
hsa-miR-596_st 2.92 1.80 1.08 
hsa-miR-602_st 4.50 1.90 2.12 
hsa-miR-638_st 4.67 3.06 2.30 
hsa-miR-654-5p_st 1.69 2.12 1.33 
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hsa-miR-663_st 3.62 2.22 1.95 
hsa-miR-664-star_st 1.29 1.85 1.87 
hsa-miR-675_st 1.59 1.52 1.67 
hsa-miR-675-star_st 1.76 1.56 1.71 
hsa-miR-762_st 4.73 2.52 2.17 
hsa-miR-768-3p_st 1.11 1.67 2.78 
hsa-miR-885-3p_st 3.26 2.56 2.34 
hsa-miR-885-5p_st 2.61 2.17 1.81 
hsa-miR-888-star_st 1.61 1.25 1.52 
hsa-miR-92b-star_st 3.45 1.19 1.61 
hsa-miR-943_st 3.41 1.69 2.13 
hsa-miR-99a-star_st 1.41 1.85 1.59 
 
Table S1. Mature microRNAs up-regulated during the induction of quiescence in HFFs. Table show 
microRNAs that were up-regulated 1.5-fold or greater in at least two-time points of serum starvation (red 
values) in comparison to proliferating HFF cells. GeneChip® miRNA 2.0 Array (Affymetrix, Santa Clara, 
CA) were used for this analysis. 
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Table S2 
 
miRNA Name 12hrs SS vs 
mock 
48hrs SS vs 
mock 
72hrs SS vs 
mock 
hsa-let-7a-2-star_st -1.92 -1.39 -1.58 
hsa-miR-106b-star_st -1.71 -1.84 -1.84 
hsa-miR-1184_st -1.17 -2.08 -1.62 
hsa-miR-1207-5p_st 1.08 -1.59 -1.59 
hsa-miR-1244_st -1.50 -1.51 1.30 
hsa-miR-1247_st -1.95 -1.80 -1.17 
hsa-miR-1249_st -1.58 -1.49 -1.74 
hsa-miR-125b-1-star_st -2.50 -2.33 -3.34 
hsa-miR-1271_st -1.54 -1.35 -1.59 
hsa-miR-1275_st -1.30 -1.95 -2.44 
hsa-miR-1285_st -1.20 -1.89 -2.51 
hsa-miR-1292_st 1.35 -1.59 -2.87 
hsa-miR-1296_st -2.18 -1.73 -2.20 
hsa-miR-1308_st -1.94 -2.64 -3.48 
hsa-miR-130b_st -1.49 -1.76 -2.24 
hsa-miR-138_st -1.33 -1.78 -2.34 
hsa-miR-138-1-star_st -1.46 -1.72 -2.31 
hsa-miR-139-3p_st -2.04 -3.03 -2.42 
hsa-miR-1470_st -7.07 -7.07 -7.07 
hsa-miR-1471_st -4.02 -1.98 -1.25 
hsa-miR-1538_st -2.36 -2.61 -1.67 
hsa-miR-155_st -1.79 -2.51 -2.42 
hsa-miR-155-star_st -1.86 -1.76 -1.63 
hsa-miR-17_st -1.20 -1.50 -1.69 
hsa-miR-181a-2-star_st -1.78 -1.46 -1.77 
hsa-miR-184_st -1.89 -2.01 -1.62 
hsa-miR-185-star_st -1.84 -1.42 -1.51 
hsa-miR-188-5p_st -1.85 -1.58 -1.28 
hsa-miR-18a_st -1.87 -1.90 -2.81 
hsa-miR-18a-star_st -1.81 -2.26 -1.57 
hsa-miR-18b_st -1.25 -1.77 -1.50 
hsa-miR-190_st -1.28 -1.70 -1.57 
hsa-miR-1914_st -4.22 -3.43 -1.18 
hsa-miR-1915-star_st -1.63 -2.08 -1.55 
hsa-miR-193b-star_st -1.54 -1.34 -1.66 
hsa-miR-197_st -1.72 -1.79 -1.25 
hsa-miR-1972_st -1.74 -1.93 -1.95 
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hsa-miR-21-star_st -2.91 -2.96 -3.50 
hsa-miR-2110_st -1.72 -1.37 -3.06 
hsa-miR-22-star_st -1.46 -2.50 -1.67 
hsa-miR-222-star_st -3.11 -3.56 -4.22 
hsa-miR-23a-star_st -2.05 -2.55 -3.15 
hsa-miR-25-star_st -1.97 -2.74 -3.91 
hsa-miR-27a-star_st -1.81 -1.84 -2.85 
hsa-miR-27b-star_st -1.48 -1.81 -1.67 
hsa-miR-296-3p_st -1.66 -2.11 -2.38 
hsa-miR-298_st -1.74 -1.23 -1.50 
hsa-miR-29b_st -1.69 -1.89 -1.52 
hsa-miR-29b-1-star_st -4.04 -2.91 -2.55 
hsa-miR-31_st -1.42 -1.60 -1.89 
hsa-miR-3130-5p_st -2.00 -1.14 -2.56 
hsa-miR-3131_st -2.08 -1.83 -1.84 
hsa-miR-3136_st -1.91 -2.01 -2.19 
hsa-miR-3158_st -1.60 -1.81 -1.39 
hsa-miR-3170_st -1.70 1.08 -1.93 
hsa-miR-3183_st -2.05 -2.32 -1.32 
hsa-miR-3198_st -1.18 -1.56 -1.93 
hsa-miR-323-5p_st -2.64 -1.93 1.25 
hsa-miR-330-3p_st -1.68 -1.31 -2.09 
hsa-miR-339-3p_st -1.75 -1.12 -1.91 
hsa-miR-339-5p_st -1.79 -1.87 -2.54 
hsa-miR-33b-star_st -1.25 -1.61 -2.71 
hsa-miR-376a_st -1.08 -2.53 -1.78 
hsa-miR-378b_st -1.35 -1.51 -1.60 
hsa-miR-423-3p_st -1.51 -1.18 -1.70 
hsa-miR-424-star_st -2.07 -1.75 -2.03 
hsa-miR-4284_st -1.48 -2.51 -2.91 
hsa-miR-4298_st -1.31 -2.18 -3.29 
hsa-miR-431_st -1.31 -1.51 -2.04 
hsa-miR-4315_st -1.17 -1.53 -1.63 
hsa-miR-487a_st 1.06 -1.56 -1.75 
hsa-miR-490-3p_st -3.55 -1.88 -1.68 
hsa-miR-490-5p_st -1.92 -2.03 -2.34 
hsa-miR-503_st -1.72 -2.19 -2.71 
hsa-miR-508-5p_st -2.34 -1.49 -1.68 
hsa-miR-519c-3p_st -1.14 -1.59 -1.55 
hsa-miR-548a-3p_st -2.24 -1.20 -1.68 
hsa-miR-550_st -1.58 -2.01 -1.86 
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hsa-miR-550-star_st -1.77 -1.85 -1.58 
hsa-miR-608_st -5.90 -2.98 -4.15 
hsa-miR-629_st -1.65 -1.81 -1.44 
hsa-miR-629-star_st -2.25 -2.62 -2.05 
hsa-miR-639_st -1.52 -1.47 -1.65 
hsa-miR-658_st -2.66 -1.88 -1.06 
hsa-miR-671-3p_st -2.03 -2.37 -3.83 
hsa-miR-720_st -1.05 -1.83 -1.56 
hsa-miR-744_st -1.34 -1.59 -2.22 
hsa-miR-758_st -1.73 -1.29 -1.50 
hsa-miR-770-5p_st -1.51 -2.69 -2.08 
hsa-miR-886-3p_st -2.39 -6.22 -5.80 
hsa-miR-886-5p_st -1.84 -2.32 -3.08 
hsa-miR-92a-1-star_st -1.71 -1.73 -1.60 
hsa-miR-92b_st -1.68 -1.90 -2.14 
hsa-miR-93_st -1.50 -1.69 -2.18 
 
Table S2. Mature microRNAs down-regulated during the induction of quiescence in HFFs. Table 
shows microRNAs that were down-regulated as defined in the legend to Table S1, shown in green. 
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Table S3 
 
 
Table S3. Primers used in this study for qRT-PCR. 
  
primers sequence (5'-3')
pri-miR-26a-2 FWD ACCTAATCATGACCTGGACAGAC
pri-miR-26a-2 REV AAGAAGCGCACACACCATGT
pri-miR-34a FWD CTGGGGAGAGGCAGGACA
pri-miR-34a REV GGCATCTCTCGCTTCATCTT
pri-miR-126 FWD AGCGCAGCATTCTGGAAGAC
pri-miR-126 REV AGGGAGGTCAAGGCTGAGGT
pri-miR-199b FWD GGGGTTCTCGGATCTCCA
pri-miR-199b REV GTCGGTCCAGCTCTCCAGT
pri-miR-638 FWD AGCTCGGTGCTGGAGAACTT
pri-miR-638 REV GAAAGCTGGGACCAGATGGA
pri-miR-1228 FWD GGGGCAGGTGTGTGGTG
pri-miR-1228 REV GGCGAGGCAGGTGTGAG
pri-miR-3188 FWD CCTTCTGGAGAGGCTTTGTG
pri-miR-3188 REV GAGGGAGGGAAGGAAGGAG
pri-miR-17 FWD AGAGAACATCACCTTGTAAAACTGAA
pri-miR-17 REV CCTGCACTTTAAAGCCCAACT
pri-miR-18a FWD CCTGCTGATGTTGAGTGCTTT
pri-miR-18a REV ACACCTATATACTTGCTTGGCTTG
pri-miR-29b FWD CCTTTCTAGGTTGTCTTGGGTTT
pri-miR-29b REV TACTTCAGAGCTGTCCCATTCA
pri-miR-155 FWD TTTATGCCTCATCCTCTGAGTG
pri-miR-155 REV CAATTTGTTCCATGTGAATGCT
pri-miR-423 FWD CGAAGTTTGAGGGAGAAACTTG
pri-miR-423 REV TCTAAGGAAGCCAGGAACTGTC
U3 FWD CGAAAACCACGAGGAAGAGA
U3 REV CACTCCCCAATACGGAGAGA
U6 FWD ATCTTGTGGAAAGGACGAAACA
U6 REV AAATATGGAACGCTTCACGAAT
mt tRNAval FWD CAGAGTGTAGCTTAACACAAAGCA
mt tRNAval REV CAAGTTAAGTTGAAATCTCCTAAGTG
Exportin-5 FWD AGTGGAAATCCAATCTTCCGTA
Exportin-5 REV ATTTTGGCTAGCATTTCTGGTG
Exportin-1 FWD AAAATACGTTGTTGGCCTCATT
Exportin-1 REV GGGCCATTCTTGTTTCAGTATC
TGS1 FWD GGATTCAAGTATGGCTCAGGAC
TGS1 REV TGTCTGCGCATGTCTAGGTACT
p27 FWD GGGGCTCGTCTTTTCGGGGTGTTT
p27 REV GAGCGGGAGGGCGGAGAGGAG
GAPDH FWD CCACTCCTCCACCTTTGAC
GAPDH REV ACCCTGTTGCTGTAGCCA
c. elegans ama-1 FWD GGAGCTCGAGTGGATCTTCG
c. elegans ama-1 REV GCGCAGAGAGTATCCTGGAC
Drosha (exon 6) FWD ACAACCGAAGATCACCATCTCT
Drosha (exon 6) REV CATTCTTGTCAGGCATGGTCT
Drosha FWD GAATGCAAAGGCATGATTGTTA
Drosha REV AAAGTGGACGATAATCGGAAAA
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Table S4 
 
 
Proliferating 
+ siRNA 
CTRL 
Proliferating 
+ siRNA 
CTRL 
Proliferating 
+ siRNA 
TGS1 
Proliferating 
+ siRNA 
TGS1 
Quiescent 
+ siRNA 
CTRL 
Quiescent 
+ siRNA 
CTRL 
Quiescent 
+ siRNA 
TGS1 
Quiescent 
+ siRNA 
TGS1 
 IP CTRL IP TMG IP CTRL IP TMG IP CTRL IP TMG IP CTRL IP TMG 
pri-
miR-
34a 
2.35 39.84 6.22 15.56 1.62 147.25 0.09 35.08 
pri-
miR-
3188 
11.87 62.32 1.84 29.57 3.46 235.98 1.48 53.29 
pri-
miR-
423 
2.86 2.97 1.00 4.02 0.58 2.68 0.38 4.09 
 
Table S4. Quiescence-induced pri-miRNAs contain a TMG cap. Amounts of pri-miR-34a, pri-miR-
3188 and pri-miR-423 immunoprecipitated with anti-rabbit serum (IP CTRL) or antibody recognizing 
TMG-cap RNA (IP TMG) in proliferating or quiescent HFFs transfected with control siRNA or siRNA 
targeting TSG1. Relative expression was obtained by comparing input RNA and normalizing against a 
spike-in of non-endogenous RNA using qRT-PCR. Values in the table were multiplied by 1000 for clarity. 
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XII. Supplementary Figures 
 
Figure S1 
 
Figure S1. Differential expression of mature miRNAs and their corresponding primary miRNAs during the 
induction of quiescence by cell confluency. (A) qRT-PCR analysis of mature miRNAs. RNA was extracted 
1, 6 and 12 days after reaching complete confluency and compared to RNA isolated from proliferating 
HFFs (P). (B) qRT-PCR analysis of primary miRNAs by using primers that bind upstream and downstream 
of the miRNA stem loop. In both A and B, red bars represent the miRNAs up-regulated during serum 
starvation by miRNA microarray analysis. Green bars represent mature miRNAs down-regulated during 
serum starvation by miRNA microarray analysis. Black bars represent miRNAs in proliferating (P) cells. 
Results were normalized to RNU43 and GAPDH mRNA expression and expressed relative to proliferating 
cells. Similar results were obtained in two independent experiments. 
 
 
  
159 
 
Figure S2 
 
 
 
 
 
Figure S2. Northern blot analysis validating several miRNAs up-regulated during the induction of 
quiescence by serum starvation or cell confluency. U6 was used as loading control. 
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Figure S3 
 
 
Figure S3. Exportin-5 expression is reduced post-transcriptionally during quiescence. (A) 
Immunofluorescence of Exportin-5 (green) in proliferating and quiescent HFFs by serum starvation. 
Nuclear fluorescence (DAPI, blue) and cytoskeleton immunofluorescence (actin, red) were used to 
visualize the nuclear localization of Exportin-5. (B) Western blot analysis showing reduction of Exportin-
5 but not Exportin-1 levels after induction of quiescence by confluency. (C) Exportin-5 protein expression 
is markedly reduced during quiescence by serum starvation in cervical carcinoma (HeLa) and murine 
mammary tumor (C127) cell lines. β-actin was used as a loading control. (D and E) qRT-PCR analysis of 
Exportin-5 mRNA, showing no changes in levels during serum starvation or confluency compared to 
proliferating cells (P). Exportin-5 mRNA levels were normalized to GAPDH mRNA. Results show the 
average of three independent experiments.   
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Figure S4 
  
Figure S4. Accumulation of MDM2 and Exportin-5 caused by the inhibition of the proteasome or the 
autophagy pathways, respectively, during the induction of quiescence. (A) Western blot quantification of 
MDM2 protein in cells treated with vehicle (DMSO) or proteasome inhibitor MG132. (B) Exportin-5 
protein in cells treated with vehicle (water) or autophagy inhibitor 3MA was measured by western blotting 
and quantified by using Image J software 1.48 (http://imagej.nih.gov/ij/download.html). Results were 
normalized to β-actin levels and compared to proliferating HFFs.  Experiment was performed in triplicate 
with similar results. The figure shows a representative experiment.   
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Figure S5 
 
 
Figure S5. The Exportin-5 3’UTR contains a conserved miR-34 binding site. Comparison of the Exportin-
5 3’UTR (nucleotide 74 to 100) in different organisms, showing a conserved binding site for the miR-34 
family (nucleotides in black box). Analysis was obtained using TargetScanHuman 6.2 software 
(www.targetscan.org).  
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Figure S6 
 
     
Figure S6. Biogenesis of quiescence-induced miRNAs requires Exportin-1 but not Exportin-5. (A) qRT-
PCR analysis showing relative expression of quiescence-induced and quiescence-repressed primary 
miRNAs (light gray bars) and their corresponding mature miRNAs (dark gray bars) in proliferating HFFs 
48 hrs after transfection with an siRNA scrambled control (dashed line) or an siRNA targeting Exportin-5 
(siRNA XPO5 #2) (IDs33191, Ambion) (dark and light gray bars). Western blot and qRT-PCR analysis of 
Exportin-1 and Exportin-5 using XPO5-depleted or control HFF lysates confirms specific knock-down of 
Exportin-5. (B) qRT-PCR analysis showing relative levels of the RNAs tested in panel (A) in proliferating 
HFFs 48 hrs after transfection with an siRNA scrambled control (dashed line) or an siRNA targeting 
Exportin-1 (siRNA XPO1 #2) (ID118206, Ambion) (dark and light gray bars). Western blot and qRT-PCR 
analysis of Exportin-1 and Exportin-5 using XPO1-depleted or control HFF lysates confirm specific knock-
down of Exportin-1. Two-tailed t-test results are indicated by * for P < 0.05 and ** for P < 0.01.  
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Figure S7 
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Figure S7. Exportin-1 knock-down during serum starvation does not alter the expression of Exportin-5, 
p27 or key proteins involved in miRNA biogenesis. HFFs were transfected with a siRNA scrambled control 
(CTRL) or a siRNA targeting Exportin-1 (XPO1) (ID s14937, Ambion) 24 hrs before the induction of 
quiescence by serum starvation. Expression of Exportin-1 (A), Exportin-5 (XPO5) (B), or p27 (C) mRNA 
in proliferating cells (Prolif) or at the indicated hours after serum starvation was determined by qRT-PCR 
and normalized to GAPDH mRNA. (D) Western blot showing repression of Exportin-1 but not other 
proteins involved in miRNA biogenesis in proliferating HFF cells transfected with an siRNA against 
Exportin-1 (XPO1). Similar results were obtained in two independent experiments. (E) Exportin-1 knock-
down do not change the entrance of HFFs to quiescence. Cell cycle assays in proliferating, quiescent (24 
hours after serum starvation), and synchronized (12 and 24 hours after the addition of serum) HFFs with 
siRNA scrambled control (CTRL) or a siRNA targeting Exportin-1 (XPO1). Similar results were obtained 
in two independent experiments. (F) Overexpression of Flag-Exportin-1. Western blot and qRT-PCR of 
HFF cells expressing Flag-tagged empty vector or Flag-tagged Exportin-1 (G) Exportin-1 physically 
associates with pri-miR-34a in quiescent cells. RT-PCR was used to detect U3 snoRNA, pri-miR-34a, or 
pri-miR-423 in control Flag-Vector (IgG) or Flag-Exportin-1 (XPO1) immunoprecipitates from quiescent 
HFFs. Similar results were obtained in two independent experiments. 
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Figure S8 
 
Figure S8. Quiescence-induced primary miRNAs are trimethylguanosine (TMG)-capped by TGS1. qRT-
PCR of anti-TMG pull-downs as in Figure 4A to quantify levels of miR-34a and miR-3188. Relative 
expression was compared to input RNA and normalized against a spike-in of non-endogenous RNA. Two-
tailed t-test results are indicated by * for P < 0.05 and ** for P < 0.01. 
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Figure S9 
 
  
Figure S9. Analysis of TGS1 protein knock-down in proliferating and quiescent HFFs. (A) TGS1 
expression increases during quiescence. Western blot (top panel) showing increased expression of the short 
isoform of TGS1 protein and qRT-PCR analysis (bottom panel) showing increased expression of total 
TGS1 mRNA in HFFs after serum starvation. (B) qRT-PCR analysis showing relative expression of TGS1 
mRNA in proliferating and quiescent HFFs transfected with an siRNA scrambled control (dark grey bars) 
or an siRNA targeting TGS1 mRNA (Ambion) (light grey bars). (C) Western blot showing partial knock-
down of TGS1 by using a siRNA against TGS1 (Ambion) in quiescent HFFs. (D) Western blot showing 
repression of full-length TGS1 but not other proteins involved in miRNA biogenesis in proliferating HFF 
cells transfected with a siRNA pool against TGS1 (Santa Cruz). Similar results were obtained in two 
independent experiments. 
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Figure S10 
 
 
Figure S10. Analysis of Drosha knock-down in proliferating and quiescent HFFs. qRT-PCR analysis 
showing relative expression of Drosha mRNA in proliferating and quiescent HFFs transfected with siRNA 
scrambled control (dark grey bars) or siRNA pool targeting Drosha (Santa Cruz) (light grey bars). Cells 
were made quiescent by serum starvation for 48 hrs. Similar results were obtained in three independent 
experiments. The figure shows a representative experiment. 
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Figure S11 
 
 
Figure S11. Comparison of pri-miRNAs present in total cell versus nuclear fraction. qRT-PCR analysis 
shows a significant reduction of pri-miR-34a and pri-miR-423 in nuclear fractions in comparison to total 
cell in quiescent HFF cells. Results show the average of three independent experiments. Two-tailed t-test 
results are indicated by * for P < 0.05 and ** for P < 0.01. 
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Figure S12 
  
 
Figure S12. Verification of double knock-down of Drosha and XPO1. Knock-down of Drosha (Santa Cruz) 
and/or Exportin-1 (ID s14937, Ambion) was performed by using siRNAs against these proteins in 
proliferating HFFs and confirmed by Western blot analysis and qRT-PCR. siRNA control was added to 
XPO1 only and Drosha only siRNA transfections to equalize total siRNA amounts. Similar results were 
obtained in two independent experiments. 
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Figure S13 
Figure S13. Transient knock-down of Drosha isoforms. (A) Western blot analysis of Drosha in proliferating 
and quiescent HFF cells 72 hrs after knock-down of both Drosha isoforms by using a pool of siRNAs 
against different regions of Drosha mRNA (Drosha pool, Santa Cruz). (B) qRT-PCR of the exon 6 region 
of Drosha mRNA (204bp for the short Drosha and 315bp for the full length Drosha) after knock-down of 
both isoforms of Drosha. (C) Western blot analysis of Drosha in proliferating and quiescent HFF cells 72 
hrs after selective knock-down of full length Drosha isoform only by using a siRNAs targeting exon 4 of 
Drosha mRNA (Drosha full length) that is absent (alternative splicing) from the short isoform of Drosha. 
(D) qRT-PCR of the exon 6 region of Drosha, as detailed in (B), in proliferating and quiescent HFF cells 
72 hrs after specific knock-down of Drosha full length. (E) To verify specificity of Drosha antibody for 
immunofluorescence, confocal microscopy images were obtained using the same settings. HFF treated with 
siRNA Drosha (Drosha pool, Santa Cruz) demonstrate a loss of Drosha staining (pseudo-color green). 
Nuclear (DAPI, blue) and cytoskeleton (actin, red) immunofluorescent staining were used to visualize the 
cellular localization of Drosha. 
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Figure S14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S14. DGCR8 is not present in the cytoplasm of quiescent HFFs and the processing of quiescent-
induced miR-34a is not affect by DGCR8 knock-down (A) DGCR8 is not interacting with the cytoplasmic 
isoform of Drosha. Immunoprecipitation (IP) of DGCR8 in quiescent HFFs shows absence of this protein 
in the cytoplasmic fraction and no pull-down of the small isoform of Drosha. DGCR8 polyclonal antibody 
(Proteintech) was used for the IP and rabbit IgG as a negative control (CTRL). Supernatant (Sup.) is also 
shown as an IP control. Similar results were obtained in two independent experiments. (B) miR-34a 
processing is not affected by DGCR8 knock-down in quiescent HFFs. Knock-down of DGCR8 was 
performed by using siRNAs against these proteins in quiescent HFFs and confirmed by qRT-PCR. siRNA 
scramble was used as a control (CTRL). Similar results were obtained in two independent experiments. 
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Figure S15 
 
 
 
Figure S15. Detection of a short isoform of Drosha in quiescent HFF cells. Tiling RT-PCR of  
The Drosha mRNA open reading frame (ORF). Colored arrows represent different pairs of primers at 
different positions in Drosha mRNA with the predicted sizes of the wild-type amplification products shown. 
P indicates proliferating HFF cells, Q indicates quiescent HFF cells, and MW indicates molecular weight 
ladder. Similar results were obtained in three independent experiments. 
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Figure S16 
 
Figure S16. Model showing an alternative miRNA biogenesis pathway of (TMG)-capped pri-miRNAs. In 
proliferating cells, most miRNAs are processed through the canonical Exportin-5-dependent miRNA 
biogenesis pathway, but the (m7G)-cap of a small group of pri-miRNAs is hypermethylated by TGS1 to 
form a (2,2,7-TMG)-cap, allowing recognition by Exportin-1. In quiescent cells, markedly reduced 
expression of Exportin-5, due to autophagy and miR-34a-mediated repression, limits the processing of most 
miRNAs, but increased expression of TGS1 supports the production of (TMG)-capped pri-miRNAs, which 
can be exported by Exportin-1 to the cytoplasm.  A short form of Drosha in the cytoplasm (possibly 
exported from the nucleus by Exportin-1) processes the (TMG)-capped pri-miRNAs. 
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XIII. Supplementary Materials and Methods 
 
A. Cell culture and reagents 
 
 Normal primary human foreskin fibroblasts (HFFs, obtained from the Yale Skin Disease Research 
Center), HeLa/E6-5K, 293T, and C127 cells were cultured in DMEM (Sigma-Aldrich, St. Louis, MO) 
supplemented with 10% fetal bovine serum (FBS), L-glutamine, 10 mM Hepes pH 7.3, penicillin–
streptomycin, and amphotericin B (DMEM-10) at 37°C in the presence of 5% CO2. 
 
B. Quiescence induced by serum starvation and confluency 
 
 HFFs, HeLa, and C127 cells were rinsed with Dulbecco’s phosphate buffered saline (DPBS, Life 
Technologies, Grand Island, NY), detached using minimal amounts of 0.25% trypsin-EDTA (Life 
Technologies) and plated in serum-free DMEM supplemented with MEM non-essential amino acids at low 
density (approx. 1 X 106 cells/150cm2 flask).  After various times at 37°C, cells were collected by scraping, 
pelleted by centrifugation, and rinsed twice with phosphate buffered saline (PBS, Sigma). For proliferating 
samples (0 h), HFFs, HeLa, and C127 cells were plated in DMEM supplemented with 10% FBS and MEM 
non-essential amino acids at a density of approximately 1.5 X 106 cells/100mm plate, cultured for 24-48 h, 
scraped, and pelleted. For quiescence induced by confluency, we plated HFFs (2 X 106 cells/100 mm plate) 
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in DMEM-10. After cells reached 100% confluency (day 0), DMEM-10 was replaced every second day.  
Cells were scraped and pelleted by centrifugation at days 1, 6, and 12.  Proliferating HFFs (Mock, day 0) 
were plated at 1 X 106 cells/100 mm plate in DMEM-10 and harvested at approximately 80% confluency. 
 
C. Immunoprecipitation of tri-methylated capped RNA 
 
 Proliferating HFFs (2 X 106 cells/100 mm plate) were transiently transfected with 500 pmol siRNA 
TGS1 (ID S14937, Ambion) or siRNA negative control #1 (Ambion) using Lipofectamine RNAiMAX 
(Invitrogen) and incubated at 37°C for 24 h in antibiotic-free DMEM-10.  Cells were then trypsinized, 
plated and incubated for 72 h in serum-free, antibiotic-free DMEM supplemented with MEM non-essential 
amino acids to induce quiescence or in the same medium supplemented with 10 % FBS for 24 h to maintain 
proliferation.  RNA was extracted from pelleted cells using Trizol Reagent (Life Technologies) per 
manufacturer’s instructions and treated with Turbo DNAfree DNase (Ambion) for 20 m at 37ºC.  RNA 
concentration was determined with a Nanodrop 2000 Spectrophotometer (Thermo Scientific, Wilmington, 
DE).  1 µL of RNasin Plus RNase inhibitor (Promega, Madison, WI) was added to 10 µg of RNA and 
incubated for 3-5 m at 85ºC; an additional 1 µL of RNase inhibitor was added after heating.  RNA diluted 
in NET-2 buffer (150 mM NaCl; 50 mM Tris, pH 7.4; and 0.05% NP-40) was incubated for 2 h at 4ºC with 
40 µL/10 µg RNA of Protein G Sepharose 4 Fast Flow beads (GE Healthcare, Buckinghamshire, UK). The 
beads were then removed by centrifugation.  Pre-cleared RNA was rotated overnight at 4ºC with 40 µL 
Protein G Sepharose 4 Fast Flow beads loaded with 15 μL normal rabbit serum (control, EMD-Millipore, 
Billerica, MA) or 15 μL rabbit m3G-cap antibody (Synaptic Systems, Goettingen, Germany).  Beads were 
rinsed 5 times with NET-2 buffer and resuspended in G-50 buffer (20 mM Tris, pH 7.5; 300 mM NaOAc; 
2 mM EDTA; and 0.25% SDS).  RNA was extracted from the beads by phenol-chloroform-isoamyl alcohol 
extraction and resuspended in 20 µL of nuclease-free water. 1 µL of GlycoBlue Coprecipitant (Ambion) 
was added to aid in visualization of the RNA pellet.  Immunoprecipitated tri-methylated capped RNA was 
analyzed by RT-PCR and qRT-PCR for pri-miRNA. Relative expression was normalized using Solaris 
RNA spike kit (Thermo Scientific, Rockford, IL). 
 
D. Microarray analysis 
 
 For global miRNA expression, we used the GeneChip® miRNA 2.0 Array (Affymetrix, Santa 
Clara, CA, USA) that assesses 1,105 mature human miRNAs. Microarray processing was carried out in the 
Yale Center for Genome Analysis (YCGA). Briefly, 1 μg of total RNA was labeled using the Flashtag RNA 
labeling kit (Genisphere, Hatfield, PA, USA) according to the manufacturer's instructions. Each sample 
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was hybridized to the array at 48°C and 60 rpm for 16 hours then washed and stained on Fluidics Station 
450 (Fluidics script FS450_0003) and finally scanned on a GeneChip® Scanner 3000 7G (Affymetrix, 
Santa Clara, CA, USA). Feature intensities were extracted by using miRNA 2.0 array library files and 
analyzed with the miRNA QC Tool software.  Array data were deposited into ArrayExpress: E-MTAB-
2760. 
 
E. Quantitative RT-PCR  
 
 Total RNA from HFFs was extracted using Trizol Reagent (Life Technologies) per manufacture 
instructions and treated with Turbo DNAfree DNase (Ambion) for 20 minutes at 37ºC. RNA concentrations 
were determined with a Nanodrop 2000 Spectrophotometer (Thermo Scientific, Wilmington, DE). For 
mature miRNAs, 1 μg of total RNA was reverse transcribed using the TaqMan® miRNA Reverse 
Transcription Kit (Life Technologies) according to the manufacturer’s instructions. For qRT-PCR of 
individual mature microRNAs, we used specific TaqMan® miRNA Assays (Life Technologies) analyzed 
on a Real-Time thermocycler iQ5 (Bio-Rad, Hercules, CA) according to the manufacturer’s protocol. To 
measure pre-miRNAs, pri-miRNAs and mRNA levels, total RNA was converted to cDNA using the iScript 
cDNA synthesis kit (Bio-Rad), followed by RT-PCR or qRT-PCR using the iQ SYBR green supermix (Bio-
Rad). Relative expression was calculated using the double delta CT method (relative expression = 2-ΔCT; 
where ΔCT =CT (Target RNA) – CT (endogenous control RNA)), where the endogenous control for 
miRNAs was the small nucleolar RNA RNU43 and for pre-miRNAs, pri-miRNAs and mRNA was 
GAPDH. For qRT-PCR normalization by exogenous spike, we used C. elegans total RNA for the 
amplification of the worm-specific ama-1 gene. Primer sequences are shown in supplementary Table 4. 
 
F. Western blot analysis 
 
 Proliferating or quiescent HFFs were lysed in NP-40 lysis buffer (50 mM Tris-HCl pH 8.0, 150 
mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS, 0.5 mM sodium metavanadate, Protease Inhibitor Cocktail 
(Sigma-Aldrich) for 12 minutes at 4°C and clarified by centrifugation at 4°C (5 min., 13,000 rpm).  The 
concentration of extracted proteins was determined by using the Pierce BCA Protein Assay (Thermo 
Scientific, Rockford, IL). Cell lysates (15-30 µg of total cell protein) were separated by SDS-PAGE, 
transferred to Immobilon-Fl membranes (Millipore, Bedford, MA) and blocked with 5% milk-TBST buffer 
(5% nonfat dried milk, 25 mM Tris-HCl pH 8.0, 125 mM NaCl and 0.5% Tween-20) for 1 h at room 
temperature.  Membranes were incubated overnight at 4°C with primary antibodies, washed with TBST 
and incubated with appropriate horseradish peroxidase (HPR)-conjugated secondary antibodies in 5% milk-
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TBST buffer for 1 h at room temperature [1:10.000; Pierce goat anti-mouse or Pierce donkey anti-rabbit 
(Thermo Scientific), anti-Rat IgG HRP-linked antibody (Cell Signaling), or donkey anti-goat (Santa Cruz 
Biotechnologies, Dallas, TX)]. After rinsing with TBST, proteins were detected using the Pierce 
SuperSignal West Pico Chemiluminescent Substrate or Pierce SuperSignal West Femto Maximum 
Sensitivity Substrate (Thermo Scientific, Rockford, IL).  The following primary antibodies were used: goat 
anti-Actin (C-11, 1:5000, Santa Cruz Biotechnologies), rabbit anti-MDM2 (1:250, Santa Cruz 
Biotechnologies), rabbit anti-p27 (C-19, 1:1000, Santa Cruz Biotechnologies), rabbit anti-p62/SQSTM1 
(NBP1-49954, 1:1000, Novus Biologicals, Littleton, CO), rabbit anti-TGS1 (1:1000, Proteintech), mouse 
anti-Exportin-1 (C-1, 1:1000, Santa Cruz Biotechnologies), mouse anti-Exportin-5 (1:1000, Abnova, 
Walnut, CA), goat anti-Exportin-5 (E-16, 1:1000, Santa Cruz Biotechnologies), rabbit anti-Drosha (1:1000 
ab12286, Abcam, Cambridge, MA), rabbit anti-Drosha (1:1000 D28B1, Cell Signaling Technology, MA), 
rabbit anti-DGCR8 (1:1000 10996-1-AP, Proteintech), rabbit anti-β-Tubulin (1:1000 9F3, Cell Signaling, 
Danvers, MA), rat anti-AGO2 (1μg/mL clone 11A9, Sigma-Aldrich), rabbit anti-Dicer (1:1000, Cell 
Signaling), and rabbit anti-HDAC1 (1:1000 H52, SantaCruz Biotechnologies). 
 
G. Immunofluorescence and signal intensity quantitation 
 
 HFFs were plated on poly-L-lysine-coated glass coverslips at 5 X 104 cells/coverslip in serum-free 
DMEM supplemented with MEM non-essential amino acids (quiescent) and at 2.5 X 104 cells/coverslip in 
DMEM supplemented with 10% FBS and MEM non-essential amino acids (proliferating).  Cells were 
rinsed with PBS and fixed with 10% buffered formalin phosphate (Fisher Scientific, Fair Lawn, NJ) for 15 
minutes at room temperature 24 h, 48 h, and 72 h after plating; proliferating cells were fixed at 24 h.  Cells 
were permeabilized for 10 minutes at room temperature with 0.4% Triton X-100 (Ameresco, Solon, OH) 
in PBS and incubated with mouse anti-Exportin-5 (1:500) or rhodamine-conjugated phalloidin (F-actin, 
1:500; Molecular Probes, Eugene, OR) in 5% bovine serum albumin (BSA) in PBS for 1 h at room 
temperature.  Immunostained cells were then incubated for one h at room temperature with Alexa Fluor 
488-conjugated goat anti-mouse secondary antibodies (1:2000; Molecular Probes) in 5% BSA in PBS.  
Cells were mounted on glass slides with ProLong Gold Anti-fade Reagent with Dapi (Life Technologies, 
Eugene, OR) to visualize nuclei.  Zeiss LSM510 confocal microscope using AIM software (Carl Zeiss 
MicroImaging, Thornwood, NY, USA) was utilized to acquire fluorescent images. For 
immunofluorescence quantification, HFF cells were plated and cultured on poly-L-lysine coated coverslips 
(Neuvitro Corp., El Monte, CA) as described above. To diminish masking of cytoplasmic signal with 
nuclear staining, HFF cells were incubated in 3 μg/mL of Digitonin (Promega, Madison, WI) in Buffer B 
(20 mM Hepes, 110 mM Potassium Acetate, 5 mM Sodium Acetate, 2 mM magnesium Acetate, 1 mM 
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EGTA and 2 mM DTT) for 3 min to selectively permeabilize only the plasma membrane 
(http://www.nature.com/protocolexchange/protocols/1994#/figures). After fixation with 3.7% 
formaldehyde in PBS, HFF cells were blocked with 5% BSA in PBS for 1 h at room temperature and 
immunolabeled as described above with rabbit anti-Drosha (D28131; 1:500; Cell Signaling) and 
Rhodamine-Phalloidin and mounted on glass slides with ProLong Gold Anti-fade Reagent with Dapi (Life 
Technologies). Confocal microscopy was used to visualize cells; fluorescent images were converted to TIF 
Files and localization of Drosha in the cytoplasm was quantitated utilizing Image J 
(http://www.macbiophotonics.ca/imagej/). In short, the area (outline) of the entire cell and nucleus were 
determined using F-actin and Dapi images, respectively, by the “Analyze/Analyze Particle” command after 
the “Threshold” was set for the images. “Nuclear” Drosha and “Total Cell” Drosha were measured by total 
pixel area from threshold Drosha image contained in the “outline” of the cell and nucleus (identified regions 
of interests, ROIs, obtained from F-actin and Dapi images). Quantification of “cytoplasmic” Drosha was 
generated by the subtraction of “Nuclear” Drosha due to partial permeabilization of the nuclear fraction 
with digitonin from “Total Cell” Drosha. Results were normalized to proliferating HFF cells; experiments 
were performed in triplicate. 
 
H. Inhibition of proteasome activity and autophagy 
 
 HFFs plated the day before at 1.5 X 106 cells/100 mm plate were pre-treated with 10 µM MG132 
(2-Leu-Leu-H Aldehyde, Peptide International, Louisville, KY) or vehicle (DMSO) for 2 h at 37°C.  
Treated cells were trypsinized and plated at 1 X 106 cells/T150 flask in serum-free DMEM supplemented 
with MEM non-essential amino acids containing 10 µM MG132 to induce quiescence.  Cells were harvested 
by scraping at 3, 6, and 12 h and pelleted.  Alternatively, MG132-treated HFF cells were scraped and 
pelleted after pretreatment for 0 h time point (mock).  Pelleted cells were lysed and analyzed by Western 
blotting. For the 3-MA treatment, HFFs were plated at 1.5 X 106 cells/100 mm plate in DMEM-10 and 
incubated overnight. Cells pre-treated with 10 mM 3-methyladenine, 3-MA (Sigma-Aldrich) or vehicle 
(water) for 2 h were induced to quiescence by trypsinizing and plating at 0.9 X 106 cells/T150 flask and 
serum starved in the presence of 10 mM 3MA.  Cells were scraped at 3, 6, and 12 h and pelleted to collect. 
Additionally, Mock (0 h) was generated by pelleting 3MA-treated proliferating HFFs. Harvested cells were 
lysed with NP40 lysis buffer and analyzed by Western blotting. 
 
I. Transient transfection of siRNAs and mimicRNAs 
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 75 μL of Lipofectamine RNAiMAX (Invitrogen, Grand Island, NY) was added to 500 pmol (total) 
of siRNAs or mimicRNAs diluted in 2.5 mL of Opti-MEM I Reduced Serum Media (Gibco).  To form 
complexes, Lipofectamine RNAiMAX/RNA solution was incubated for 20 minutes at room temperature 
then spread in a 100 mm plate.  2.0 X 106 HFFs were added dropwise to the 100 mm plate containing 
complexes and incubated for 48 h.  siRNAs and mimicRNAs were preMir Negative Control #1 (Ambion, 
Grand Island, NY), Silencer Select Negative Control #1 (Ambion), Silencer Select Validated siRNA 
Exportin-1 (ID s14937, Ambion), Silencer Select Validated Exportin-1 (ID118206, Ambion), Silencer 
Select Predesigned siRNA TGS1 (ID s41313, Ambion), siGenome siRNA Exportin-5 (Thermo Scientific, 
Dharmacon), Silencer Select Validated Exportin-5 (IDs33191, Ambion), Silencer Select Validated 
RNASEN (Drosha long, IDs26491, Ambion), PIMT (TGS1) siRNA (280 pmol, sc-45875, Santa Cruz), and 
hsa-miR-34a (ID PM11030, Ambion). For cellular fractionation to determine localization of pri-miRNA in 
the cytoplasm; 280 pmol of a pool of 3 target-specific 19-25 nt siRNAs against Drosha (sc-44080, Santa 
Cruz) or siRNA Control was utilized as detailed above to knockdown Drosha in HFF cells. 
 
J. Transient transfection of plasmids 
 
87 μL of Lipofectamine 2000 (Invitrogen) was diluted in 1.2 mL of Opti-MEM I Reduced Serum Media 
(Gibco) and incubated at room temperature for 5 minutes.  Separately, 11 μg of plasmid was diluted in 1.2 
mL of Opti-MEM I Reduced Serum Media. The Lipofectamine solution and the DNA/OptiMEM solution 
were mixed and incubated for 20 minutes at room temperature.  The Lipofectamine/DNA complexes were 
added drop-wise to HFFs plated the previous day at a density of 1.5 X 106 cells/100mm plate in antibiotic-
free DMEM-10.  Antibiotic-free DMEM 10 medium was changed after 4-6 h, and HFFs were incubated 
overnight at 37°C. 
 
K. Retroviral infection of plasmids 
 
293T cells were transiently transfected with the retroviral plasmid pBABE-puro-Flag-XPO1 or pBABE-
puro-Flag-vector and retroviral packaging plasmids (pCL-Eco and VSV-G) using calcium phosphate 
transfection.  Retrovirus was collected after 48 hrs, filtered and supplemented with polybrene (4 μg/mL) to 
increase infection efficiency. HFF cells were exposed to retrovirus for 8 hrs and allowed to recover for 48 
hrs before use. 
 
L. Luciferase assays 
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Luciferase plasmids pmirGlo dual-luciferase expression vector (Promega) and derivatives containing the 
wild-type or mutant Exportin-5 3’UTR (three point mutations in the binding sequence of the miRNA seed 
region) were transiently transfected into HFFs by using Lipofectamine 2000 as described above. After 
incubation for 24h, transfected cells were trypsinized and plated at a density of 5.0 X 104 cells/well in 6-
well plates in antibiotic-free, serum-free DMEM medium supplemented with MEM non-essential amino 
acids (for quiescent cells) and 1.0 X 105 cells/well in antibiotic-free, DMEM supplemented with 10% FBS 
and MEM non-essential amino acids (for proliferating cells) and incubated for 48 h. Luciferase activity was 
analyzed by using the Dual-Luciferase Reporter Assay System (Promega) per manufacturer’s protocol.  In 
short, cells were lysed with Passive Lysis Buffer (250 μL for quiescent cells and 500 μL for proliferating 
cells) by rapid shaking for 30 minutes at room temperature and aliquoted (20 μL for proliferating cells, 80 
μL for quiescent cells) into 96 well Costar white plate (Corning Incorporated, Corning, NY).  Luminescence 
was measured by using a Modulus II Microplate Luminometer with dual injector system (Turner 
BioSystems, Sunnyvale, CA). All transfections and luciferase assays were done in triplicate. For microRNA 
and anti-miR transfections, we transiently transfected 7 X 104 cells/well in a 24 well plate with 17 pmol 
pmiR Negative Control #1 (Ambion) or hsa-miR-34a (PM11030, Ambion) diluted in 87 μL OptiMEM I 
Reduced Serum Medium mixed with Lipofectamine RNAiMAX (Life Technologies) as described above.  
Transfected cells were incubated overnight and then transiently transfected with pmirGlo dual-luciferase 
expression vector, Exportin-5 3’UTR WT, and Exportin-5 3’UTR MT (0.5 μg/well) using Lipofectamine 
2000 (1 μL/well) as described above.  Cells were then incubated 48 h in antibiotic-free DMEM 
supplemented with 10% FBS and non-essential amino acids and luciferase assays were performed. Firefly 
luciferase activity was measured, normalized to Renilla luciferase activity and converted to Relative 
luciferase units (RLUs). Data average ratios were obtained in each experiment from three replicates; the 
graph shows the average of two individual experiments with a standard deviation shown as error bars. Two-
tailed t-test results are indicated by * for P < 0.05 and ** for P < 0.01. 
 
M. Cellular Fractionation 
 
Proliferating and quiescent HFF cells were pelleted and immediately processed for cell fractionation to 
extract either protein or RNA (protocol adapted from Wang, Y. et. al. 2006) (63). Pelleted cells were 
resuspended in RSB buffer (10 mM Tris, pH 7.5; 0.3 mM sodium chloride; 0. 1 mM magnesium chloride), 
incubated on ice for 5 min, and centrifuged at 1500 rpm for 4 min to re-pellet. Swollen pellets were 
resuspended in a volume of RSBG40 buffer (10 mM Tris, pH 7.5; 0.3 mM sodium chloride; 0. 1 mM 
magnesium chloride; 10% glycerol; 0.5% NP-40; 100 U/mL RNasin Plus RNase inhibitor (Promega, 
Madison, WI) and 0.5 mM DTT) at least 4 times the volume of the pellet. Cells were disrupted using an 
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autoclaved Dounce homogenizer; homogenate was centrifuged at 4000 rpm for 4 min to pellet the nuclear 
fraction. The cytoplasmic fraction (supernatant) was collected.  The pelleted nuclear fraction was 
resuspended in RSB-G40; 3.3% of sodium deoxycholate and 6.6% of Tween 20 was added to 1/10th of the 
volume of RSB-G40. Nuclei were re-pelleted by centrifugation at 7000 rpm for three min after five min 
incubation on ice. The supernatant was collected and added to the cytoplasmic fraction, which was then 
subjected to Western blot protein analysis, or RNA was extracted using Trizol Reagent (Life Technologies) 
per manufacturer’s instructions and treated with Turbo DNAfree DNase (Ambion) for 20 minutes at 37ºC.  
RNA concentrations were obtained using a Nanodrop 2000 Spectrophotometer (Thermo Scientific, 
Wilmington, DE). The nuclear pellet was washed with RSB-G40 and resuspended in NP-40 lysis buffer for 
protein analysis by Western blot or Trizol for RNA extraction and RT-PCR analysis. 
 
N. Immunoprecipitation of Exportin-1 
 
Immunoprecipitation protocol was adapted from Niranjanakumari S et al. 2002; Vasudevan S and Steitz 
JA. 2007; and Vasudevan S et al. 2007 (38, 64, 65). Quiescence was induced in HFF cells expressing 
pBABE-puro-Flag-XPO1 or pBABE-puro-Flag-vector pFlag by serum-starvation (48 hrs). Quiescent HFFs 
were crosslinked with 1% formaldehyde in PBS for 10 min at RT on a shaker. Glycine was added to a final 
concentration of 0.125M to quench the reaction for 5 min at RT, shaking occasionally. HFF cells were 
washed with PBS, scraped and pelleted by centrifugation. Cell pellets lysed with RIPA buffer (50mM tris, 
pH 7.5, 1% NP-40, 0.5% sodium deoxycholate, 0.05% SDS, 1mM EDTA, 150mM NaCl), and sonicated. 
Pre-washed anti-Flag M2 Magnetic Bead (20 μL, Sigma-Aldrich) were incubated with 275-300μg of 
lysates, RNasin Plus RNase Inhibitor (Promega), and 100 μg/mL tRNA (Sigma-Aldrich) while rotating for 
approximately 4 hrs at 4˚ C. Beads were washed 6 times with RIPA buffer. RNA/beads were un-crosslinked; 
briefly, beads were resuspended in 6M urea, 50mM Tris, pH 6.8, and 3mM DTT and incubated for 45 min 
at 60˚ C. Proteinase K buffer (50mM Tris-HCL, pH 8.0, 10mM CaCl2) was added to dilute urea and 75 
μg/mL Proteinase K (Fisher Scientific) was added to digest protein. Samples were incubated for 1 hr at 45˚ 
C, pelleted and supernatant was collected. RNA was extracted with TRIzol Reagent (Invitrogen) per 
manufacturer’s instructions; GlycoBlue Coprecipitant (Life Technologies) was added. 
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Chapter 4 
 
Overall Discussion and Future Directions 
 
 Traditionally, biomedical research was conducted based on the central dogma of molecular biology, 
which is that DNA contains the genomic information, RNA is the "messenger" of this information, and 
proteins are the final product. In 2007, the Encyclopedia of DNA Elements (ENCODE) showed that more 
than 80% of the human genome is transcribed, but less than 3% of these molecules become proteins(1). 
These numerous newly discovered transcribed RNAs are classified as non-coding RNAs (ncRNAs) and 
have now evoked researchers to identify novel ncRNA regulators of cellular pathways besides the 30,000 
protein-coding genes encoded by the human genome. A single ncRNA can regulate many different genes 
involved in many different cellular pathways, so it is critical to further study the role(s) of these individual 
ncRNAs in more detail.  
  
 NcRNA expressions are altered by a variety of cellular processes that are involved with the 
progression to cancer, such as those occurring after infection with oncogenic viruses (e.g. human 
papillomavirus)(2, 3) or specifically involved with cell cycle regulation, such as cellular growth arrest (e.g. 
quiescence) (Chapter 3)(4). Our group's overall goal is to continue to identify early molecular changes in 
ncRNAs that occur in response to cellular stresses and contribute to carcinogenesis. In the context of cancer, 
traditionally, ncRNA expression changes are identified by comparing established tumors to normal tissues. 
One of the specific goals of our group is to continue to elucidate early molecular events that cause initial 
dysregulation but are also critical enough to be maintained throughout carcinogenesis.  
  
 Oncogenic viruses, such as human papillomavirus (HPV), are useful models to study early events 
in cancer because they are single exogenous agents involved in the initial steps of carcinogenesis. HPV 
infection can regulate some unique cellular pathways, but also some analogous pathways other carcinogenic 
factors utilize. Thus, identifying early molecular events that are critical for progression to carcinogenesis 
in HPV-associated cancers could potentially be applicable to other cancers and would add to the 
marketability of these involved genes as therapeutic targets or diagnostic markers.   
 
 Additionally, it is necessary to continue to study HPV, as it continues to be linked to development 
of 4.5% of total cancer incidences worldwide. Certain HPV-associated cancers, such as the oropharyngeal 
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subset of head and neck squamous cell carcinoma (HNSCC), are on the rise even in industrialized 
countries(5). In principle, HPV-associated cancer should be preventable as there are prophylactic 
vaccinations available to prevent infection with strains commonly associated with oncogenesis. However, 
more than two-thirds of the cervical cancer incidences occur in less-developed countries(6), which are 
limited by financial and logistical issues for access to the vaccines(7). Worldwide, as of October 2014, only 
a small minority (7.5%) of 10 to 20-year-old females are estimated to have been administered at least one 
shot of an HPV vaccine(8), and this statistic does not guarantee that all of these patients completed the full 
administration of shots required for full efficacy. Additionally, since the HPV vaccinations are prophylactic, 
they do not protect those who have already been exposed to the virus. According to the CDC, "HPV is so 
common that nearly all men and women get exposed to the virus at some point in their lives" 
(https://www.cdc.gov/std/hpv/stats.htm). Thus, these many individuals who already have been exposed to 
oncogenic strains of the virus risk persistent infection contributing to carcinogenesis, and new cancer 
therapies need to be developed.  
  
 HPV regulates a variety of downstream genes to contribute to carcinogenesis(9, 10). Our group 
recently revealed novel coding genes (including LAT1 and NAP1L3) that are differentially expressed in 
HPV-positive compared to HPV-negative cervical cancer lines and normal cervical keratinocytes. Future 
studies will be conducted to elucidate downstream effects of their up-regulation as well as potential use as 
biomarkers associated with the development of cervical cancer. Different types of ncRNAs [microRNAs 
(miRNAs) and long non-coding RNAs (lncRNAs)] also exhibit global differential expression when 
comparing cervical cancer patients (expressing the full HPV genome) to normal matched cervical tissues 
(2, 3).  
 
 Notably, lncRNAs are a more recent field of interest and many have not been fully characterized. 
There is not a clear, set standard collection of lncRNAs that all research groups analyze; certain lncRNAs 
might not be analyzed in every dataset so it can be difficult to compare between different groups' studies. 
In the initial stages of the project presented in Chapter 2, MD Anderson's The Atlas of ncRNA in Cancer 
(TANRIC) database (http://ibl.mdanderson.org/tanric/_design/basic/index.html) was the most user-
friendly, open access resource for extracting information from large high-throughput RNA sequencing 
(RNA-seq) datasets showing lncRNAs expression changes involved in cancer. More recently, additional 
resources are available such as The Cancer LncRNome Atlas (TCLA) (http://tcla.fcgportal.org/) database 
hosted by University of Pennsylvania.  
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 Two specific oncogenic components of the HPV genome, E6 and E7, affect two main tumor 
suppressors p53(11) and Rb(12), respectively, however they have been found to regulate a plethora of genes 
involved in cancer progression(10, 13). Since the HPV oncogenes regulate pathways commonly altered in 
cancer (even in HPV-negative cancers), looking at downstream pathways regulated by the HPV oncogenes 
can also be applicable to other types of cancers. In addition to coding gene regulation specifically by HPV 
oncogenes, certain studies have shown ncRNA regulation. Martinez et al. showed high-risk HPV-16 E6 
regulation of a miRNA (miR-218) that regulates a coding gene (LAMB3) to potentially increase viral 
infection of surrounding tissue and contribute to carcinogenesis (14). Additionally, a couple previous 
studies showed that the HPV-16 E6/E7 oncogenes regulate the expression of lncRNA MALAT1(15) and 
CCEPR(16) to contribute to cervical cancer. Our group recently showed that HPV E6 expression alone 
causes differential expression alterations in additional host lncRNAs (Chapter 2, Figure 1A and 
Supplementary Table S1). Future studies elucidating the mechanism(s) of these HPV E6-regulated 
lncRNAs could contribute significantly to the cancer field.  
 
 Another interesting future route to study HPV E6 regulation of lncRNAs is to evaluate if any 
lncRNAs are directly bound to the HPV-16 E6 oncoprotein. A variety of proteins are shown to directly 
interact with HPV-16 E6(17), but enhancement of knowledge on ncRNA E6 binding partners could reveal 
alternative downstream regulators of carcinogenesis. Since HPV-16 E6 is localized to the nucleus(18), it is 
predicted the bound ncRNAs will be nuclear. The primary goal of this direction would be to identify host 
lncRNAs that are bound to E6, however, with advanced high-throughput RNA sequencing technologies it 
would be possible to identify novel host and viral ncRNAs bound to HPV. The Martinez lab has un-
published data showing HPV produces viral circular RNAs that alter different hallmarks of cancer 
(proliferation and apoptosis) (data not shown). Our lab has not yet elucidated if this is directly or indirectly 
by HPV-16 E6 or the presence of the full genome. Preliminary experiments were conducted to attempt to 
transfect a Flag-HPV-16 E6 construct into cervical cells and immunoprecipitate out by an antibody against 
Flag. There are well-known technical difficulties in the HPV field when trying to detect HPV-16 E6 because 
good quality antibodies are lacking and it has such a low molecular weight (~21 kDa) that is difficult by 
Western Blot analysis.   
 
 Our lab is particularly interested in researching the host lncRNA FAM83H-AS1, which our group 
identified to be HPV-16 E6 regulated in cervical cells (Chapter 2, Figure 3A-C, Supplementary Figure 
S4A,B), and its importance in cancer initiation and progression. Most lncRNAs are tissue specific(19). 
FAM83H-AS1 is classified as an "onco-lncRNA", which describes the few lncRNAs that have been 
determined to be altered in many different cancer tissue lineages unrelated to HPV infection. This is an 
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important feature because if a lncRNA is affected in multiple types of cancers, it suggests its universal 
importance in essential cellular pathways involved in carcinogenesis. The study of these onco-lncRNAs 
could increase the ability to develop potential diagnostic, prognostic, or therapeutic applications for several 
types of cancers(20). FAM83H-AS1 expression was shown to be up-regulated in the following cancers and 
high expression of FAM83H-AS1 in each of these cancers correlates with poor overall survival: breast(20, 
21), colorectal(20, 22, 23), lung(20, 24), pancreatic(25), brain(26), and cervical (Chapter 2, Figure 6) 
(Figure 1). Therefore, further elucidating the FAM83H-AS1 in HPV-related cancers could be beneficial to 
a broad range of cancer patients. 
  
 Our group showed for the first time that FAM83H-AS1 expression is altered at an early stage of 
HPV infection in cervical cells (Chapter 2, Figure 2A), and this alteration is maintained throughout later 
stages of cervical carcinogenesis (Chapter 2, Figure 2B and Figure 6A,B). These results could be further 
strengthened in the future with access to larger sample sizes of normal, pre-malignant (cervical 
intraepithelial neoplasia), and cancerous human patient tissues to analyze FAM83H-AS1 expression 
differences. These data would contribute to the conclusion that initial up-regulation of FAM83H-AS1 is an 
early event similar to HPV infection itself. This increases its applicability for utilization as a biomarker to 
predict patients with high FAM83H-AS1 expression changes early on with HPV infection who will likely 
progress to cervical carcinogenesis.  
 
 Our group analyzed FAM83H-AS1 expression after persistent HPV infection by extracting data 
from TANRIC to show high expression of FAM83H-AS1 in cervical squamous cell carcinoma and 
endocervical adenocarcinoma (CESC) patients and that high expression of FAM83H-AS1 correlated with 
poor overall survival (Chapter 2, Figure 6B,C). HPV is detected in almost all cervical cancers. HPV-16 is 
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the most prevalent strain (50%), HPV-18 the second most common (15%), and there are many other strains 
(-31, -33, -35, -39, -45, -51, -52, -56, -58, -59, and 68) classified as carcinogenic(27). Dividing TANRIC 
CESC patients into subgroups by strain could increase the impact if it is found that FAM83H-AS1 
expression is altered in more than just HPV-16 positive samples. The original article that classified 
FAM83H-AS1 as an onco-lncRNA showed that, in their analysis, its expression in head and neck cancer is 
an outlier, where "outlier" is defined as a subset that had an alteration in expression(20). It is speculated 
that if these head and neck samples were divided into HPV-positive and HPV-negative subsets that there 
could have been a correlation determined. Further data mining from TANRIC of other cancer types, and 
segregation of samples based on HPV status, could be utilized to enhance the idea that FAM83H-AS1 is 
up-regulated in an HPV-dependent manner in certain cancer types. 
 
 HNSCC is a significant cancer type to study further as recently it was identified that the incidence 
of HPV-positive oropharyngeal cancer has surpassed cervical cancer in the United States(5). Our group 
showed that FAM83H-AS1 expression was also shown to be higher in HPV-positive versus HPV-negative 
HNSCC cell lines (Chapter 2, Figure 2C). Future access to human HPV-positive oropharyngeal HNSCC 
tissue samples as well as functional assays after FAM83H-AS1 knockdown in HNSCC cell lines would be 
beneficial to strengthen the HPV regulation of FAM83H-AS1 in HNSCC samples.  
 
 Overall, since individual knockdown of FAM83H-AS1 showed positive responses desired for 
cervical cancer cells (decreased proliferation and migration, and increased apoptosis) (Chapter 2, Figure 5 
and Supplementary Figure S7), FAM83H-AS1 expression could potentially be targeted in either early 
stages of HPV infection (when the increase in expression is detected such that it could potentially prevent 
progression to carcinogenesis) or in later stages of cervical cancer. 
 
 Genes can be alternatively spliced under cellular stresses, which can contribute to carcinogenesis, 
and specifically HPV gene expression is controlled by alternative splicing to regulate its viral life cycle(28). 
Our group has obtained unpublished data showing alternative splicing events upon HPV infection can 
produce a viral circular RNA that regulates proliferation in cervical cancer cells (data not shown). Our lab 
plans to continue to elucidate alternatively spliced host and virus-produced ncRNAs critical for the 
initiation and progression to cancer.  
 
 Certain lncRNAs are predicted to have multiple isoforms according to online databases such as 
LNCipedia (lncipedia.org). We plan to fully sequence the specific functional isoform(s) of FAM83H-AS1 
that is important in cervical cancer. Northern Blot probes, developed by in vitro transcription, will be used 
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to detect the sizes of the FAM83H-AS1 isoforms. Then, TANRIC's RNA sequencing data of FAM83H-
AS1 could be extracted and bioinformatics analysis conducted to determine the frequency of reads at certain 
regions of RNA transcript. The sequences of these regions could be extracted from UCSC Genome Browser 
and used to design sets of primers to confirm (via RT-PCR) the presence of these certain RNA segments 
and map the entire functional RNA sequence. Once the functional FAM83H-AS1 isoform(s) is 
characterized in cervical cells, the presence and functionality of this specific isoform(s) in other cancer 
lineages could be determined to increase the universal potential of this lncRNA as a therapeutic target 
and/or diagnostic marker. Sequencing the functional isoform of FAM83H-AS1 would enable multiple 
future studies described in the paragraphs below.  
 
 Elucidation of upstream regulators of FAM83H-AS1 could determine ways to control and/or 
predict the lncRNA's expression changes. Our group showed that FAM83H-AS1 expression is regulated 
by HPV-16 E6 in cervical cells (Chapter 2, Figure 3A,B,C, Supplementary Figure S4A,B). This regulation 
of FAM83H-AS1 by HPV could be characterized further. Reporter assays, using a luciferase reporter vector 
containing the promoter region of FAM83H-AS1, could be transfected into HPV-positive and HPV-
negative cells with or without siRNAs against HPV oncogenes E6 and/or E7. It is expected that there will 
be changes in luciferase activity in HPV-positive cell lines after the repression of the HPV oncogenes, 
suggesting a regulation of FAM83H-AS1 at the transcriptional level. If the hypothesis is correct, different 
luciferase constructs with specific mutations in the FAM83H-AS1 promoter could be used to identify the 
regulatory region in the genomic sequence. 
  
 HPV-16 E6 contributes to the degradation of the tumor suppressor p53, which alters the expression 
of many p53-regulated genes and affects critical cellular pathways (e.g. proliferation, DNA repair, and 
apoptosis)(9, 29) to contribute to carcinogenesis. Interestingly, FAM83H-AS1 was determined to be 
regulated in a p53-independent manner in cervical keratinocytes (Chapter 2, Figure 3D, Supplementary 
Figure S4C). Since HPV-16 E6 interacts directly with p300(17, 30, 31), and that there are three p300 
binding sites in the predicted promoter region of FAM83H-AS1 (Chapter 2, Figure 3E) as determined by 
using the transcription factor binding site prediction software ConTra v3(32) we analyzed FAM83H-AS1 
regulation by p300. The transcription activator p300 was identified as a regulator of FAM83H-AS1 
expression in cervical keratinocytes (Chapter 2, Figure 3F, Supplementary Figure S4D). To further 
strengthen this, an inducible p300 knockdown construct could be stably transduced into cervical cancer 
cells and FAM83H-AS1 expression could be monitored by a dose-dependent progressive knockdown of 
p300. Reciprocally, p300 could be added to cervical keratinocytes (likely exhibiting low baseline 
expression of p300) and FAM83H-AS1 expression could be monitored; it would be expected that 
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FAM83H-AS1 expression would increase with p300 expression. A reporter assay, using a luciferase 
reporter vector containing the promoter-region of FAM83H-AS1, could be used to determine direct binding 
between p300 and FAM83H-AS1. The expression of FAM83H-AS1 could be monitored between a 
luciferase reporter vector containing the wild-type promoter as well as different constructs containing 
mutations in each of the individual p300 binding sites. Additionally, to confirm direct binding, chromatin 
immunoprecipitation (ChIP) with a p300 antibody could be used to determine direct binding of p300 to the 
FAM83H-AS1 promoter region of the genome.  
 
 Since other groups previously showed FAM83H-AS1 expression is altered in cancers not regulated 
by HPV expression(20-26), HPV is not the only potential driver of increased FAM83H-AS1 expression. It 
is speculated that HPV-16 E6 could be regulating a downstream factor, and this downstream factor is more 
directly responsible for regulating FAM83H-AS1 expression. A group previously analyzed specific 
proteins that are bound to the E6 oncoproteins expressed by different high-risk strains of HPV. Interestingly, 
of the high-risk strains that were analyzed, the only high-risk strain E6 oncoprotein that bound transcription 
activator p300 was HPV-16(17) (Figure 2). Our group performed preliminary analysis of FAM83H-AS1 
expression in an HPV-18 positive cervical carcinoma cell line (HeLa) and found that FAM83H-AS1 is 
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expressed at similar levels to normal cervical keratinocytes (Chapter 2, Supplementary Figure S4E). 
Therefore, our group speculates that HPV-16 E6 regulates FAM83H-AS1 indirectly in cervical cancer, and 
p300 is directly regulating FAM83H-AS1 expression in HPV-16 positive cervical cancer. Furthermore, 
other types of cancers where FAM83H-AS1 is found overexpressed also showed overexpression of the 
transcription factor p300(33-37).  
 
 Many antisense lncRNAs can share the same promoter as nearby coding genes and their 
expressions correlate(38, 39). LncRNA FAM83H-AS1 is located near the coding gene FAM83H in the 
genome and transcribed antisense to the coding gene. Thus, it was hypothesized that they share the same 
promoter. FAM83H is up-regulated in many different types of cancer(40), and HPV-16 E6 up-regulates 
FAM83H as well as FAM83H-AS1 expression (Chapter 2, Figure 3E, Supplementary Figure S5B).  Thus, 
it can be speculated that the lncRNA and coding gene share the same promoter. To confirm this, the sense 
and antisense sequences could be cloned independently in a luciferase reporter vector and their activity 
verified. Additionally, knocking down p300 and analyzing for changes in FAM83H expression would 
provide evidence that FAM83H and FAM83H-AS1 share the same promoter region. 
 
 In addition to identifying upstream regulators of FAM83H-AS1, it is critical to identify specific 
downstream effects of dysregulated FAM83H-AS1 expression. Previous publications showed that 
FAM83H-AS1 regulates CDKN1A in glioma cells(26), Notch signaling in colorectal cancer(22), and 
MET/EGFR signaling in lung cancer(24). These publications specifically looked at FAM83H-AS1 
downstream regulation in single cancer types, thus it could be determined if FAM83H-AS1 functions 
similarly in other cancer types including cervical cancers.  
 
 In the ncRNA field, it is understood that the stoichiometry between a ncRNA and its targets can 
predict the chances of interactions and consequential downstream effects. NcRNA expression is usually 
quantified using techniques such as qRT-PCR analysis that show relative expression. However, it is 
important to determine absolute expression of RNAs in cells. To do this, in vitro transcription followed by 
qRT-PCR analysis can be used. We believe, however, that FAM83H-AS1 is expressed at a reasonable 
functional level, as its RPKM value in our RNAseq data is similar to the RPKM values of known functional 
lncRNAs (Chapter 2, Supplementary Table S2).  
 
 Determining the localization of a lncRNA can aid in elucidating the downstream function of the 
lncRNA. For example, if a lncRNA is nuclear it can be speculated that it regulates at the transcriptional 
level. Other groups have shown the localization of FAM83H-AS1 in the nucleus in lung and breast cancer 
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cells(24, 26), and our group recently found FAM83H-AS1 in the nucleus of cervical cancer cells (as seen 
in Chapter 2 with cellular fractionation in Figure 4A,B). Fully sequencing FAM83H-AS1 would provide 
information necessary to design RNA fluorescent in situ hybridization (FISH) probes that could be used to 
detect the localization of lncRNAs and strengthen the finding that FAM83H-AS1 is localized in the nucleus. 
RNA FISH probes could hybridize with cervical cells as well as cervical tissue microarrays to analyze 
FAM83H-AS1 expression levels in human cervical samples at early stage infection (cervical intraepithelial 
neoplasia) through late stage carcinogenesis. Successful design of RNA FISH probes for FAM83H-AS1 
would be beneficial to study other cancer types as well, as RNA FISH probes have not been used to detect 
FAM83H-AS1 in any cellular context to our knowledge.  
 
 Many nuclear lncRNAs can function in cis(41). Since FAM83H-AS1 is localized in the nucleus in 
cervical cancer cells (Chapter 2, Figure 4A,B), it was initially hypothesized that FAM83H-AS1 regulates 
the nearby coding gene FAM83H in cis. Knockdown of FAM83H-AS1 lncRNA does not appear to regulate 
FAM83H expression (Chapter 2, Supplementary Figure S5C), thus our group speculates that FAM83H-
AS1 does not regulate FAM83H in cis in our system. FAM83H-AS1 is likely functioning in trans in our 
model, but it does not eliminate the possibility that FAM83H-AS1 could function in cis in other cancer 
types or cellular stress situations (e.g. serum starvation and hypoxia).  
  
 Determining RNA and protein expressions that are affected by FAM83H-AS1 would potentially 
allow us to further narrow down the lncRNA mechanism of action. Using samples with efficient knockdown 
of FAM83H-AS1 in cervical cancer cells, it is proposed to conduct RNA high-throughput sequencing and 
mass spectroscopy to determine specific direct and/or indirect downstream effectors of FAM83H-AS1 that 
are contributing to the observed carcinogenic effects. A previous study analyzed differential gene 
expression changes with two different siRNAs against FAM83H-AS1 in a pancreatic cancer cell line, 
Aspc1(25). The theoretical dataset in cervical cancer could be compared to the pancreatic cancer dataset to 
identify similar molecular regulation by FAM83H-AS1 between cancer types. To elucidate direct binding 
partners, FAM83H-AS1 could be pulled out by a biotinylated RNA probe to identify its direct RNA/DNA 
(high-throughput RNA sequencing) and protein (mass spectroscopy) binding partners. A previous 
publication showed that in glioma cells, FAM83H-AS1 binds to EZH2(26), thus this would be a binding 
target we would look for in cervical cancer cells, as EZH2 regulates many genes at the transcriptional level 
by DNA methylation. Both cytoplasmic(42) and nuclear(43) lncRNAs can bind to miRNAs to act as 
competing endogenous RNAs. To verify potential binding interactions between FAM83H-AS1 and 
miRNAs to suggest a post-transcriptional regulation of miRNAs, crosslinking immunoprecipitation (CLIP) 
assays using Argonaute antibodies (that is the protein of the RNA induced silencing complex that miRNAs 
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are loaded into) could be conducted. Once the analysis is narrowed down to critical lncRNAs, Target scan 
could be used to determine potential FAM83H-AS1 miRNA binding sites. To confirm direct miRNA 
binding to lncRNA, luciferase reporter experiments could be conducted by cloning FAM83H-AS1 regions 
with potential miRNA binding sites to a luciferase reporter vector. Subsequently, FAM83H-AS1 activity 
could be measured by using siRNAs against specific miRNAs and then mutating the potential binding sites 
in these constructs. Other FAM83H-AS1 binding partners are yet to be determined, thus this experiment 
would provide novel information. 
  
 In addition to specific genes regulated by 
FAM83H-AS1, we are interested in 
monitoring functional changes with alterations 
in FAM83H-AS1 expression. Knockdown of 
FAM83H-AS1 in cervical cancer cells resulted 
in decreased proliferation and migration, 
increased cells in S-phase, and increased 
apoptosis (Chapter 2, Figure 6 and 
Supplementary Figure S7). An ideal next step 
would be to express the FAM83H-AS1 in cells 
with low baseline FAM83H-AS1 expression 
and monitor for functional changes. The 
hypothesis for this future direction is that 
expression of FAM83H-AS1 would increase 
proliferation and migration. There was a group 
recently that cloned the PCR-amplified complementary DNA (cDNA) sequence that encoded FAM83H-
AS1 into an expression vector and transfected this into cells to monitor functional changes(26).  However, 
to ensure expression of the entire functional lncRNA, we propose cloning the full FAM83H-AS1 sequence 
into a retroviral plasmid (e.g. PLPCX) or use the lentiviral CRISPR-Cas9 mutant technology known as 
SAM complex (Figure 3). This system requires sequentially expressing the lentiviral plasmids (Addgene) 
MS2-P65-HSF1_Hygro (Plasmid #1), dCAS9-VP64_Blast (Plasmid #2), and sgRNA(MS2)_Zeo (Plasmid 
#3)(44). Briefly, Plasmid #1 expresses the MS2 protein that binds to p65 and heat-shock factor 1 (HSF1) 
proteins that enhance transcription factor signals. Plasmid #2 contains a mutant Cas9 (dCas9) that inhibits 
its endonuclease activity, and is bound to the transcription factor VP64. Plasmid #3 was cloned such that it 
would specifically target a predicted FAM83H-AS1 promoter site. Preliminary data was obtained in the lab 
showing successful stable transfection of Plasmids #1 (MS2 mRNA), #2 (dCas9 mRNA), and #3 (Zeocin 
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mRNA) in an HPV-negative cervical carcinoma cell line (C-33A) and immortalized keratinocytes (HaCat). 
However, there was not significant up-regulation of FAM83H-AS1 observed (Figure 4). After further 
analysis, it was determined that the predicted promoter sequence inserted into Plasmid #3 was not the region 
that we currently believe is the predicted promoter site (region containing p300 binding sites). This would 
explain the lack of increased FAM83H-AS1 expression observed in Figure 4. A future direction is to re-
design sgRNAs to target the more characterized FAM83H-AS1 promoter site and over-express FAM83H-
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AS1 in cervical cells. This system would be useful to study the effects of increased FAM83H-AS1 
expression in other cancers as well.   
   
 In the knockdown experiments described in Chapter 2, FAM83H-AS1 expression was transiently 
knocked down. It would be required to develop a system to stably knockdown FAM83H-AS1 for future in 
vivo experiments and long-term in vitro experiments (e.g. colony formation assays); it is important to note 
that the transient knockdown of FAM83H-AS1 was maintained for at least 120 hours (Chapter 2, 
Supplementary Figure S6). In developing a system to stably knockdown FAM83H-AS1, it would also be 
ideal to develop a stable population from a single cell clone population to ensure that all cells have 
knockdown of FAM83H-AS1 and there is a lack of non-transfected cell background.  
  
 It is clear that a significant portion of the cells had knockdown of FAM83H-AS1, as we saw 
significant functional changes, however the transfection efficiency was not determined. In the future, a 
system could be developed to express a fluorescent protein (e.g. GFP) to confirm siRNA successfully 
transfected into cell nuclei. This would allow for either visualization under fluorescent microscope to 
qualitatively determine efficiency, or flow cytometry could be potentially used to sort and collect the GFP 
positive population for future experiments. It is speculated that cells that had successful knockdown of 
FAM83H-AS1 were the ones that underwent apoptosis, therefore there would be technical difficulties if 
this was true; if knockdown efficiency was increased then there would not be any viable cells to conduct 
experiments with. One alternative strategy could be the knockdown of FAM83H-AS1 using tetracycline-
inducible shRNA viral vector that could express an siRNA against FAM83H-AS1 in a dose-dependent 
manner. If successful knockdown of FAM83H-AS1 induced cellular death in cells with knockdown, 
however, it would be a beneficial therapeutic approach to induce cell death in cancer cells. It would be 
critical to determine the effect of FAM83H-AS1 knockdown on surrounding normal and microenvironment 
cells, however, before moving forward. Simply transfecting normal cervical keratinocytes with siRNA 
against FAM83H-AS1 would be a good start to obtain this data.  
  
 If it is confirmed that knockdown of FAM83H-AS1 kills all the cells, it would eliminate the 
potential in vivo experimental set-up to knockdown siRNA in cervical cancer cells prior to injecting into a 
human tumor to see the reduction in tumor formation. It would be ideal to develop an in vivo system to 
develop a mouse tumor and then reduce FAM83H-AS1 expression and observe alterations in tumor growth. 
Currently, patient-derived xenograft (PDX) murine models are utilized in the cancer field as they allow for 
direct engraftment of human tumor tissues. A group previously showed the utilization of a PDX model with 
cervical cancer tumor engraftment(45). The Martinez lab has collaborated with West Virginia University 
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(WVU) PDX core to establish PDX cervical cancer tumors. It would be ideal to have the molecular 
background (FAM83H-AS1 expression) of the human tumors prior to implantation into the mouse so we 
could compare therapeutic effects with higher and lower FAM83H-AS1 expression in the tumor. 
Additionally, we could compare the therapeutic effects observed in our model to the human clinical 
outcomes. In the future, siRNA against FAM83H-AS1 could be injected into the mice and tumor size could 
be monitored. There is a collaborator at WVU with expertise in targeted drug delivery with nanoparticles 
(Dr. Werner Geldenhuys). Theoretically, siRNAs could be bound to nanoparticles to increase the 
internalization of siRNA into the nucleus. FAM83H-AS1 knockdown could be combined with current 
chemotherapies to improve their efficacy. If benefits are observed with FAM83H-AS1 knockdown with 
siRNAs, further studies could be developed on a drug to target FAM83H-AS1 that might be more clinically 
appealing than siRNAs.  
 
 Overall, FAM83H-AS1 regulates many of the cellular hallmarks of cancer in a variety of different 
cancers and should be studied further as a therapeutic target, diagnostic, and/or prognostic marker. 
  
 Another interesting phenomenon is that artificial inhibition of the HPV oncoproteins E6 and E7 in 
cervical cancer cells can induce cellular growth arrest by recovering the expression of the wild-type p53 
and Rb tumor suppresor genes. More specifically, Martinez et al. showed that inhibition of HPV E7 can 
induce an irreversible form of growth arrest known as senescence through the Rb pathway by regulating 
specific miRNAs(46). Another important form of reversible growth arrest, known as quiescence, has been 
shown to be important in maintaining the homeostasis between differentiation and self-renewal of stem 
cells, and dysregulation of quiescence is related to cancer(47).  Increasing knowledge on this cellular 
process will benefit research on aging-related diseases, wound healing treatment, organ regeneration, and 
cancer prevention. Our group, and others, have shown that ncRNAs (e.g. miRNAs and lncRNAs) are 
dysregulated in cellular quiescence (Chapter 3, Figure 1)(4).  
 
 Our group discovered that quiescent cells display an alternative miRNA biogenesis pathway in 
normal, primary foreskin fibroblast cells (Chapter 3), and further characterization of this pathway could 
reveal novel therapeutic and diagnostic markers. Currently, research on abnormal cellular growth arrest is 
focused on genetic alterations or mutations in cellular factors involved in the canonical pathway, and it has 
been demonstrated that mutations of some miRNA-processing factors have been linked to tumor 
formation(48). The findings in Chapter 3 show that there are alternations in the miRNA biogenesis pathway, 
which are not due to genetic mutations, that need to be researched further. It is hypothesized that quiescent 
cells disrupt the canonical miRNA biogenesis pathway to induce cellular growth arrest but continue the 
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production of essential miRNAs by the alternative pathway identified in Chapter 3. Other groups have 
demonstrated certain cells exhibit non-canonical miRNA processing(49, 50), but these non-canonical 
pathways only affect certain miRNAs without modifying the global canonical biogenesis pathway.   
  
 Specifically, our group discovered that Exportin-5 (XPO5) expression is reduced in quiescence by 
autophagy and miR-34a (Chapter 3, Figure 2), and certain miRNAs are induced in quiescence despite the 
absence of XPO5 (Chapter 3, Figure 3). Primary microRNAs (pri-miRNAs) corresponding to the 
quiescence-induced miRNAs are exported by Exportin-1 (XPO1) (Chapter 3, Figure 3) potentially via a 
trimethylguanosine (m2,2,7G, TMG)-cap (Chapter 3, Figure 4).  
 
 Pri-miRNAs are canonically processed into precursor miRNAs (pre-miRNAs) in the nucleus(51), 
however certain pri-miRNAs (e.g. pri-miR-34a) were identified in the cytoplasm in quiescent cells (Chapter 
3, Figure 5). The components involved in processing of these pri-miRNAs are not fully characterized. It is 
unclear if the pri-miRNA cap modification of these quiescence-induced miRNAs occurs in the nucleus or 
the cytoplasm. Future studies could identify the molecular components (and their localization) necessary 
for TMG capping of these pri-miRNA. (m7G)-capped nuclear RNAs [small nuclear RNAs (snRNAs)] can 
be exported by XPO1 in collaboration with cap-binding complex (CBC) and the phosphorylated adaptor 
for RNA export (PHAX)(52). In the cytoplasm, these snRNAs are recognized by Sec1/Munc18 (Sm) 
proteins and the cap is hypermethylated into a (m2,2,7G, TMG)-cap by TGS1. These snRNAs are then 
imported back into the nucleus by Snurportin-1 in association with other factors(53). It is hypothesized that 
quiescence-induced pri-miRNAs could be capped in a similar fashion. To test this hypothesis, cellular 
localization of (m2,2,7G, TMG)-capped pri-miRNAs will be determined. Briefly, quiescent cells will be 
fractionated, an anti-TMG cap antibody will be used to perform RNA immunoprecipitation (RIP) and 
recovered RNA will be sent for RNA-seq. Our group published a protocol to immunoprecipitate TMG-
capped RNA that could be used (Appendix). It will be determined if Sm protein is directly binding to these 
pri-miRNAs in the cytoplasmic fraction by performing RIP assays and mutational experiments.  
  
 Typically, Drosha does not cleave pri-miRNAs alone, as it forms a nuclear microprocessor complex 
with DGCR8 in the nucleus of cells to recognize and cleave pri-miRNAs and form pre-miRNAs. DGCR8 
acts as a molecular anchor necessary for the recognition of pri-miRNAs at the double-stranded RNA 
junction and directs Drosha to cleave and release the hairpin-shape pre-miRNAs in the nucleus(54). Our 
group additionally showed that there is a cytoplasmic short form of Drosha in quiescent cells that is 
functional and potentially involved in the processing (Chapter 3, Figure 6), thus it was speculated that 
DGCR8 would also be detected in the cytoplasm. Interestingly, we were unable to detect DGCR8 in the 
200 
 
cytoplasm during quiescence (Chapter 3, Figure 6B). DGCR8 was knocked down by siRNA in quiescent 
cells and the biogenesis of quiescence-induced miR-34a was not affected (Chapter 3, Supplementary Figure 
14B). It is possible, however, that DGCR8 in the cytoplasm has a cleaved form present in the cytoplasm 
(similar to Drosha) that was not targeted by the siRNA against DGCR8 or detected by the specific DGCR8 
antibody used. If this is not the case, it is speculated that there are alternative DGCR8-like, double stranded 
RNA binding proteins in the cytoplasm aiding Drosha in miRNA processing. A future study to characterize 
the Drosha-cytoplasmic microprocessor complex during cellular quiescence would be to conduct co-
immunoprecipitations using an antibody against Drosha in cytoplasmic fractions of quiescent cells, 
followed by mass spectroscopy. Once a DGCR8-like protein(s) is identified as an interactor with Drosha in 
the cytoplasm, it would need to be proven to be involved in the pri-miRNA processing. Briefly, the DGCR8-
like protein(s) could be knocked out by CRISPR/Cas9 technology and downstream pri-miRNA and mature 
miRNA levels could be monitored.  
  
 A specific group of miRNAs is induced during cellular quiescence. Individually identifying genes 
targeted by these individual miRNAs could identify critical regulators in cellular growth arrest. It would be 
interesting to further identify global regulation by these induced miRNAs during quiescence. To identify 
interaction between the active miRNAs and their real biological mRNAs, high-throughput sequencing of 
RNA isolated by crosslinking immunoprecipitation (HITS-CLIP) could be conducted in quiescent cells.   
 
 Normal human foreskin fibroblasts were used in Chapter 3 to identify and study the non-canonical 
miRNA biogenesis pathway in quiescent cells. To broaden the applications, future studies analyzing 
miRNA biogenesis of stem cells and cancer stem cells, which undergo quiescence before they differentiate 
or start self-renewal, could be conducted.  
 
 Overall, further elucidation of this quiescence-induced miRNA biogenesis pathway could identify 
specific novel target genes that are involved in cellular proliferation, apoptosis inhibition, and autophagy 
pathways and could be potential therapeutic targets or diagnostic markers. These findings could thus be 
globally impactful, as essentially every cell in the human body has the potential to undergo these critical 
cellular processes.  
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I. Abstract 
  
 Cellular quiescence (also known as G0 arrest) is characterized by reduced DNA replication, 
increased autophagy, and increased expression of cyclin-dependent kinase p27Kip1. Quiescence is essential 
for wound healing, organ regeneration, and preventing neoplasia. Previous findings indicate that 
microRNAs (miRNAs) play an important role in regulating cellular quiescence. Our recent publication 
demonstrated the existence of an alternative miRNA biogenesis pathway in primary human foreskin 
fibroblast (HFF) cells during quiescence. Indeed, we have identified a group of pri-miRNAs (whose mature 
miRNAs were found induced during quiescence) modified with a 2,2,7-trimethylguanosine (TMG)-cap by 
the trimethylguanosine synthase 1 (TGS1) protein and transported to the cytoplasm by the Exportin-1 
(XPO1) protein. We used an antibody against (TMG)-caps (which does not cross-react with the (m7G)-caps 
that most pri-miRNAs or mRNAs contain [Luhrmann et al., 1982]) to perform RNA immunoprecipitations 
from total RNA extracts of proliferating or quiescent HFFs. The novelty of this assay is the specific isolation 
of pri-miRNAs as well as other non-coding RNAs containing a TMG-cap modification. 
 
II. Background  
 
 Cellular quiescence, a type of reversible growth arrest, is an important cellular state involved in 
wound healing, organ regeneration, and preventing neoplasia (Coller, 2011; Valcourt et al., 2012). Small 
non-coding RNAs such as miRNAs have been found involved in the regulation of cellular quiescence. 
miRNAs are small non-coding RNAs ~22-nucleotides long that regulate the expression of protein-coding 
genes by base-pairing with the 3’ untranslated region (3’UTR) of messenger RNAs (mRNAs) (Esteller, 
2011). The canonical miRNA biogenesis pathway is based on a stepwise processing machinery (Ha and 
Kim, 2014; Kim et al., 2016). miRNAs are transcribed to produce a primary miRNA (pri-miRNA) with an 
imperfect loop structure that is recognized by the enzyme Drosha and its binding partner DGCR8 in the 
nucleus. Cleavage of the pri-miRNA generates a precursor miRNA (pre-miRNA) that is recognized and 
transported to the cytoplasm by the Exportin-5 (XPO5) protein. The pre-miRNA is cleaved by the enzyme 
Dicer (mature miRNA) and loaded into the RNA-induced silencing complex (RISC). On the other hand, 
precursors of small nuclear RNAs (snRNAs) involved in mRNA processing such as U1, U2, U4, and U5 
have a (m7G)-cap, which is recognized by cap-binding complex (CBC) and the phosphorylated adaptor for 
RNA export (PHAX) in the nucleus to enable their export to the cytoplasm by XPO1 (Ohno et al., 2000). 
These snRNAs are then recognized by Sec1/Munc18 (Sm) proteins (by binding to Sm binding site 
sequences) in the cytoplasm and TGS1 is recruited to hypermethylate the (m7G)-cap into a (m2,2,7G, TMG)-
cap. This modification is recognized by Snuportin-1 in association with Importin-β and other factors to 
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import the snRNAs back into the nucleus (Palacios et al., 1997; Kiss, 2004). Interestingly, XPO1 also has 
high affinity for the (TMG)-capped small nucleolar RNA (snoRNA) U3 in the nucleus and transports it 
from Cajal bodies to the nucleoli (Boulon et al., 2004). A previous study showed that TGS1 enhances Rev-
dependent HIV-1 RNA expression by (TMG)-capping viral mRNAs in the nucleus, thereby increasing 
recognition by XPO1 for transport to the cytoplasm (Yedavalli and Jeang, 2010). These findings suggest 
that TMG-capping of RNAs gives plasticity to different types of RNA molecules in order to regulate their 
processing and cellular localization. Our recent findings demonstrated the existence of a group of pri-
miRNAs modified with a 2,2,7-trimethylguanosine (TMG)-cap by TGS1 protein and transported to the 
cytoplasm by XPO1 during quiescence. Previous publications have shown the ability to pull-down (TMG)-
cap RNAs, such as snRNAs and snoRNAs, with specific antibodies against (TMG)-cap RNAs (Luhrmann 
et al., 1982). Our previous publications demonstrated for the first time the pull-down of (TMG)-cap pri-
miRNAs in human cells (Martinez et al., 2017).  Understanding which RNAs could be modified with a 
TMG-cap will provide new important insights into RNA biogenesis in normal or disease-related conditions. 
 
C. Materials and Reagents 
 
1. 1.5 ml microcentrifuge tubes (Fisher Scientific, catalog number: 05-408-129) 
2. 15 ml conical centrifuge tubes (DNase-/RNase-free) (Corning, catalog number: 430052) 
3. GilsonTM EXPERTTM University Fit pipette filter tips (Gilson, catalog numbers: F1731031, 
F1733031, F1735031, F1737031) 
4. Gel-loading pipet tips (Fisher Scientific, catalog number: 02-707-139) 
5. Large-orifice pipet tips (Fisher Scientific, catalog number: 02-707-134) 
6. Sterile polystyrene disposable serological pipettes (Greiner Bio One International, catalog number: 
710180) 
7. Serological pipettes  
2 ml serological pipettes (Fisher Scientific, catalog number: 13-678-11C) 
5 ml serological pipettes (Fisher Scientific, catalog number: 13-678-11D) 
10 ml serological pipettes (Fisher Scientific, catalog number: 13-678-11E) 
25 ml serological pipettes (Fisher Scientific, catalog number: 13-678-11) 
8. 150 cm2 vented tissue culture treated flasks (Corning, Falcon®, catalog number: 355001) 
9. 100 mm TC-treated cell culture dish (Corning, Falcon®, catalog number: 353033) 
10. Cell Scrapers (Fisher Scientific, catalog number: 08-100-242) 
11. HFF cells (obtained from the Yale Skin Disease Research Center) (Alternative source of HFF cells 
from ATCC: Hs27 (ATCC, catalog number: CRL-1634) 
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12. DMEM (Sigma-Aldrich, catalog number: D7777) 
13. Minimum essential medium (MEM) non-essential amino acids, 100x (Thermo Fisher Scientific, 
catalog number: 11140076) 
14. 0.05% Trypsin-EDTA with phenol red (Thermo Fisher Scientific, catalog number: 25300054)    
15. 10x PBS (Sigma-Aldrich, catalog number: P5493) 
16. Nuclease-free water (not DEPC-Treated) (Thermo Fisher Scientific, catalog number: AM9937) 
17. TRIzolTM Reagent (Thermo Fisher Scientific, catalog number: 15596026) 
18. RNase AWAYTM Surface Decontaminant (Thermo Fisher Scientific, catalog number: 7002) 
19. Chloroform (Sigma-Aldrich, catalog number: C2432) 
20. Ethanol, molecular biology grade (Fisher Scientific, catalog number: BP2818-500) 
21. Isopropanol, molecular biology grade (Fisher Scientific, catalog number: BP26184) 
22. GlycoBlueTM Coprecipitant (15 mg/ml) (Thermo Fisher Scientific, catalog number: AM9516) 
23. TURBO DNA-freeTM Kit (Thermo Fisher Scientific, catalog number: AM1907) 
24. Anti-m3G-cap, rabbit polyclonal, antiserum (Synaptic Systems)* 
Note: *Synaptic Systems discontinued the production of the Anti-m3G-cap, rabbit polyclonal, 
antiserum. Creative Diagnostics has a rabbit anti-TMG antibody (Anti-m3G-cap polyclonal 
antibody, Creative Diagnostics, catalog number: DPAB29202) that would be similar to the one we 
previously used but the experimental conditions have to be re-evaluated. 
As we mentioned above, the company (Synaptic Systems) discontinued this antibody. For that 
reason, we recommend to use a similar antibody from Creative Diagnostics. We agree to not 
mention the catalog number of the previous company to avoid confusion.  
25. Protein G Sepharose® 4 Fast Flow Beads (GE Healthcare, catalog number: 17061801) 
26. Normal rabbit serum (control, EMD Millipore, catalog number: NS01L-1ML) 
27. NaCl (Fisher Scientific, catalog number: S671-3) 
28. NP-40 (Thermo Fisher Scientific, catalog number: 28324) 
29. Tris base (Fisher Scientific, catalog number: BP152-5) 
30. HCl (VWR, catalog number: BDH7204-1) 
31. RNasinTM Plus RNase inhibitor (Promega, catalog number: N2611) 
32. NaOAc (Amresco, catalog number: 0602) 
33. EDTA, pH 8 (Thermo Fisher Scientific, catalog number: AM9260G) 
34. EDTA (Amresco, catalog number: 0105) 
35. SDS (Thermo Fisher Scientific, catalog number: AM9822) 
36. Phenol/Chloroform/Isoamyl Alcohol; 125:24:1 mixture, pH 4.5 (Thermo Fisher Scientific, catalog 
number: AM9720) 
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37. Agarose LE (Denville Scientific, catalog number: CA3510-8) 
38. iScriptTM cDNA Synthesis Kit (Bio-Rad Laboratories, catalog number: 1708891) 
39. Sso AdvancedTM Universal SYBR® Green Supermix (Bio-Rad Laboratories, catalog number: 
1725274) 
40. PARISTM Kit (Thermo Fisher Scientific, catalog number: AM1921) 
41. Boric acid (Fisher Scientific, catalog number: A73-1) 
42. NET-2 Buffer (see Recipes) 
43. G-50 Buffer (see Recipes) 
44. 1x TBE (see Recipes) 
 
D. Equipment 
 
1. Micropipettes (Gilson, model: Pipetman® L, catalog number: F167370) 
2. FormaTM Steri-CycleTM CO2 Incubator (Thermo Scientific, model: FormaTM Steri-CycleTM CO2 
Incubators, catalog number: 370) 
3. -80 °C freeze 
4. SorvallTM LegendTM Micro 21R Microcentrifuge (Thermo Fisher Scientific, model: SorvallTM 
LegendTM Micro 21R, catalog number: 75002490) 
5. EppendorfTM ThermomixerTM R (Eppendorf, model: Thermomixer R, catalog number: 05-412-401) 
6. LabquakeTM Tube Shaker/Rotator (Thermo Fisher Scientific, catalog number: C4152110Q) 
7. SorvallTM ST 40R Centrifuge (Thermo Fisher Scientific, model: SorvallTM ST 40R, catalog number: 
75004525) 
8. NanoDropTM 2000 Spectrophotometer (Thermo Fisher Scientific, model: NanoDropTM 2000, 
catalog number: ND-2000) 
9. T100TM Thermal Cycler (Bio-Rad Laboratories, catalog number: 1861096) 
10. CFX ConnectTM Real-Time PCR Detection System (Bio-Rad Laboratories, catalog number: 
1855200)  
11. UV transilluminator 
 
E. Procedure 
 
1. Plate HFF cells in serum-free DMEM supplemented with MEM non-essential amino acids at low 
density (approx. 1 x 106 cells/150 cm2 flask). Incubate HFF cells in humidified atmosphere of 5% 
CO2 at 37 °C for 48 h (Figure 1). 
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Notes: 
a. In order to obtain enough RNA for each experiment, use 4 to 6 150 cm2 flasks. 
b. To plate HFF cells in serum-free DMEM; wash 70-80% confluent HFF cells (100 mm TC-
treated cell culture dish) three times each with 10 ml phosphate buffered saline, add 1 ml 0.05% 
trypsin with phenol red to detach cells, add 10 ml serum-free DMEM media and collect cells 
in 15 ml conical tube, pellet cells by centrifuging at 300 x g at room temperature, and re-
suspend pellet in serum-free DMEM supplemented medium. 
c. It is important to remove trypsin from HFF cells before re-plating since medium doesn’t 
contain FBS to inactive the trypsin. 
2. Collect HFF cells by scraping flask on ice, pellet at 300 x g for 5 min at 4 °C, and wash two times 
each with 2 ml of phosphate buffered saline. Cell pellets can be frozen at -80 °C until RNA 
extraction (cell pellets must be kept on ice until lysed with TRIzolTM) (Figure 1). 
 Notes: To pellet HFF cells, remove old serum-free DMEM from cells and add 3 ml of fresh serum-
free DMEM. Use the blade of cell scraper to collect cells in one corner of flask taking care to not 
splash the cells in flask. Add 1-2% of volume of FBS or BSA to cells on ice to assist in pelleting. 
Extract RNA from pelleted cells using TRIzolTM Reagent per manufacturer’s instructions: 
 Note: All steps in this protocol should be performed in an RNase free bench area by using RNase 
AWAYTM Surface Decontaminant to spray and wipe most surface areas including micropipettes and 
ice bucket. 
a. Resuspend cell pellets thawed on ice in 1 ml of TRIzolTM Reagent for 5 min to lyse.  
b. Add chloroform (20% of TRIzolTM Reagent volume), mix samples well, and incubate at room 
temperature for 2-3 min.  
c. Centrifuge samples at 12,000 x g for 15 min at 4 °C to separate red phenol-chloroform 
(red/lower layer), interphase, and aqueous phase (clear/upper layer).  
d. Collect aqueous layer and precipitate RNA for 10 min at room temperature with isopropanol 
(0.5 volume of original TRIzolTM Reagent); GlycoBlueTM Coprecipitant (15 μg) can be added 
at this time to aid RNA precipitation.  
e. Pellet precipitated RNA by centrifugation (12,000 x g for 10 min at 4 °C).  
f. Wash RNA pellets with 75% ethanol (add an equal volume of 75% ethanol to TRIzolTM 
Reagent and briefly vortex) and re-pellet by centrifuging at 7,500 x g for 5 min at 4 °C.  
g. Air-dry RNA pellets for a few minutes and re-suspend in nuclease-free water. 
Note: Do not completely dry the RNA pellet because it will be difficult to re-suspend. Incubation 
at 55 °C for 10 min can help solubilize the RNA. 
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3. Use DNase from TURBO DNA-freeTM Kit to digest DNA contamination in RNA samples 
according to manufacturer’s protocol:  
a. Mix RNA with 10x TURBO DNase Buffer (0.1 volume) and 1 μl of TURBO DNase.  
b. Incubate RNA at 37 °C for 20 min and halt the reaction by adding DNase Inactivation Reagent 
(0.1 volume).  
c. Incubate RNA samples for 5 min with intermittent mixing by flicking tube then centrifuge at 
10,000 x g at room temperature for 2 min.  
d. Collect RNA (supernatant) and quantitate with NanodropTM 2000 Spectrophotometer. 
Note: The average amount of total RNA obtained from each flask is 1.5-2 μg. 
4. Pre-load Protein G Sepharose® 4 Fast beads with rabbit serum control or anti-m3G-cap antibody 
(Figure 1). 
Note: Use large-orifice pipet tips or clip the tip off of a pipet tip to aid the transfer of Protein G 
Sepharose® 4 Fast beads. 
a. Wash 4 times the Protein G Sepharose® 4 Fast beads (40 μl slurry/IP sample) each with 1 ml 
NET-2 Buffer (see Recipes) using short 30 sec spins at 1000 x g to pellet beads. 
Note: Non-filtered gel-loading pipet tips can be used during ‘wash’ steps to help prevent 
accidental loss of beads.  
b. Dilute washed Protein G Sepharose beads in 500 μl of NET-2 Buffer and add rabbit anti-m3G-
cap antibody (15 μl/IP sample, approximately 150 μg) or rabbit serum control (15 μl/IP sample, 
approximately 150 μg). To achieve equal loading of beads with antibodies only use one 
microcentrifuge tube/antibody; aliquot the beads into separate tubes after they are pre-loaded. 
c. Incubate beads/antibody for 1.5 h at room temperature on tube rotator; make sure samples are 
actually mixing. 
d. Remove excess antibody by washing Protein G Sepharose Beads 5 times each with 1 ml NET-
2 Buffer (short 30 sec spins at 1,000 x g); Resuspend beads in NET-2 Buffer (50 μl/sample).  
e. Aliquot antibody-bound Protein G Sepharose Beads into 1.5 microcentrifuge tubes; use enough 
tubes to have one of each antibody (Anti-m3G-cap and control) per sample.  
5. Pre-clear RNA with Protein G Sepharose Beads to reduce non-specific binding: 
a. Add RNasin Plus RNase inhibitor (1 μl) to RNA (10 μg/500 μl diluted with NET-2 buffer) and 
incubate for 3 to 5 min at 85 °C.  
Note: Plunge RNA into ice immediately after heating to avoid refolding of RNA. 
b. After heating, add an additional 1 μl of RNasin Plus RNase inhibitor to RNA. 
Note: Remember to wipe tubes with RNase AWAYTM Surface Decontaminant before opening to 
prevent possible contamination and degradation of RNA. 
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c. Rotate RNA (10 μg/sample for each antibody) slowly (without vibration) with 40 μl of NET 2-
washed Protein G Sepharose 4 Fast Flow beads (without antibody) for 2 h at 4 °C.  
d. Centrifuge RNA at 1,000 x g for 2 min to remove pre-clearing beads. 
6. Rotate pre-cleared RNA slowly (without vibration) with anti-m3G-cap or control pre-loaded 
Protein G Sepharose® 4 Fast beads for 4 to 16 h at 4 °C. Confirm that samples are mixing (Figure 
1). 
7. Collect the beads by centrifuging at 1,000 x g for 2 min and remove supernatant (save 250 μl for 
RNA extraction). 
8. Wash beads 5 times with 1 ml of NET-2 Buffer using short 30 sec spins at 1,000 x g. 
Note: RNasin Plus RNase inhibitor can be added to NET-2 Buffer (see Recipes) to prevent 
degradation of RNA.  
9. Resuspend beads in 250 μl of G-50 Buffer (see Recipes) to elute TMG-capped RNA (Figure 1). 
10. Purify RNA by Phenol-chloroform-isoamyl alcohol (PCI) extraction (also extract RNA from TMG-
capped depleted supernatant) 
a. Add 250 μl of Phenol-chloroform-isoamyl alcohol to RNA in G-50 Buffer. 
b. Vortex RNA samples for 20 sec (10 up and 10 angled) and centrifuge samples for 10 min at 
12,000 x g at room temperature. 
c. Transfer the aqueous phase with RNA (upper layer) to a clean microcentrifuge tube containing 
50 μl of 3 M sodium acetate (NaOAc), pH 5.2. 
d. Add 1 ml of 100% ethanol (precooled to -20 °C) to precipitate RNA; 1 μl of GlycoBlue can be 
added to help precipitate RNA and visualize pellets.  
e. Incubate RNA at -20 °C for 48 h. 
f. Pellet RNA by centrifuging sample at 12,000 x g for 10 min at 4 °C. 
g. Aspirate ethanol and wash RNA pellet with 500 μl of 75% ethanol (precooled to -20 °C). 
h. Re-pellet purified RNA by short spin for 1 min at 12,000 x g at 4 °C and aspirate 75% ethanol.  
i. Dissolve the dried m3G-capped RNA pellet in nuclease-free water (20 to 30 μl). 
Note: The average amount of pull-down m3G-capped RNA obtained from each experiment (5 
flasks) is 1.5-2 μg. 
11. RT-PCR of m3G-capped RNAs by using iScriptTM cDNA Synthesis Kit and 2x SsoAdvancedTM 
SYBR® Green Supermix PCR according to manufacturer’s protocols: 
Note: Perform RT-PCR using un-processed RNA (input) and RNA extracted from supernatant to 
determine expression levels of RNA of interest (m3G-capped and uncapped).  
a. Mix 5 μl of m3G-capped RNA with 5x iScript Reaction Mix (0.2 volume) and 1 μl of iScript 
Reverse Transcriptase.  
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b. Process RNA to cDNA in a thermocycler by undergoing the following conditions: 25 °C for 5 
min, 46 °C for 20 min, 95 °C for 1 min, and held at 4 °C. The reaction can be stored at 4 °C for 
short-term storage or -20 °C for long-term storage.  
c. Mix the resulting cDNA (around ¼ of the total cDNA reaction mix) with 2x SsoAdvancedTM 
SYBR® Green Supermix (0.5 volume) and the desired forward and reverse primers (12.5 μM 
stock; 0.04 volume).  
d. cDNA then undergoes the following conditions to produce a PCR product: 95 °C for 1.5 min; 
40 cycles: 95 °C for 30 sec, 60 °C for 30 sec.   
e. The PCR product is ran on a 1% agarose gel (made with 1x TBE [see Recipes] and ethidium 
bromide) at 100 V for 2 h, and bands are imaged with a UV transilluminator. 
 
 
Figure 1. Main steps diagram of this protocol 
 
F. Data analysis 
 
The recovery of (TMG)-capped RNAs was measured by RT-PCR amplification of well-known 
hypermethylated RNAs such as small nuclear RNA (snRNA) U7 (Figure 2) or small nucleolar RNA 
(snoRNA) U3 (Martinez et al., 2017). 
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Figure 2. RNA immunoprecipitation of (TMG)-capped primary miRNAs (Pri-miRNAs) in 
quiescent human foreskin fibroblasts (HFFs). RT-PCR data shows the RNA 
immunoprecipitation of Pri-miR-34a and Pri-miR-3188 in quiescent HFFs (as well as the positive 
control snRNA U7), but not Pri-miR-423 using an antibody against (TMG)-capped RNAs. Total 
RNA was extracted using TRIzol Reagent, and 10 μg of RNA was diluted in NET-2 buffer, 
precleared and incubated with Protein G Sepharose 4 Fast Flow beads loaded with 15 μl of control 
antibody (Normal Rabbit Serum, EMD-Millipore) or with antibody recognizing the (TMG)-cap 
(Anti-m3G-cap, rabbit polyclonal, Synaptic Systems). Beads were rinsed five times with NET-2 
buffer and were resuspended in G-50 buffer. RNA was extracted from the beads by phenol-
chloroform-isoamyl alcohol extraction and resuspended in 20 μl of nuclease-free water. 
Immunoprecipitated tri-methylated capped RNA was converted to cDNA using iScript cDNA 
synthesis kit (Bio-Rad), followed by RT-PCR, and visualized after gel electrophoresis. 
 
G. Notes 
 
This protocol could be modified to determine the location of TMG-capped RNA by separation of 
nuclear and cytoplasmic RNA fractions from fresh cultured cells (PARISTM Kit). 
 
H. Recipes 
 
Note: All reagents should be made with nuclease-free water and autoclaved.  
1. NET-2 Buffer 
150 mM NaCl  
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0.05% NP-40  
50 mM Tris-HCl, pH 7.4 
2. G-50 buffer 
20 mM Tris, pH 7.5  
300 mM NaOAc  
2 mM EDTA, pH 8  
0.25% SDS  
3. 1x TBE 
216 g Tris base  
110 g boric acid  
80 ml 0.5 M EDTA, pH 8  
1.5 L water  
(Bring solution to pH 8.3) 
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